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Abstract 
Introduction: The concept of oncolytic adenoviruses has been validated in pre-
clinical studies but clinical trials have demonstrated that the virus spread remains 
limited and the virus fails to infect all cancer cells in a tumour. Arming an 
oncolytic virus with a therapeutic trans gene would enhance the antitumour effect of 
these viruses by killing adjacent non-infected cells. The aim of this thesis is to test 
armed oncolytic adenoviruses targeting a constitutive activation of the Wnt 
signalling pathway in pre-clinical models of colorectal cancer. 
Methods: The Nail symporter was inserted into the genome of Wnt-selective 
oncolytic adenoviruses to visualise adenoviral spread in the tumour and assess 
image-guided radiotherapy. 
Results: In vitro testing of the virus has demonstrated that the Wnt-selectivity of 
the virus remains intact. The virus we generated has an equal or greater cytopathic 
effect than wild type adenovirus in Wnt-expressing cancer cell lines. The ability of 
the infected cells to take up iodine has been confrrmed by iodine uptake assays. 
The virus has been injected into subcutaneous human tumour implants in nude 
mice. Images obtained with a SPECT/CT camera have demonstrated that viral 
propagation can be visualised in vivo. Finally, we have used the imaging data to 
determine the correct timing for the administration of therapeutic doses of 131 I. 
Conclusion: We have validated a non invasive method to image viral propagation 
and transgene expression in a preclinical model of colonic cancer. Sequential 
imaging can provide information on the ideal time point for therapeutic 
intervention. In pilot experiments, the aim was to exploit the potential of the Nail 
symporter for the concentration of radioactive iodine, but it did not lead to 
increased therapeutic efficacy in vivo in preclinical models. There is strong 
evidence that if these experiments were repeated, therapeutic efficacy could he 
demonstrated. 
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CHAPTER 1: Introduction 
The aim of the work described in this thesis was to investigate a novel gene therapy 
for colorectal cancer. 
I will start with the description of the statistics and molecular biology of colorectal 
cancer. Since I have received samples of desmoid tumours from patients, I will 
dedicate a subsection to desmoid tumours. 
I will then carryon describing the different modalities available for gene therapy. 
Adenoviruses will be described in greater detail for they are the agents I will be 
working with. 
A chapter will be dedicated to molecular imaging and more specifically the sodium 
iodine symporter which is the transgene I will use. 
Lastly, I will discuss the potential benefits of combining imaging and molecular 
therapy. 
1. Colorectal cancer and the Wnt-signalling pathway 
1.1. The statistics of colorectal Cancer 
Statistics were obtained from the National Statistics website from the U.K. 
government (2007/02/08). 
Between 1971 and 2005, the incidence of cancer increased by around 21 % in males 
and 44% in females. In women, colorectal cancer is the second most common 
cancer after breast cancer. In men, colorectal cancer takes third position after 
prostate cancer, which remains the number one and lung cancer, the number two 
cancer (figure 1.1). 
England alone counted 238,977 new registered cases of cancer in 2005, out of 
which 29,565 were colorectal cancers (12.37%). Out of all new colorectal cancer 
cases 55% were males (16,282) and 45% were females (13,283). The incidence of 
colorectal cancer as rate per 100,000 population is 65.8 for males and 51.7 for 
females. 
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Figure 1.1: Overview of all newly diagnosed cancers in 2005 represented as percentage of total 
number of cancers for each sex (data source: www.statistics.gov.uk). 
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In 2005 malignant neoplasms accounted for 26% of all registered deaths in 
England and Wales (135,252 out of 512,692 total deaths). Colorectal cancer deaths 
represent approximately 10.5% (14,146). Over the last 50 years the cancer 
mortality rate has changed very little in England and Wales. However the mortality 
rate from other major causes like cardiovascular incidents and infectious disease 
has decreased. Cancer has subsequently been the most common cause of death in 
women since 1969 and in men since 1995. 
The five-year survival rate for colonic cancer in England and Wales is around 50%. 
A higher proportion of women than men survive for at least five years after 
diagnosis. For colorectal cancer patients diagnosed between 1999 and 2003 the 5-
year survival was 49.6% in men and 50.8% in women. This is an increase of 2.7% 
and 2.9% respectively compared to the period between 1996 and 1999. 
The considerable improvement of the survival rate for colorectal cancer is due to 
the recent development of new adjuvant therapies. The treatment of choice for 
stage I (superficial tumour) and stage II (invasion into subsero a, visceral 
peritoneum or neighbouring structures) colon cancer, where there is no lymph node 
involvement or distant metastasis, is surgery. Adjuvant therapy for tage II di ea e 
ha not hown to significantly improve survival rate in random controlled clinical 
trial and i therefore controver ial. Patients with tage III (lymph node meta ta i 
and IV (di tant and/or lymph node meta ta is) di ea e clearly benefit from adjuvant 
th rapy (W lpin et aI., 2007). The ba i of y ternic treatment for col rectal can r 
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IS 5-fluoro-uracil (5-FU), an antimetabolite that interferes with pyrimidine 
nucleotide synthesis, in combination with Leucovorin, which is thought to stabilise 
5-FUs interaction with thymidylate synthetase. Two newer cytotoxic drugs have 
recently been added as adjuvant agents. Irinotecan, a topoisomerase I inhibitor, 
which interferes with DNA synthesis by blocking the ligation step of the cell cycle 
and Oxaliplatin, an alkylating agent have shown to work synergistic when 
combined with 5-FU and improve disease free survival rate (Wolpin et aI., 2007, 
Capdevila et aI., 2007). The recent development of monoclonal antibodies that 
block signalling pathways has provided novel opportunities in the treatment of 
colorectal cancer. The most advanced drugs that have been tested in combination 
with chemotherapy in phase III clinical trials are Cetuximab, an anti-epidermal 
growth factor receptor monoclonal chimeric human/mouse immunoglobulin G 1 
and Bevacizumab, a humanised anti-Vascular endothelial growth factor antibody. 
These drugs have shown promising results and are currently being evaluated in 
larger scale randomised control clinical trials (Capdevila et al., 2007, Wolpin et aI., 
2007). Rectal cancer, due to its location in the pelvis is best treated by surgery, 
consisting of total mesorectal excision, in combination with chemoradiotherapy. 
1.2. APC, FAP and Cancer 
Familial adenomatous polyposis (FAP) is an autosomal dominant inherited disease 
characterised by the development of multiple adenomatous polyps in the colon and 
rectum and development of colorectal cancer by the age of 35-40 if left untreated. 
Adenomatous polyposis was frrst clinically described in the 18th century but it was 
not until recently that the molecular mechanisms were discovered (Kinzler and 
Vogelstein, 1996). The observation of a deletion of chromosome 5q in a patient 
with polyposis led to further studies that linked the disease to markers on 
chromosome 5q21. Mutation analysis in unrelated FAP families and sporadic 
colorectal tumours led to the identification, characterisation and cloning of the 
adenomatous polyposis coli (APC) gene (Kinzler and Vogelstein, 1996). Somatic 
mutations of APC occur in approximately 80% of sporadic colorectal cancers 
(Fearnhead et aI., 200 1). 
APC is a tumour-suppressor gene located on chromosome 5q21 that encodes a 
large multidomain 312kDa protein, 2843 amino acids long (Fearnhead et aI., 200 1 ). 
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The main function of APe is that of a scaffolding protein affecting cell adhesion 
and migration. F AP patients have inherited one faulty APe allele. Spontaneous 
somatic mutation of the second (wild-type) APe allele occurs at a low frequency in 
colorectal epithelial cells and is a requirement for the development of neoplasia 
(two hit hypothesis of Knudson (Knudson, 1971) (Kinzler and Vogelstein. 1996). 
Additional genetic mutations in later life are required for adenomas (polyps) to 
develop into invasive cancer. Nearly all mutations in APe (>95%) result in a 
truncated protein with abnormal function (Fearnhead et aI., 2001). In FAP patients 
there is a complex relationship between the position of the inherited APe mutation 
(genotype) and the clinical manifestation of disease (phenotype) (Fearnhead et al .. 
2001, Kinzler and Vogelstein, 1996, Galiatsatos and Foulkes. 2006). 
In addition to the multiple colonic polyps other clinical manifestations of F AP are: 
• Congenital hypertrophy of the retinal pigment epithelium: present in 
approximately 70-80% of patients with FAP (Galiatsatos and Foulkes. 
2006). This condition is present at birth and does not impair sight. These 
ophthalmic lesions are specific to FAP. Screening of FAP families by 
ophthalmoscope can identify affected family members before the 
appearance of polyps (Fearnhead et aI., 2001, Galiatsatos and Foulkes, 
2006) . 
• Upper gastrointestinal polyps are present in nearly 90% of FAP patients by 
the age of 70 years with a median age of diagnosis of 38 years (Bulow et 
aI., 2004). If left untreated these adenomas may progress and become 
cancerous. Periampullary carcinoma is a common cause of death in patients 
who have undergone prophylactic colectomy (Fearnhead et aI., 2001) 
(Offerhaus et al., 1992). Routine endoscopic surveillance is therefore 
important. 
• Desmoid tumours are large fibromatous lesions that usually arise from the 
abdominal wall, bowel mesentery or retroperitoneal space. They are a major 
cause of morbidity and the second leading cause of death in FAP patients 
after metastatic colorectal carcinoma (Galiatsatos and Foulkes, 2006). The 
overall prevalence of desmoid disease in FAP is 15% (Sturt et aI.. 2004). It 
is a general belief that desmoids are related to trauma. especially abdominal 
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surgery such as a prophylactic colectomy. Twice as many females develop 
desmoids compared to males (Sturt et al., 2004). Treatment today remains a 
challenge. Surgical incision involves the risk of bleeding and short bowel 
syndrome and includes high recurrence rates. Non-steroidal drugs have 
been used with varying success and the results of chemotherapy or 
radiotherapy have been disappointing. 
• FAP patients have an increased risk of developing thyroid cancer. The 
incidence is estimated at 1-2% (Truta et al., 2003). The age of diagnosis is 
25-33 years, affecting predominantly females (17: 1). The majority of 
carcinomas are papillary, with a cribriform pattern. They appear 
multicentric, unilateral and with a predominance for the left lobe. Lesions 
are well-circumscribed, non-aggressive and have a low metastatic potential 
and 10-year mortality (Truta et aI., 2003). 
• Children of F AP families have an increased risk of developing 
hepatoblastomas (Fearnhead et aI., 2001, Galiatsatos and Foulkes, 2006). 
• Other extra-intestinal cancers associated with FAP are adrenal, pancreatic and 
biliary tract malignancies. 
Two specified variants of FAP have been described. Gardner Syndrome is 
characterised as the association of gastrointestinal polyps with epidermal cysts, 
multiple soft-tissue adenomas and osteomas of the mandible and long bones 
(Fearnhead et aI., 2001, Galiatsatos and Foulkes, 2006). Turcot Syndrome refers to 
the combination of primary central nervous system tumours with multiple polyps in 
the colon and rectum (Fearnhead et al., 2001, Galiatsatos and Foulkes, 2006). 
1.3. The Wnt-signalling pathway 
Inactivation of the APC gene product constitutes the initial step in the development 
of colorectal cancer in FAP patients and the majority of sporadic colorectal cancers 
(80%). APC is part of a protein complex that is regulated by the canonical Wnt-
signalling pathway, which regulates the phosphorylation and consequent 
degradation of ~-catenin (Fearnhead et ai., 2001). The Wnt genes are defined by a 
sequence that is homologous to the Wingless gene in Drosophila, hence the name 
Wnt. The Wnt proteins are a large family of secreted ligands that are important for 
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tissue development in embryos and tissue homeostasis in the adult. The W nt 
pathway is in control of the temporal and spatial regulation of cell growth, cell 
movement and cell survival. Continuous activation of the Wnt-signalling pathway 
leads to uncontrolled cell growth and survival and can lead to tumour genesis and 
cancer (Logan and Nusse, 2004) (Barker and Clevers, 2006). A simplified model of 
the Wnt-signalling pathway is presented in figure 1.2. A complete and detailed 
outline of the pathway can be found in the Kyoto encyclopaedia of Genes and 
Genomes (http://www.genome.jp/dbget-binlwww bget'?pathway+hsa04310). 
In adult tissues, under normal circumstances, a W nt signal is absent and ~-catenin 
levels in the cell are kept low through continuous degradation by the actions of a 
protein complex. Within this complex APC and Axin form a scaffold that binds ~­
catenin and facilitates the phosphorylation of ~-catenin by casein-kinase lu (CKlu) 
and glycogen synthetase kinase 3~ (GSK3~). Phosphorylated ~-catenin is 
subsequently ubiquitinylated and degraded at the proteasome. Within the nucleus 
the DNA-binding T -cell factor/lymphoid-enhancer factor (TcflLef) proteins 
interact with transcriptional co-repressors and effectively block transcription of 
target genes. In the presence of a Wnt signal, Wnt-signalling proteins bind to 
Frizzled (Fzd) receptors on the cell surface of target cells, which results in the 
formation of a Fzd-Dishevelled (Dvl) complex and inhibition of the 
phosphorylation of ~-catenin. This results in the accumulation of ~-catenin in the 
cytoplasm and its transfer to the nucleus where it binds to and interacts with 
TcflLef proteins to activate the transcription of Wnt-target genes which include the 
proto-oncogene c-myc, cyclin-D, which regulate cell proliferation through cell 
cycle regulation (Logan and Nusse, 2004, Barker and Clevers, 2006) and 
Metalloproteinase matrylisin (MMP-7) (Oving and Clevers, 2002). Target genes 
affect the proliferation, differentiation, migration and apoptosis of cells. 
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Figure 1.2: Schematic overview of the Wnt signalling pathway_ The left hand panel how the 
situation in the absence of a Wnt signal. B-catenin is pho phorylated by the kina e CKla and 
GSK-3~ and is subsequently ubiquitinylated and degraded in the proteasome which en ure that the 
nuclear DNA-binding proteins of the TcflLef transcription family actively repre s target gene _ The 
right hand panel shows the situation in the presence of a Wnt signal. Interaction of a Wnt ligand 
with the Frizzled (Fzd) receptor results in the formation of Dishevelled (Dvl)-Fzd complexe and 
inactivation of the complex which results in the accumulation of ~-catenin in the cytopla rna and it 
translocation to the nucleus where it binds to Tcf proteins converting them to potent tran criptional 
acti vators. 
Frizzled 
B·Catenln 
Approximately 90% of sporadic colonic cancers have the Wnt-signalling pathway 
continuously activated (Barker and Clevers, 2006). This is usually the result of 
mutations in APC (80%) but can also be caused by mutations in ~-catenin or axin 
(Oving and Clevers, 2002, Barker and Clevers, 2006). The resulting accumulation 
of ~-catenin in the nucleus drives the chronic activation and transcription of Tcf 
target genes which are considered to be the initiating event in colon cancer 
formation. Wnt activation forces the transformation of intestinal epithelial cell into 
adenomas that continue to grow and eventually acquire additional mutation that 
re ult in their progre ion to malignant, inva ive and/or meta tatic growth. Even in 
late tage, colonic cancer cell remain dependent on chronic Wnt- ignalling 
activity t maintain their growth advantage, which make the Wnt- ignaUing 
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pathway a good candidate for therapeutic targeting (Barker and Clevers, 2006). In 
vitro experiments performed in colon cancer cell lines show that suppression of 
Wnt-signalling blocks cell growth and forces them to differentiate into epithelial 
cells (Barker and Clevers, 2006). Non-steroidal anti-inflammatory drugs are 
routinely used in F AP patients and reduce the number of intestinal polyps (Phillips 
et aI., 2002). It is thought that these drugs act through suppression of Wnt-
signalling activity (Barker and Clevers, 2006). 
1.4. Desmoid tumours 
Desmoid tumours are rare, benign, sometimes aggressive tumours resulting from 
unregulated proliferation of fibroblast-like cells (Sturt and Clark, 2006, Sakorafas 
et aI., 2007). Desmoid tumours have a natural history of slow growth and 
progressive infiltration of surrounding soft tissues leading in some cases to 
strangulation of nerves and blood vessels. Abdominal desmoids are the most 
common and can be classified into sporadic and familial forms (Sakorafas et al., 
2007). Inherited desmoid tumours are most frequently associated with FAP. The 
development of desmoid tumours has been associated with a constitutive activation 
of the Wnt-signalling pathway at the molecular level (Tejpar et al., 2005, Sturt et 
al., 2004, Wunder et aI., 2007). FAP-associated desmoids are caused by germ-line 
APC mutations followed by somatic inactivation of the wild-type APe allele (as 
described above) (Tejpar et aI., 2005, Sturt et al., 2004). Sporadic desmoid tumours 
are usually characterised by oncogenic mutations in the ~-catenin gene. 
The management of patients is difficult and these tumours are prone to local 
recurrence. Surgery is an obvious option but the development of 10-30% of 
sporadic abdominal wall desmoid tumours and 68-86% of F AP associated intra-
abdominal desmoid tumours has been associated with surgical trauma (Tolan et al., 
2007). As a result there is currently no satisfactory treatment for these tumours, 
especially in the context of F AP-related desmoid tumours which represent a major 
cause of morbidity and mortality (Sturt and Clark, 2006, Latchford et al., 2006). 
There is a need for complementary or alternative therapies that could delay surgery 
if not eradicate the tumour. 
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ZCancergenetherapy 
2.1. Definition 
The Department of Health's Gene Therapy Advisory Committee has defined Gene 
Therapy as: "The deliberate introduction of genetic material into human somatic 
cells for therapeutic, prophylactic or diagnostic purposes. "(GT AC, 2008) This 
includes techniques for delivering synthetic or recombinant nucleic acids (DNA 
and RNA) into humans. Such techniques include, but are not limited to, the use of: 
• Genetically modified biological vectors (such as viruses or 
plasmids); 
• Genetically modified stem cells; 
• Oncolytic viruses; 
• Nucleic acids associated with delivery vehicles; 
• Naked nucleic acids; 
• Antisense techniques (for example, gene silencing, gene correction 
or gene modification); 
• Genetic vaccines; 
• DNA or RNA technologies such as RNA interference; 
• Xenotransplantation of animal cells (but not solid organs)(GTAC, 
2008). 
One of the major goals in cancer gene therapy is to target a toxic agent specifically 
and selectively to cancer cells and to spare the normal tissue from damage. This 
could be achieved by combining highly specific gene delivery with highly specific 
gene expression (Greco and Dachs, 2001). For gene therapy to be successful three 
important issues need to be addressed: (1) delivery of a gene to the tumour, (2) 
regulation of gene expression and (3) therapeutic efficacy (Greco and Dachs, 
2001). 
2.2. Different approaches to cancer gene therapy 
2.2.1. Suicide gene therapy 
Suicide gene therapy, has two approaches: toxin gene therapy, in which genes for 
toxins are transfected directly into the cancerous cells, and enzyme-activating 
prodrug therapy. where the eDNA for an enzyme is introduced into tumour cells 
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where it can convert an administered drug, which is not toxic per se (prodrug) into 
a potent cytotoxin that causes tumour cell death (Springer and Niculescu-Duvaz, 
2000). In gene-directed enzyme/prodrug therapy (GDEPT), a DNA construct 
containing an enzyme encoding gene is delivered into the tumour. 
In an ideal situation, the selected prodrug should be inert, even at high 
concentrations, should diffuse freely through the tumour cells, should be 
chemically stable under physiological conditions and should have suitable 
pharmacological and pharmacokinetic properties (Greco and Dachs, 2001). 
In order to have a sufficient therapeutic effect, the released drug should be more 
toxic than the prodrug and have a sufficiently long half-life in order to allow 
diffusion into or active take up by the surrounding non-transfected cells (bystander 
effect) (Springer and Niculescu-Duvaz, 2000). The toxic effect should be 
independent of cell cycle phase or proliferation in order to kill a wide range of 
tumour cells (Greco and Dachs, 2001). 
The enzyme should have a low molecular weight and not require glycosylation. In 
physiological conditions, the enzyme should have a high catalytic activity and 
activate the prodrug rapidly and efficiently, even at low concentrations of the 
substrate, without depending on further catalysis by other enzymes. The expression 
of the enzyme per se should not have any toxic effect on cells. The reaction 
catalysed by the transgene should be different from endogenous enzymes in order 
to avoid activation of the prodrug in normal tissues (Greco and Dachs, 2001). 
Figure 1.3 shows the mechanism of action of GDEPT. 
27 
Figure 1.3: The strategy of gene-directed enzyme/prodrug therapy. 
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The enzymes for GDEPT can be of xenobiotic origin, with or without a human 
homologue, or of human origin (Vassaux and Martin-Duque, 2004) (Springer and 
Niculescu-Duvaz, 2000). Enzymes of human origin should be absent or expressed 
at very low levels in normal cells. 
A large variety of combinations of enzyme/prodrug have been developed over the 
years and some have shown therapeutic effects in vitro, in vivo and even in clinical 
trials (Vassaux and Martin-Duque, 2004). The majority of combinations do not 
meet all the "ideal" criteria stated above. The two most studied genes are the 
herpes simplex virus thymidine kinase (HSV -TK) gene and the bacterial cyto ine 
deaminase (CD) gene. Cells expressing the HSV -TK gene are able to 
phosphorylate nucleoside analogues such as acyclovir and gancyclovir, leading to 
the accumulation of cytotoxic metabolites which intercalate into replicating DNA 
(Elion, 1983). Active DNA replication (S-phase) is an absolute requirement for 
cytotoxicity. The active ub tance is not membrane-permeable and depend on cell 
to cell contact to diffu e into neighbouring cell . Tumour cell expre ing the CD 
gene a fir t de cribed by Au tin and Huber (Au tin and Huber, 1993, an 
selectively convert 5-fluorocytosine (5-FC) into the anticancer drug 5-fluorouracil 
(5-FU). 5-FU requires further metabolisation by endogenous enzymes. 
Several factors contribute to the success of suicide gene therapy. Enzyme/prodrug 
combinations have to be delivered to the tumour cells. The currently available gene 
delivery vectors (described later) fail to transduce all cells in a tumour. The 
bystander effect, killing cells adjacent to non-transfected cells is therefore very 
important for the success of this therapy. The nature and the extent of the bystander 
effect depend largely on the enzyme/prodrug combination used. The immune 
system could play an important role in the bystander effect by the induction of 
tumour-specific immunity. Apoptosis (e.g. activated gancyclovir induces 
apoptosis) and the phagocytosis of apoptotic bodies by neighbouring non-
transfected cells could also playa role in the bystander effect (Vassaux and Martin-
Duque, 2004, Springer and Niculescu-Duvaz, 2000). 
2.2.2. Immunotherapy 
Immunotherapy aims to generate an anti-tumour response through activation of the 
host immune defence mechanisms. It relies on the ability of the immune system to 
recognise and destroy tumour cells and to retain a long-lasting memory of this 
event (Wei et aI., 2005). Different types of cancer immunotherapy can be employed 
(Wei et aI., 2005). 
1. Passive specific immunotherapy: specific antibodies or immune cells, such 
as cytotoxic T-Iymphocytes, tumour infiltrating lymphocytes (TIL's) or 
genetically modified TIL's, are injected into the patient. An example of this 
type of therapy are monoclonal antibodies against the proto-oncogene 
HER2/neu (Trastuzumab, Herceptin®) which have become an accepted 
standard in the treatment of the subgroup of HER2/neu over expressing 
breast cancer patients (Untch et aI., 2008). 
2. Passive non-specific immunotherapy: transfer of lymphokine-activated 
killer cells. 
3. Active non-specific immunotherapy: aims to induce an immune response by 
using microorganisms, microbial components (e.g. endotoxins) or 
imnlunomodulators (e.g. cytokines) or genetically modified 
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microorganisms. The frrst observed case of anticancer immunotherapy was 
in 1890 when injection of the bacterium Streptococcus Pyogenes into a 
tumour lead to tumour regression (Wei et aI., 2005), original article for 
reference: (Coley, 1891). 
4. Active specific immunotherapy: immunisation of the patient with anti-
idiotype or tumour-based vaccines or gene-transfer/gene-modified immune 
cells or vaccines. Cancer vaccines are able to induce an anti-tumour 
response mediated by immunological effector cells such as CD8+ T-
lymphocytes, CD4+ lymphocytes and natural killer cells. The ideal antigen 
should be highly immunogenic, should be expressed at high levels in 
tumour tissue but either not or at low level in normal tissue. Ideally all the 
cells in a tumour should express the antigen (Jager and Knuth, 2005). 
Several anticancer vaccines have progressed to the stage of clinical trials 
and encouraging results have been reported especially for patients with 
limited disease (Stebbing et aI., 2008). 
2.2.3. Anti-angiogenesis 
In the adult, neovascularisation is limited to the female reproductive system and 
healing wounds. In any other circumstance neovascularisation is the result of a 
pathological process such as cancer. Small tumours (up to 3mm) can depend on 
existing blood vessels for their blood supply. A tumour larger than 1-3mm needs 
additional vasculature in order to survive (Jain, 2005). Angiogenesis occurs when 
the effect of pro-angiogenic factors outweighs the effect of anti-angiogenic factors. 
This has been described as the "angiogenic switch", which promotes the formation 
of new vessels and allows the tumour to survive and grow. Once this event has 
occurred, the tumour becomes invasive locally and/or systemically (Jain, 2005). 
Numerous pro- and anti-angiogenic factors are involved in the different steps of 
vessel formation. These molecules can be grouped into three categories (Jain, 
2005): (I) ligands and receptors, (2) molecules that manage cell to cell interactions 
and (3) molecules that manage cell to matrix interactions. 
Depending on the hypothesis that tumour growth depends on angiogenesis, anti-
angiogenic therapies aim to stop or inhibit the blood supply to a tumour, depriving 
cancer cells of nutrients and thus indirectly kill the cells (Jain, 2005). 
30 
A large number of anti-angiogenic agents are currently on the market and new ones 
are being developed continuously. Some agents have been especially developed for 
their anti-angiogenic property, others are drugs licensed for other treatment but 
with anti-angiogenic properties (Lenz, 2005). An anti-angiogenic drug currently 
undergoing further clinical trials to determine its efficacy in the adjuvant treatment 
of colorectal cancer in combination with conventional chemotherapy is the anti-
vascular endothelial growth factor monoclonal antibody Bevaclusimab (Avastin®) 
(Wolpin et aI., 2007). 
Anti-angiogenic targeted gene therapy is directed at tumour endothelial cells and 
their micro-environment. This can be achieved by arming delivery vectors for anti-
angiogenic genes with endothelial cell-specific promoters like endothelin I or with 
ligands to endothelial cell-surface specific receptors like alpha v beta 3 integrin 
(av~3) and alpha v beta 5 (av~5) integrin (Tandle et aI., 2004). 
2.2.4. Gene replacement therapy 
The discovery that specific gene families playa role in the development of cancer 
has led to the idea that targeting these genes and their products may prevent or cure 
cancer (Roth et aI., 1994). Gene replacement therapy therefore aims to repair the 
genetic defects caused by loss of tumour suppressor genes or activation of 
oncogenes. 
The most famous example of gene replacement therapy is the replacement of the 
gene encoding the yc cytokine receptor subunit of interleukin-2, -4, -7, -9 and -15 
receptors which are essential for the growth and differentiation of lymphoid 
progenitor cells. Patients with X-linked severe combined immunodeficiency 
(SCID-Xl) syndrome are born with a mutation in the yc gene. Successful 
replacement was achieved by ex vivo delivery to CD34+ bone marrow cells with a 
retroviral vector (Cavazzana-Calvo et aI., 2000). Despite the enormous therapeutic 
success, two out of ten treated patients developed a leukaemia-like disease within a 
year of treatment due to insertion of the retroviral delivery vector into the host 
DNA and the subsequent activation of an oncogene (Hacein-Bey-Abina et al., 
2003). 
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In cancer, tumour suppressor genes play an important role in the control of cell 
proliferation by regulating the transcription of certain genes (Roth et aI., 1994). The 
p53 gene is the most commonly mutated gene in human cancers. Under normal 
circumstances the gene plays a role in activating transcription of genes essential for 
the regulation of the cell cycle, for DNA repair, apoptosis and other regulatory 
molecules important for genetic stability (Roth et aI., 1994). Abnormalities in the 
gene lead to the abrogation of its tumour suppressor function. Restoration of wild 
type p53 gene is able to suppress the growth of transduced cells in vitro and 
expression of wild type p53 in vivo may inhibit local tumour growth in nude mice 
(Roth et aI., 1994). 
To date p53 replacement has been extensively researched and several clinical trials 
have been conducted in a variety of cancers to study the feasibility of p53 
replacement therapy. Phase I clinical trials conducted in non small cell lung 
cancer, head and neck cancer, bladder cancer, recurrent glioma and ovarian cancer 
all showed a reduction in tumour size or stabilisation of disease in a significant 
number of patients after intra-tumoural or loco-regional injection (Fujiwara et aI., 
2006b). Advexin®, an adenoviral-CMV -p53 is being evaluated in phase 2-3 clinical 
trials in the USA and Europe for intra-tumoural injection in head and neck cancer 
(March 2008). China has become the frrst country to licence replacement gene 
therapy as a regular treatment for head and neck cancer combining adenoviral 
delivery of the p53 gene by intra-tumoural injection with conventional radiotherapy 
(Peng, 2005, Garber, 2006). 
2.2.5. Virotherapy 
Oncolytic therapy or virotherapy will be described in more detail below. 
2.3. Delivery vectors for gene therapy 
Suicide gene therapy, replacement gene therapy, anti-angiogenesis and, to a lesser 
extent, immunotherapy require vectors or vehicles capable of efficient and selective 
delivery of the therapeutic genes to the cancerous cells. These vectors can be of 
viral origin (adenoviruses, adeno-associated viruses (AA V), herpes simplex virus 
(HSY), parvovirus, lentivirus, vaccinia virus and retroviruses), naked plasmid DN A 
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(with or without electroporation), antisense RNA, small interfering RNA, bacteria, 
bacteriophages, cationic lipids, liposomes, nanoparticles, polyethyleneimine (PEl), 
polyaminoacids, peptides and dendrimers. 
Three issues are of major importance in selecting a delivery vector: 
(1) The specific targeting to cancer cells, (2) the efficiency of transduction and (3) 
the safety of administration to human subjects. 
Non-viral methods for gene delivery have the advantage that they are chemically 
defined, have the capacity to incorporate large genes and are easy to manufacture. 
The limitation in these methods is that transduction is transient and the level of 
expression is low. New and better synthetic vectors are being investigated and hold 
promise for the future (Young et aL, 2006). 
Viruses currently are the most efficient gene delivery system available for clinical 
purposes. They have evolved over millions of years to transfer genetic material in 
human cells and express their genes while evading the immune system. They can 
easily be manipulated to express the desired genes and/or to replicate only in the 
selected cells (Young et aL, 2006). The choice of a specific virus depends on the 
target and the desired effect. Some viruses have a tropism for certain tissues, e.g. 
HSV for neuronal cells, while other viruses infect a wide range of different cell 
types, e.g. adenovirus. Retroviruses and lentiviruses integrate DNA stably into the 
host-cell genome, which is then transmitted to all subsequent cell generations 
(Young et al., 2006, Waehler et al., 2007). 
Non-replicating viruses have been used safely in clinical trials, but there have been 
difficulties with inadequate distribution and delivery, insufficient levels of gene 
transfer and expression and short-term efficacy due to immune responses. 
Exploiting bystander effects can overcome these hurdles to a certain extent. 
Another approach to circumvent the obstacle of successfully infecting all cells in a 
tumour is to use replication-competent viruses and exploit the ability of these 
viruses to replicate selectively in cancer cells, to kill the cells and to spread in the 
tumour. Such viruses are called oncolytic viruses. 
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2.4. Oncolytic viruses 
One of the earliest reports on the ability of viruses to replicate in and kill tumour 
cells, was the case described by De Pace in 1912 (Sinkovics and Horvath, 1993) 
(and for reference (De Pace, 1912)). De Pace describes the regression of a 
fungating cervical tumour after the patient was bitten by a dog and inoculated with 
attenuated rabies vaccine. 
In the 1940s and early 1950s clinicians started to infect cancer patients 
intentionally with live viruses, obtaining in some cases partial remissions (Huebner 
et aI., 1956, Sinkovics and Horvath, 1993). 
Over the last 20 years the advances in molecular biology have increased our 
understanding of the molecular mechanisms of carcinogenesis, viral infection, viral 
replication and viral toxicity. These advances have allowed the development of 
genetically engineered viruses with improved safety, cancer selectivity and efficacy 
(Sinkovics and Horvath, 1993). 
The concept of oncolytic virotherapy is described in figure 4. When an oncolytic 
virus infects a normal, non-target cell, replication is inhibited and the infected cell 
is either recognised and destroyed by the immune system or undergoes apoptosis. 
In the target cancer cells, the virus is able to use the host cell machinery to replicate 
its genome. When the host cell is loaded with newly produced viral particles, the 
virus initiates cell death and viral progeny can spread to and infect neighbouring 
cells. 
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The ideal features of a candidate oncolytic virus are as follows: 
(1) Broad tissue specificity is required to allow the virus to deal with cancer 
originating from or metastasising to a variety of different tissues. 
(2) The virus needs to replicate to high titres so that an immune response can not be 
mounted until after infection is well established. 
(3) The virus must be lytic, killing infected cells. 
(4) The viral genome must be easy to manipulate and allow the insertion of large 
transgenes. 
Several methods have been developed to target viruses selectively to tumour cell 
(Post et aI., 2003, Hawkins et aI., 2002). 
(I) Some viruses are innately tumour-specific and do not require additional genetic 
modifications. Examples of such viruses that have been used in clinical trial are: 
Reovirus that only replicates in cells with an activated Ras-signalling pathway 
Newca tIe di ea e virus and Vesicular stomatitis viru that only replicate in 
interferon-defective cell, Measle viru and Vaccinia viru (Norman and Lee 
2000, Liu and Kirn, 2007, Aghi and Martuza, 2005, Parato et aI., 2005). 
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(2) Viruses can be targeted to cancer cells through the use of promoters that are 
only functional in target cells. Examples of tissue-specific promoters that have 
been developed so far are alpha-fetoprotein (AFP), which is expressed in several 
tissues through development but is only expressed in tumours of hepatic andlor 
intestinal origin in adult life (Hallenbeck et aI., 1999), prostate specific antigen 
(PSA) and rat probasin promoter for prostate cancer, mucin-1 (MUC 1), which is 
over-expressed in breast carcinoma, human telomerase reverse transcriptase 
(hTERT) for a wide variety of cancers (Li et aI., 2008), vascular endothelial growth 
factor VEGF, which is hypoxia-specific, carcinoembryonic antigen (CEA) for 
gastrointestinal cancer, the tyrosinase promoter, which is specific for melanoma 
and many more (McCormick, 2001). 
(3) Targeting can be achieved trough discrete mutations in the viral genome. An 
example is the retinoblastoma (Rb) pathway. Viruses need to inhibit this protein in 
order to replicate in normal cells. Certain tumour cells are defective in the Rb 
pathway and as a result adenoviral E 1 A-deleted mutants that fail to neutralise Rb 
should therefore only replicate in targeted cells (Heise et al., 2000, McCormick, 
2001). 
(4) The tropism of a virus can be manipulated in such way that the virus can only 
be taken up by cancer cells. In order to redirect a virus, all its native cell interaction 
mechanisms must be ablated. In case of adenoviruses, this includes ablating CAR, 
integrin and heparin sulphate glycosaminoglycan (HSG) binding and replacing 
them with a tumour-specific binding mechanism. This can be achieved by 
complexing viruses with bispecific molecules where one component blocks CAR-
binding of the knob and another component assures receptor binding. Ligands that 
have been used include epidermal growth factor (EGFR) and angiotensin-
converting enzyme (ACE) (Green and Seymour, 2002). 
Another strategy involves genetically modifying viruses to ablate interaction with 
native receptors and incorporate targeting sequences. By altering the fibre protein 
for instance, the virus no longer recognises its receptor on normal cells but instead 
attaches to target specific cells receptors (Waehler et al., 2007). Insertion of the 
arginine-glycine-aspatic acid (RGD) motif or polylysine (pK7) into the fibre 
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protein enhances CAR independent binding to integrins and HSG respectively (Wu 
et aI., 2002). 
3. Adenoviruses 
3.1. General considerations 
Adenoviruses were fIrst discovered in 1953 by Rowe et al. who extracted them 
from human adenoids (Young et aI., 2006, Rowe et aI., 1953). One year later, 
Hilleman and Werner found that extracts from respiratory secretions of people 
suffering from an acute respiratory illness were able to lyse human cells in culture 
(Hilleman and Werner, 1954). Clinically, adenoviruses are responsible for mild 
upper respiratory tract infections, mild gastrointestinal infections and eye 
infections. 
3.1.1. Classification 
The family of adenoviridae has been subdivided into four genera: Atadenovirus, 
Aviadenovirus, Mastadenovirus and Siadenovirus. The human adenovirus belongs 
to the genus Mastadenovirus and 51 serotypes have currently been identified based 
historically on immunological criteria. Human adenoviruses are grouped from A to 
F according to genome size, hemagglutination properties, oncogenicity in rodents, 
DNA homology and genomic organisation (Young et aI., 2006, Zhang and 
Bergelson, 2005). The tissue tropism of viruses varies between the subgroups. 
Groups B 1, C and E cause respiratory infections, group B2 infects the kidneys and 
urinary tract, group F causes gastroenteritis and group D viruses infect the eyes 
(Zhang and Bergelson, 2005). 
The most commonly used vector for gene therapy is adenovirus 5 subgroup C. 
3.1.2. Structure 
Figure 5 shows a schematic drawing of an adenoviral caspid. 
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Figure 1.5: Adenovirus. Picture adopted from www.nobelprize.org 
single-stranded DM 
Adenoviral particles measure 80-110 nm, are not enveloped and consist of a capsid, 
fibers, a core and associated proteins. 
The capsid has an icosahedral symmetry and is composed of 252 units called 
capsomers: 240 hexons and 12 pentons. Hexons are arranged in 20 triangular faces. 
Each hexon consists of a trimer of polypeptide II with a central cavity. VI, VIII and 
IX are minor polypeptides that are also associated with the hexon. They are thought 
to be involved in the stabilisation and/or assembly of the particle. The base of a 
penton is made up by a pentamer of peptide In and five molecules of peptide IlIa. 
Pentons are responsible for penetration of the cell membrane. Purified penton can 
cause cell death in the absence of any other viral components. From each of the 12 
vertices extends a fibre protein which is attached to the penton base protein and 
consists of a trimer of peptide IV. The knob at the end of each fibre is re pon ible 
for recognising receptors on the cell membrane. The core contain the genome and 
at lea t four proteins. Terminal protein (TP) is attached to the 5'end of the 
genome. Protein V and VII are protein that are wrapped around the genome to 
form a "chromatin-like" structure. Mu i a mall protein who e functi n i 
unknown. 
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Figure 1.6: Known adenovirus capsid proteins, adopted from: 
hup://www.microbiologybytes.comlvirologyladenoviruses.html 
~ame: ;Location: Known Functions: 
~I Hexon monomer Structural 
~II lPen ton base Penetration 
~IIa IAssociated with penton base Penetration 
~V fibre Receptor binding; haemagglutination 
~ ~ore: associated with DNA & penton base Histone-like; packaging? 
~I lHexon minor polypeptide Stabilisation/assembly of particle? 
tvII ~ore Histone-like 
!VIII lHexon minor polypeptide Stabilisation/assembly of particle'? 
~X lHexon minor polypeptide Stabilisation/assembly of particle? 
rrp \Genome Terminal Protein Genome replication 
The adenoviral genome is linear, double-stranded with a length of 30-40k base 
pairs (bp). At the end of each strand are inverted terminal repeats (lTR) of 
approximately 50-200 bp, which act as origins of replication (Buchen-Osmond, 
2003) (http://microbiologybytes.com!virology/adenoviruses.html, 2007). 
3.1.3. The adenoviral entry in the cell 
The flfSt step in adenoviral infection is the binding of the fibre knob with the 
cellular receptor. The main receptor for human adenoviruses of subgroup C is 
identical to the one for coxsackie virus and is therefore called the 
coxsackie/adenovirus receptor (CAR) but these viruses also bind to the major 
histocompatibility class I molecule (MHC-I) (Russell, 2000). CAR is a plasma 
membrane protein with extracellular, transmembrane and cytoplasmic domains. 
The extracellular domain is sufficient for attachment of the virus to the cell surface. 
CAR is expressed at variable levels in a broad variety of tissues in epithelial cells 
(Fechner et al.. 1999). 
The next step IS the internalisation of the ViruS through receptor-mediated 
endocytosis, which is mediated by the interaction of the penton base proteins and 
av proteins on the cell surface. The avp3 and avp5 integrins are know to facilitate 
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adenoviral internalisation. In the absence of integrins on the cell urface CAR-
mediated uptake is possible but much slower (Fechner et aI., 1999) (Rus ell, 2000). 
In the endosome toxic activity of the penton base proteins is responsible for the 
disruption of the endosome membrane and the release of virus into the cytoplasm 
(Russell, 2000, http://microbiologybytes.com!virology/adenoviru es.html, 2007). 
In the cytoplasm the virus is partially disassembled and transferred to the nuclear 
membrane. The genome is passed through the nuclear pore and into the nucleu 
where its TP forms a tight complex with nuclear matrix component and viral 
transcription is initiated (Russell, 2000). 
The adenoviral genes are grouped into transcriptional units which are expressed at 
different stages through the adenoviral life cycle: immediate early (EIA), early 
(EIB, E2A, E2B, E3, E4) and late genes (LI to LS). Immediate early and early 
genes are encoded at various locations on both strands of the DNA ( ee figure 6). 
Each gene leads to multiple protein products through alternative plicing of mRN A 
transcripts (http://microbiologybytes.com!virology/adenoviruses.html, 2007). 
Figure 1.7: Transcription of the adenovirus genome. The early tran cripts are outlined in blue, the 
late in green. Arrows indicate the direction of transcription. MLP = Major late promoter. 
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3.1.4. Transcription 
3.1.4.1. The function of EIA 
The fIrst gene to be expressed after the viral DNA has been transported to the 
nucleus is the EIA gene. The EIA gene contains three regions that are conserved 
across all adenoviral serotypes called CR1, CR2 and CR3. The gene encodes two 
proteins called 243R (or 12s mRNA transcript) and 289R (or 13s mRNA transcript) 
called after the number of amino acids. CR 1 and CR2 are present in both proteins 
but CR3 is unique for the 289R protein. It is predominantly through these domains 
that EIA binds to key cellular proteins that play an important role in the 
transcriptional regulation of viral and host genes (Russell, 2000, Frisch and 
Mymryk, 2002). 
The retinoblastoma family of genes include the retinoblastoma gene Rb, pi 07 and 
p130 which have common functional characteristics of which the most important 
function is the ability to control the cell cycle. Cell cycle control is mostly achieved 
through inactivation of transcription factors such as the E2F family which promote 
the cell entrance into S phase (Felsani et ai., 2006). Binding of E 1 A proteins to the 
Rb-E2F complex disrupts the interaction between Rb and E2F proteins (figure 1.8). 
The released E2F proteins can activate transcription of target genes that are 
required for the induction of S phase of the cell cycle (Frisch and Mymryk, 2002). 
Target genes include Cyclin A, Cyclin E and cyclin-dependent kinase 2 (Felsani et 
ai., 2006). 
Inactivating retinoblastoma gene products also leads to induction of p53. This is 
one of the mechanisms by which EIA causes apoptosis in cells. EIA binds to 
p300/CBP (CREB-binding protein), which are co-activators of transcription. 
Binding of EIA to p300/CRB facilitates the acetylation of Rb by p300 which 
promotes it interaction with MDM2, which is known for its ability to bind p53. Rb 
forms a stable complex with p53 and MDM2 which prevents the degradation of 
p53, thus repressing the transcription of target genes and promoting apoptosis 
(Frisch and Mymryk, 2002). 
The function of EIA proteins is complex and EIA interacts in many other ways 
both directly and indirectly with cellular proteins. 
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EIA products also playa role in immune modulation by inhibiting the activation of 
genes induced by interferon and interleukin-6 (Russell, 2000) (Weitzman and 
Ornelles, 2005). 
Figure 1.8: ElA disrupts the interaction between retinoblastoma protein and E2F, allowing E2F to 
activate transcription of target genes that are required for S phase induction of the cell cycle. In 
addition to freeing E2F from Rb, ElA promotes the acetylation ofRb by p300/CBP which i know 
to promote its association with the MDM2 protein. RB and MDM2 form a complex with p53 which 
blocks p53 degradation, transcriptional activation and p53-mediated growth arrest and allow 
transcriptional repression and induction of apoptosis by p53 (Frisch and Mymryk, 2002). 
• I I _ 
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The expression of EIB genes is important to avoid cell death, which would inhibit 
viral production. Expression of EIA results in the stabilisation of p53 a de cribed 
above. p53 interacts with p21 which results in cell cycle arrest in G 1. p53 also 
activates cellular pro-apoptotic genes such as the bcl-2 family member Bax and 
Bale Bak is also activated by the destabilisation of its binding partner MCL-I, a 
re ult of induction of a DNA damage response by adenovirus infection. Bak and 
Bax cooperate to form pore in the mitochondrial membrane, thereby facilitating 
the relea e of pro-apoptotic protein (Berk, 2005). The EIB-19k protein i 
functionally imilar to the cellular bcl-2 protein and bind to both Bak and Ba , 
thu. pr v nting th r lea e of pro-apoptotic protein . 
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The EIB-SSk protein binds to pS3, thereby increasing the intracellular 
concentration and binding affmity of pS3. The EIB-SSk/pS3 complex is a potent 
repressor of pS3 target genes, which prevents transcriptional activation of cell cycle 
arrest and pro-apoptotic programs (Berk, 200S). The E4orf6 protein is involved in 
the interaction between EIB-SSk and pS3 and influences the stability of pS3. The 
E 1 B-SSk/E40rf6/ubiquitin ligase complex targets pS3 for degradation at the 
proteasome (Berk, 200S). The E I BIE40rf6 protein complex also interacts with the 
cellular MRN complex which is involved in DNA repair. Degrading the MRN 
subunits is essential for viral DNA replication. When MRN is not inactivated, it 
treats the ends of linear viral DNA strands like a double-stranded DNA break. 
resulting in random stretches of viral DNA (Berk, 2OOS). EIB-S5k and E40rf6 both 
play a role in the expression of late viral genes. They assist in the preferential 
transport of late viral mRNA from the nucleus to the cytoplasm in the late stages of 
infection (Russell, 2000, Weitzman and Ornelles, 2005). 
3.1.4.3. The function of E2 
Adenoviral E2 gene products provide the necessary machinery for the replication 
of viral DNA and the transcription of the late viral genes. The E2A gene encodes a 
DNA-binding protein that is required for viral DNA replication and that regulates 
the transcription and translation of late viral genes. The E2B gene encodes a DNA 
polymerase that synthesises viral DNA (Russell, 2000) (Weitzman and Ornelles, 
200S). 
3.1.4.4. The function of E3 
The E3 gene products (figure 2.1) have been called the "stealth" genes 
(http://microbiologybytes.comlvirology/adenoviruses.html, 2007) because they 
play an important role in the evasion of the host immune responses. E3 genes are 
not required for viral replication in cultured cells. 
The function of the E3-12.Sk gene product has not yet been elucidated. 
The E3-6.7k protein plays a role as a general repressor of apoptosis and associates 
with the receptor internalisation and degradation (RID) protein complex which 
consists of RIDa (E3-10.4k) and RIDP (E3-14.5k) proteins to internalise and 
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mediate degradation of cell surface receptors for tumour necrosis factor (TNF), Fas 
and TNF-related apoptosis inducing ligand (TRAIL). TNF is a cytokine that is 
released by activated lymphocytes and macrophages. T -lymphocytes and natural 
killer (NK) cells use TRAIL to induce apoptosis in virus infected and tumour cells. 
Thus by reducing cell surface receptors, the virus reduces immune-mediated 
destruction of infected cells. E3-6.7k is a membrane protein that is localised in the 
endoplasmic reticulum (ER) and the plasma membrane. In the ER it functions as a 
general repressor of apoptosis by maintaining calcium homeostasis in the cytosol 
(Lichtenstein et aI., 2004). E3-6.7k is required in the plasma membrane In 
conjunction with the RID complex to internalise and degrade TRAIL receptor 2. 
RIDa. and RID~ are co-expressed together in the plasma membrane but 
individually they are expressed in the Golgi apparatus (RIDa.) or the Golgi 
apparatus and the ER (RID~). The RID complex mediates the internalisation and 
destruction of cell surface receptors such as Fas, TRAIL receptor 1, TRAIL 
receptor 2 and epidermal growth factor receptor (Lichtenstein et al., 2004). 
The RID complex also plays a role in preventing TNF-mediated activation of the 
large cytoplasmic phospholipase A2 which cleaves arachidonic acid from 
membrane phospholipids. Arachidonic acid is a potent mediator of inflammation 
(Lichtenstein et aI., 2004). 
The E3-gp 19k protein is localised in the ER membrane and binds to MHC class [ 
proteins, preventing their transport to the cell surface where they would be 
recognised by cytotoxic T -lyphocytes (CTLs) (Russell, 2000). Viral antigens form 
complexes with MHC class I molecules in the membrane of the ER. CTLs 
recognise these complexes (Ag-MHC I) on the cell surface. This interaction leads 
to the release of perforin, resulting in cell lysis, thus eliminating the infected cell 
even before the viral life cycle has been completed. E3-gp 19k thus prevents 
premature cell death induced by CTLs. 
The 11.6k adenoviral death protein (ADP) is responsible for cell lysis after viral 
replication to allow virions to leave the cell and infect neighbouring cells. 
The 14.7k protein protects the infected cell from apoptosis induced by tumour 
necrosis factor (TNF). The mechanism through which E3-14.7k achieves inhibition 
of TNF-mediated apoptosis is not clear (McNees and Gooding, 2002). 
3.1.4.5. The function of E4 
The adenoviral E4 is not needed for growth in tissue culture. While the E3 region is 
aimed at avoiding cell lysis by extracellular action of the host immune respones, E4 
gene products are important to counteract the cell's intracellular antiviral defences. 
They also promote viral protein synthesis and shut down host protein synthesis 
(Russell, 2000). Early in the infection a single E4 promoter is activated by E 1 A to 
produce the E4 transcript, which through alternative spicing results in the creation 
of several E4 proteins, called E4-orfl-6/7 (Weitzman and Ornelles, 2005). 
E40rf6/7 binds the E2F that has been displaced from Rb by EIA and thereby 
stabilizes the binding of E2F to the E2 promoter and promotes DNA replication 
(Leppard, 1997). E40rf negatively regulates EIA expression and has a role in 
regulating late viral mRNA splicing and protein phosphorylation (Leppard, 1997). 
E4-orf4 can induce p53 independent apoptosis and this may contribute to lysis of 
infected cells at the end of the infectious cycle (Weitzman and Ornelles, 2005). E4-
orf6 promotes the degradation of cellular proteins and acts in combination with 
EIB-55k as described above to prevent the initiation of the cellular DNA damage 
response and to promote nuclear export of late viral mRNAs for translation (section 
3.1.4.2). E4-0rf3 interacts with nuclear structures that are implicated in multiple 
cellular functions including DNA repair, transcriptional control, apoptosis and the 
interferon response (Weitzman and Ornelles, 2005). E4-0rf3 is able to relieve the 
EIB inactivation of p53 (Russell, 2000). 
3.1.4.6. The function of late viral genes 
The late adenoviral genes encode structural viral proteins including hexon, penton 
and fibre, which are necessary for the assembly of progeny virions. The L4-100k 
protein blocks host translation and promotes late viral mRN A translation. Mature 
virus particle production precedes cell lysis. 
3.2. Adenoviruses for cancer therapy 
Adenoviruses are useful tools to deliver genetic material to host cells. They have a 
broad tissue tropism and can infect most mammalian cell types. They infect both 
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dividing and quiescent cells and they do not integrate in the host genome. The 
expression of the transgene is transient. Adenoviruses support simultaneous 
expression of multiple genes. The total amount of DNA that can be effectively 
packaged into virions is 105% of the wild type genome, which allows for the 
insertion of approximately 2kb of foreign DNA. The capacity of the adenovirus to 
accommodate foreign DNA can be increased by deleting non-essential viral genes. 
Adenoviruses possess a lytic life cycle, which can be exploited for oncolytic viral 
therapy. Because adenoviruses are stable and resistant to physical manipulations, 
they can be produced to high titres (up to 1013 viral particles/ml) and frozen for use 
at later times. Another advantage is that wild type virus causes only mild 
pathology. Intravenous injection of adenovirus generally is well tolerated and 
causes mild flu-like symptoms (Mathis et aI., 2005). 
A major disadvantage of adenoviral therapy is that after systemic injection the 
majority of viral particles are trapped in the liver by the Kuppfer cells and to a 
lesser extent in the adrenal glands, lungs, pancreas and spleen (Fechner et aI., 1999, 
Wang et aI., 2003a, Groot-Wassink et aI., 2002). Apart from being predominantly 
targeted to the liver, adenoviruses also interact with blood cells. Incubation of 
human and murine blood cells ex vivo demonstrated that more than 90% of the 
viral particles administered were associated with human (not murine) erythrocytes 
and in blood obtained from a patient infected with adenovirus during a clinical 
trial, more than 98% of the adenoviral genomes were associated with blood cells. 
This interaction may seriously reduce adenoviral delivery to extra-vascular target 
cells and tissues in humans (Baker et aI., 2007). Furthermore adenoviruses were 
shown to bind to a number of plasma proteins, including coagulation factor IX, X 
and binding protein-4, which allow CAR-independent infection of liver cells 
(Waddington et aI., 2008). Adenoviruses have therefore only been used intra-
arterially or intra-venously for targeting the liver but in other organs intratumoural 
injection is preferred. 
Systemic immune responses to viral capsid proteins may playa significant role in 
the outcome of adenoviral gene therapy and may prevent repeated administration 
(Chirmule et aI., 1999). The extent to which an immune response is elicited is 
related to the amount of virus administered but also by individual variations of the 
immune response in humans. This became apparent when a patient died after 
administration of an adenoviral vector, while another patient receiving a similar 
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dose did not exhibit any side effects (Lehrman, 1999). Jesse Gelsinger developed a 
fever and disseminated coagulation within hours of intra-hepatic artery treatment 
with an adenovirus to correct partial ornithine transcarbamylase deficiency. The 
severe response by this patient may have been related to the amount of virus (3.5 x 
1013 viral particles) and the pre-existing enzyme deficiency in his liver, which 
emphasises the importance of appropriate patient and dose selection (Chirmule et 
aI., 1999). As a result of this event, the U.K. gene therapy advisory committee has 
issued several recommendations. These include the assessment of the patient's 
immune status prior to treatment and the use of standardised methods to assess 
viral titre to ensure consistency through clinical trials (Relph et aI., 2004). 
It is therefore important to engineer viruses that in addition to containing the 
transgene, specifically target cancer cells (or target tissues) and evade the immune 
response. 
3.3. Adenoviruses targeted to cancer cells 
3.3.1. Deletions 
The prototype for oncolytic adenoviral therapy is the virus Onyx-OI5/d1l520. This 
mutant virus has a deletion for the adenoviral EIB 55kDa protein that plays a role 
in inactivating the cellular tumour suppressor protein p53 (Bischoff et aI., 1996). 
Under normal circumstances the p53 tumour suppressor gene acts as a protective 
mechanism against DNA damage. Induction of p53 by such damage results in 
apoptosis or cell cycle arrest. More than 50% of human cancers have therefore 
inactivated the p53 pathway (Levine, 1997). The Onyx-015 virus was thought to 
replicate in and kill p53-deficient tumour cells only but unable to replicate in cells 
with a functional p53. It became clear that the virus is not specific for p53 null cells 
but the virus still kills cancer cells preferentially and exhibits significant antitumour 
activity (Mathis et aI., 2005). The EIB-55k protein binds to E4-orf6 to mediate late 
viral RNA transport from the nucleus to the cytoplasm. Recent studies have 
confrrmed that it is the loss of this function that restricts Onyx-015 replication in 
normal cells that are not able to take over the export function of E 1 B-55k (O'Shea 
et aI., 2004). This virus has been tested extensively in Phase I, II and III clinical 
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trials as a single agent or in combination with conventional chemo- or radiotherapy 
with variable clinical responses (Mathis et aI., 200S). 
An almost identical virus HI0l, which contains an E3 deletion in addition to the 
EIB-SSk deletion is the frrst oncolytic virus that recently has been licensed in 
China for head and neck cancer treatment in combination with conventional 
therapy (Garber, 2006). 
The selectivity and safety of this virus have been encouraging for oncolytic viral 
gene therapy but durable objective responses with this virus as a single agent have 
been uncommon. Onyx-OlS virus was severely attenuated due to the mRNA 
transport deficiency and possibly other functions attributed to EIB-SSk. This has 
led to the development of tumour-selective adenoviruses in which other viral genes 
have been deleted. Deleting viral genes to increase tumour specificity can reduce 
the potency of the virus. It is important therefore to select those mutants that 
increase selectivity but leave viral replication and/or cytotoxicity unaffected. 
Deleting the adenoviral E3-gp 19k gene for example results in enhanced 
intratumoural gene expression and/or replication in immunocompetent tumour 
models as compared to the common E3B (E3-RID genes + E3-14.7k) gene 
deletion (Wang et aI., 2003b). 
An example of newer second-generation adenoviral mutants is the adenoviral 
mutant dI922-947, which has a deletion in the EIA gene. Under normal 
circumstances the E 1 A-CR2 protein interacts with the host cell retinoblastoma 
protein and is important for inducing S-phase entry in the infected cell. The 
retinoblastoma pathway is abnormal in the majority of human cancers and therefore 
this d1922-947 virus should replicate in cancer cells but not in quiescent normal 
cells (Heise et ai., 2000) (Lockley et ai., 2006). 
3.3.2. Promoters and markers 
Placing the adenoviral EIA and or EIB gene under the control of cancer-specific 
promoters is another way of controlling adenoviral gene expression and replication. 
In the case of prostate cancer, the rat probasin promoter and the prostate-specific 
antigen (PSA) promoter or a combination of both have been used to drive the 
expression of E 1 A and/or E 1 B in oncolytic adenoviruses. Synergistic effects 
between prostate-specific replicating adenoviral vectors and chemo- or 
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radiotherapy have been demonstrated in animal models and phase I-II clinical trials 
(Young et aI., 2006) (DeWeese et aI., 2001). 
Other cancer specific promoters include the telomerase promoter that is deregulated 
in a wide range of cancers, the a-fetoprotein promoter in liver cancer, the MUC-l 
promoter in breast cancer (see also section 2.4) (Young et al., 2006). 
Placing cancer-specific markers under the control of adenoviral promoters lS 
another way to target viruses to cancer cells. In the context of colonic cancer, 
Richard Iggo and co-workers have constructed a series of Wnt-specific replicating 
adenoviruses by inserting Tcf-binding sites in multiple early adenoviral promoters. 
Viruses containing Tcf-responsive elements in the ElA, ElB and E4 gene 
promoters were selective for cells with an activated Wnt-signalling pathway and 
were active in most of the colon cancer cell lines studied in cytopathic effect assays 
(Fuerer and Iggo, 2002, Homicsko et aI., 2005). 
3.3.3. Receptors 
Another retargeting strategy consists of diverting the adenovirus away from its 
binding on the CAR receptor by introducing changes in the fibre or knob domain. 
CAR, integrin and heparin sulphate glycosaminoglycan binding must all be 
abolished and replaced with a tumour targeting mechanism (Green and Seymour, 
2002) in order to guarantee tumour specificity. Several mechanisms can be used to 
achieve altered viral tropism. These have been discussed in section 2.4. 
3.3.4. Conclusion 
Clinical studies conducted so far with tumour-specific replicating adenoviruses 
have demonstrated that these agents are safe but convincing clinical responses have 
been obtained only in studies where they were administered in combination with 
conventional therapies (Russell, 2000, Green and Seymour, 2002, O'Shea, 2005, 
McCormick, 2005). The observation that oncolytic adenoviruses lack efficiency 
when used in mono therapy has led to the conclusion that additional features or 
combination therapies were necessary. Arming oncolytic viruses with transgenes is 
therefore one way to increase the efficacy of viral oncolysis. 
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4. Molecular imaging of gene expression 
In clinical trials the endpoints for measuring the effect of oncolytic viral therapy 
are limited to tumour size measurement and biopsies. Alternative endpoints are 
required to direct future development of new oncolytic viruses. In this context, 
non-invasive imaging of gene expression could provide information about the 
location, magnitude and kinetics of gene expression and provide the explanation as 
to why these oncolytic adenoviruses have only limited efficacy. 
Molecular imaging has been defined broadly as: "the in vivo characterisation and 
measurement of biological processes at the cellular and molecular level using 
remote imaging detectors" (Sharma et aI., 2002). 
Molecular imaging methods employed to detect and visualise gene expression in 
vivo in animal models and humans require expression of a reporter gene that alters 
the distribution of a radioactive tracer compound, activates a substrate or 
concentrates a contrast agent (Vassaux and Groot-Wassink, 2003). 
The devices used for molecular imaging need to be able to detect very low amount 
of reporter probes that are designed to accumulate in cells that express a reporter 
ectopically (Penuelas et aI., 2005b). The ideal molecular imaging technique needs 
to be highly specific, highly sensitive, have a high temporal-spatial resolution and 
be non-invasive (Rudin et aI., 2005). A number of technologies have been 
developed for non-invasive molecular imaging. 
4.1. Optical imaging 
Optical imaging can be performed when the reporter genes encode bioluminescent 
(frrefly luciferase is an enzyme that transforms a substrate into a light-emitting 
product) or fluorescent proteins (e.g. green fluorescent protein) or when fluorescent 
dyes are used as ligands to label a biologically interesting molecule. The emitted 
light energy can be detected externally by the use of sensitive photon detection 
systenlS (Contag et al., 2000). 
The emission of light photons in cells expressing the transgene transmits through 
the tissues after activation of substrate by the enzyme (in the case of luciferase) or 
upon gene expression (in the case of fluorescent transgenes) in the absence of 
background noise since mammalian cells do not normally express light-emitting 
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proteins. The disadvantage of this technique is the poor spatial resolution. The 
anatomical definition is high at the surface but deteriorates quickly with increasing 
depth due to the scattering of light in tissues (Rudin et aI., 2005). 
While in small animals optical imaging techniques can provide informative data, it 
is highly unlikely that these techniques could be used for in vivo gene imaging in 
human subjects (Penuelas et aI., 2oo5a). 
In addition to the poor spatial resolution, the reporter genes described are of 
xenogenic origin. They will be recognised by the immune system as "non-self' and 
the cells expressing these genes may be destroyed by cytotoxic immune cells, 
which in tum may prevent viral replication and oncolytic activity. 
4.2. Radionuclide based imaging 
Radionuclide-based imaging technologies are Positron Emission Tomography 
(PET) and Single Photon Emission Computed Tomography (SPECT). 
Radionuclides or radio labelled molecules are injected intravenously in trace 
quantities and are retained in tissues as a result of binding to a receptor, cell 
entrapment due to enzyme-catalysed conversion or intracellular uptake through a 
transporter (Penuelas et aI., 2005a). 
These modalities can be performed repeatedly in VIVO In humans, are highly 
sensitive, have a high spatial resolution and can give precise quantitative data 
(Gambhir et aI., 2000b). A non-invasive, clinically applicable method for 
quantitative imaging of transgene expression in human subjects would enable 
clinicians to define the location(s), magnitude and persistence of gene expression 
over time (Gambhir et aI., 2oo0b). 
Positron-emitting isotopes are required for PET scanning. A positron is a particle 
with the same mass as an electron but with a positive charge. Positron-emitting 
radionuclides have a short half life ("C: 20 minutes, 18F: 2 hours) and are thus 
generally produced in cyclotrons in or near the laboratory or hospital where the 
scanning takes place. Emitted positrons interact with atoms they encounter in their 
path. They travel for some distance depending on their energy and the density of 
the surrounding matter. When the velocity is low. they may combine with an 
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electron in their vicinity and annihilate. During the process of annihilation two 
photons with energy of 511 MeV are released simultaneously in opposite directions 
at an angle of 1800 (provided positron and electron are at rest when they combine). 
Detectors are arranged in a ring around the subject and register only photon pairs 
that arrive within a certain time span of each other at an angle of 
acquired data are analysed by computer and a three-dimensional 
reconstructed (Levin, 2005). 
tmage tS 
Single photon-emitting isotopes (used for SPECf) are isotopes that result in the 
emission of gamma ray photons or high energy X-ray photons. The photon is 
emitted directly from the radioactive atom. Single photons are emitted in all 
directions and are attenuated as they travel through the body. The photons that 
leave the body can be detected by rotating detector panels around the subject. The 
exact provenance of the photon can be determined by the use of collimators 
consisting of a well defined configuration of holes for the photons to enter. Photons 
that hit the collimator at the wrong angle will not make it through the hole and are 
filtered out. The acquired data are analysed by a computer and reconstructed to 
create three-dimensional tomographic images. The spatial resolution depends on 
how well the photons can be collimated. High spatial resolutions (l-2mm) have 
been obtained by using magnifying collimators e.g. pinhole collimator (Levin, 
2005). 
C. S. Levin (Levin, 2005) has written an extensive review of all the imaging 
modalities including technical specifications, drawbacks and advantages. 
PET and SPECT both provide accurate quantitative information on gene expression 
in vivo in small animal studies. Both imaging modalities are available for use in 
humans. However, since human subjects have a greater mass, spatial resolution is 
reduced and the information obtained is thus less accurate. 
In order to increase the amount of information obtained from images, molecular 
imaging modalities can be combined with conventional radiography. 
PET/Computed tomography (CT) and SPECT/CT have become available for 
clinical use combining the exact, high-resolution anatomical information from the 
CT with the molecular information obtained from PET or SPECT. 
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In addition to the radioactive tracer, molecular imaging of gene expression requires 
a reporter gene that will concentrate the tracer in the transduced tissue (Va aux 
and Groot-Wassink, 2003). Currently three types of reporter genes are available: 
enzymes, receptors and transport proteins. 
4.2.1. Enzymes 
Upon intravenous injection, a radiotracer can freely diffuse into the subject and 
cross the plasma membrane of all cells. In cells which express the transgene, the 
radio tracer is metabolised through enzymatic reaction (usually phosphorylation). 
As a result the tracer can no longer cross the cell membrane and remains trapped 
within the cell (figure 1.9A). The degree of accumulation of radio labelled substrate 
reflects the level of enzyme activity and thus the level of gene expression (Vassaux 
and Groot-Wassink, 2003). 
Figure 1.9: General principles of radionuclide-based imaging: A. enzymes: the radiotracer can 
freely cross the cell membrane. In cells expressing the enzyme the radiotracer is metaboli ed 
(usually phosphorylated) and as a result becomes trapped in the cell. B. Receptors: expre sion of the 
transgene leads to expression of an intra- or extracellular receptor to which the radiolabelled ligand 
binds. The receptor Ugand can be internalised. This leads to the accumulation of detectable ligand in 
transduced tissues. C. Transporter: upon expression of the transporter in transduced cell the 
radiotracer is selectively transported into the cell where it concentrates. The tracer is then either 
trapped in the cell or released when the extracellular concentration decreases, leading to a transient 
signal. 
Ligand o Radiotracer 
Radlotracer 
Intemallsatlon 
Enzyme 
Concentration 
Radlotracer-P P ~I.a.e 
The herpe simplex virus 1 thymidine kinase (HSV I-tk) gene is an example of a 
reporter gene encoding an enzyme. Several thymidine analogue have been 
de igned that are preferential ub trate for the HSVI-tk rather than the cellular 
thymidine kina e. Radiolabelled derivative can be u ed for imaging and therapy. 
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5-iodo-2'tluoro-2' deoxy-l-~-D-arabino-furanosyl-uracyl (FIAU) can be labelled 
with several different radionucleotides including 99mTc, 1231, 1241 and 131 1, which 
makes it appropriate for imaging and therapy with PET and SPECT (Vassaux and 
Groot-Wassink, 2003). Several investigators have created or are in the process of 
creating and evaluating other reporter probes with improved sensitivity and 
specificity (Penuelas et al., 2005a). The group of Ghambir, S. S. (Gambhir et al., 
2oo0a) has investigated mutant HSVl-tk reporter genes, which present a higher 
specificity to the reporter probe 9-( 4-esF] tluoro-3-hydroxymethylbuthyl) guanine 
(FHBG), providing a further increase in the sensitivity. 
Studies in cell cultures and small animals have demonstrated that the [ISF] FHBG 
PET in vivo signal correlates with transgene expression as determined by mRN A 
and protein levels (Gambhir et al., 1999). For a review of animal studies see (Min 
and Gambhir, 2004). 
PET images monitoring the in VIVO expressIon of mutant HSVl-tk gene in 
xenografts of stably transfected cell lines in nude mice were able to predict the 
response to therapy (Yaghoubi et aI., 2005). 
PET imaging with eSF] FHBG has been used to monitor HSV1-tk expression after 
intratumoural injection of Ad-CMV -tk in patients with hepatocellular carcinoma 
(Penuelas et al., 2005b). Radiotracer accumulation was detected in all lesions 
treated with an adenoviral dose above 1012 viral particles. Fused PETtCT images 
provided precise anatomic-metabolic correlation between the tumour location and 
the site of HSV1-tk gene expression. These data provide evidence that PET 
imaging could monitor transgene expression in cancer patients. It was also 
suggested that PET imaging of gene expression could be used as a non-invasive 
tool to predict the efficacy of gene therapy in patients. 
4.2.2. Receptor 
Intra- or extracellular receptors can be expressed as transgenes and specific 
radio labelled ligands can be developed that bind reversibly or irreversibly to the 
receptor (figure 1.9 B). 
An example of such a receptor is the Dopamine 02 receptor (02R), which is 
expressed in the plasma membrane of cells and is endogenously present in the 
striatum of the brain and the pituitary gland. Several ligands have been developed 
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that allow imaging by PET or SPECT (Sharma et aI., 2002, Gambhir et aI., 2000b) 
(Vassaux and Groot-Wassink, 2(03). 
3-(2' -[ 18F] fluoroethyl) spiperone ([ 18F] FESP) can bind to D2 receptors, leading to 
the accumulation of the ligand in the cells expressing the transgene, and can be 
. 18 lmaged by PET. The levels of [ F] FESP accumulation thus reflect the level of 
transgene expression. Because ectopic expression of the D2 receptor may sensitise 
cells to circulating adrenergic signals a mutant receptor (D80RA) has been 
developed that uncouples receptor occupancy from intracellular signalling (Sharma 
et aI., 2002, Gambhir et aI., 2oo0b, Vassaux and Groot-Wassink, 2003). 
In vivo imaging studies in mice after intravenous injection of a replication-deficient 
adenovirus carrying a D2R reporter gene driven by the CMV promoter with [18F] 
FESP-PET have shown very high expression of the reporter gene in the liver. The 
amount of radiotracer retained in the liver as determined by region of interest 
measurements from the PET images was proportional to the amount of hepatic 
FESP present and to D2R mRNA levels (Gambhir et aI., 2000b, Vassaux and 
Groot-Wassink, 2003). 
4.2.3. Transport protein 
Transport proteins can be expressed in the plasma membrane of cells and act as 
reporter genes. They have a high specificity for certain compounds and use active 
transport mechanisms to concentrate a specific radiotracer into a defined 
compartment such as the cell cytosol (Figure 1.9 C) (Vassaux and Groot -Wassink, 
2003). 
The sodium/iodine symporter is such a transport protein and will be discussed in 
greater detail. 
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5. The human sodium iodine symporter (hNIS) 
5.1. What is the hNIS? 
E. Bauman reported in 1896 for the frrst time the ability of the thyroid cells to 
concentrate iodine (Dohan et aI., 2003) (for reference (Baumann, 1896». Iodine is 
scarce in the environment and consequently dietary intake is low. The capacity of 
the thyroid follicular cells to concentrate iodine up to 40 times the plasma 
concentration is essential for the production of thyroid hormones. 
Over the past 60-70 years radioactive iodine isotopes and technetium-99m have been 
used for the diagnosis of thyroid diseases, the treatment of hyperthyroidism and 
benign thyroid diseases and the diagnosis and treatment of thyroid cancer. Thyroid 
cancer was treated for the frrst time with radioiodine in 1941 (Chung, 2002), but it 
was not until 1996 that Dai et ai. isolated the rat cDNA that encodes the protein 
involved in the uptake of iodine and technetium in the thyroid, the sodium iodine 
symporter (NIS) (Dai et aI., 1996). In the same year the human homologue was 
isolated by Smanik et al. (Smanik et al., 1996). 
The human NIS gene (hNIS) is localised on chromosome 19pI2-13.2 and consists 
of an open reading frame of 1929 nuc1eotides. The coding region comprises 15 
exons interrupted by 14 introns and it codes for a 3.9-kb mRNA, which in its turn 
generates a glycoprotein of 643 amino acids with a molecular mass ranging from 
70 to 90 kDa as a result of variable levels of glycosylation (Smanik et al., 1997). 
The secondary structure of the hNIS is thought to consist of 13 transmembrane 
segments of which the amino-terminus is located extracellularly and the carboxyl 
terminus intracellularly. Three of its Asp residues, position 225, 485 and 497 are 
glycosylated but glycosylation is not essential for the function, stability or targeting 
to the cell membrane of the NIS (Levy et al., 1998). 
5.2. The function of hNIS in the thyroid 
The hNIS mediates iodine uptake in the thyroid and several other extra-thyroidal 
tissues like stomach, salivary glands and lactating mammary glands. The transport 
of iodine across the basolateral membrane of the thyroid follicular cells is the first 
step in the production of thyroid hormones T3 and T4 (Dohan et at.. 2003). 
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Figure lOis a graphic depiction of the function of hNIS in the thyroid. 
Two sodium ions are translocated inward together with inward translocation of one 
iodine ion across the basolateral membrane, which makes the odium iodine 
transporter a symporter as both substrates are transported at the same time in the 
same direction. The driving force is the sodium gradient generated by the N a/K 
adenosine triphosphatase (De La Vieja et aI., 2000) (Dohan et al., 2003). NIS 
activity in the body is blocked by the specific competitive inhibitors perchlorate 
and thiocyanate. It was in 1936 that Barker et al. (Dohan et al., 2003) discovered 
for the fIrst time that patients treated with thiocyanate for hypertension develop 
hypothyroidism and/or goitre. 
Figure 1.10: The function of the NIS in thyroid cells. AIT: Apical Iodine Tran porter. ATP: 
Adenosine Tri Phosphate, Cl: Chlorine, K: potassium, NIS: Sodium (Na) Iodine (I) Symporter, Tg: 
Thyroglobulin, TPO: Thyroid Peroxidase, TSH: Thyroid Stimulating Hormone. 
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iodothyrosine residues and stored in the colloid until they are needed. Iodine 
accumulation in the thyroid in contrast to other tissues is stimulated by thyroid 
stimulating hormone (TSH) (Dohan et at, 2(03). This organification is the key to 
the success of radioiodine therapy in thyroid cancer. 
5.3. hNIS in extra-thyroidal tissues 
Scintigraphic studies have demonstrated that iodine is also accumulated in tissues 
other than the thyroid. Iodine concentrating extra-thyroidal tissues include: the 
salivary and lacrimal glands, the gastric mucosa, the lactating mammary gland, the 
choroid plexus, the thymus, the adrenal gland, the lung, the heart and the ciliary 
body of the eye (Dohan et at, 2003). Iodine uptake in these tissues is also inhibited 
by thyocianate and perchlorate and iodine concentration gradients of the same 
magnitude are generated (Dohan et aI., 2(03). In contrast to the thyroid, non-
thyroidal tissues lack the ability to organify iodine and TSH does not influence 
iodine uptake in the cells. Gastric mucosa and salivary glands concentrate 
thiocyanate in contrast to the thyroid where it is metabolised and eliminated after 
uptake (Dohan et aI., 2003). 
The isolation of NIS and the production of monoclonal antibodies have permitted 
investigators to study the distribution of NIS in tissues. Surprisingly, iodine uptake 
appears to be mediated by the same NIS, which is regulated and processed 
differently in each tissue (Dohan et aI., 2003). 
Radioiodine and iodine analogues used for thyroid scintigraphy continue to play an 
important diagnostic and therapeutic role in thyroid disease and thyroid cancer. The 
recent discovery of hNIS has permitted the investigation of new strategies that 
extend the use of iodine therapy through the ectopic expression of hNIS in the cell 
membranes of cancer cells with the use of gene delivery vectors. Ectopic 
expression of hNIS in cancer cells allows the entry of iodine in these cells and 
renders them susceptible to radioiodine therapy. Specific targeting of the hNIS 
gene to malignant cells can be achieved by the use of tissue-specific promoters 
thereby maximising cancer specific therapeutic effect and minimising toxic side 
effects in non-malignant cells (Dohan et aI .. 2(03). 
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5.4. hNIS and molecular imaging 
The hNIS is a unique imaging tool for cancer gene therapy. 
The hNIS is not a foreign protein since it is expressed endogenously in the thyroid 
and several other tissues and is thus not immunogenic. The endogenous expression 
is limited to a small number of tissues, which results in limited background 
interference for exogenous hNIS function. Iodine and other chemical elements (e.g. 
T 99m Rh . 188 A . 211 . C , enlum , statIn ) transported by the hNIS are m themselves the tracers 
and radiochemistry is therefore not required, which offers significant logistic and 
cost-effective advantages. Decaying isotope does not produce cold tracers (which 
could compete with the radio tracer) but disappears rapidly from the circulation. 
The radionuclides are specific to hNIS-expressing cells, which further reduces 
unwanted background noise (Vassaux and Groot-Wassink, 2003) (Marsee et aI., 
2004). Radioisotopes transported by hNIS are available for in vivo imaging by both 
PET and SPECT. 
Shimura et aI. (Shimura et aI., 1997) performed the first imaging experiment with 
NIS. Undifferentiated rat thyroid cancer cells were stably transfected with the NIS 
gene and transplanted into rats. 1251 was injected intraperitoneally and radioiodine 
accumulation was visualised by autoradiography. Iodine uptake in the tumours 
peaked 90 minutes after injection and diminished rapidly attaining 50% after 6 
hours. Following this first experiment a large number of in vivo preclinical animal 
experiments have been performed using the same principles. 
In our laboratory, Thomas Groot-Wassink has performed adenoviral biodistribution 
studies in nude mice using hNIS as a reporter gene (Groot-Wassink et aI., 2002). 
Intravenous injection of a non-replicating Ad-CMV -hNIS construct and subsequent 
(after 48h) injection of 1251 lead to the accumulation of radioactivity, measured by 
post mortem y-counting of organs, mainly in the liver and the adrenal glands and to 
a lesser extent in the lungs, spleen and pancreas. These data were confirmed by 
Northern blot analysis of total hNIS RNA. In vivo imaging of gene expression was 
obtained with PET after injection of 1241. 
In a second experiment, it was demonstrated that the combination of 1241 and PET 
can provide quantitative information on gene expression in vivo (Groot-Wassink et 
al.. 2004b). They found a correlation between the intensity of the PET signal and 
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iodine uptake measured by post mortem y-counting and between the PET signal 
and hNIS mRNA amount determined by quantitative real time PCR and the 
number of hNIS positive cells seen by immunohistochemistry using an hNIS 
specific antibody. These data validate the iodine uptake induced by ectopic 
expression of hNIS as a quantitative reporter system to evaluate gene expression. 
They also assessed the feasibility of using the hNIS reporter gene to visualise 
cancer selectivity of different promoters incorporated in non-replicating adenoviral 
vectors with 124I1PET imaging (Groot-Wassink et aI., 2004a). Intravenous injection 
of a non-replicating adenoviral vector encoding the human telomerase promoters 
(Ad-hTR-NIS and AdhTERT -NIS) driving hNIS expression in tumour free animals 
does not yield a signal with 124I1PET imaging suggesting that the promoters are not 
functional in normal tissues infect able by adenovirus. This conclusion was 
confrrmed by post mortem y-counting of tissues, immunohistochemistry and 
quantification of hNIS mRNA levels. When injected in subcutaneous experimental 
human tumours in nude mice, the Ad-hTR-hNIS virus injected tumours showed 
increased iodine uptake as measured by quantitative analysis of PET images and 
post mortem radioactive counting compared to tumours injected with a control 
virus and similar to Ad-CMV -hNIS injected tumours, suggesting that the hTR 
promoter is a potent cancer-specific promoter. 
Altogether these data suggest that PET imaging of the hNIS reporter gene could be 
applied to measure the activity of cancer-selective promoters in humans, providing 
unique information on the pattern of gene transfer and transgene expression in 
patients (Groot-Wassink et al., 2004a). 
6. Combining imaging with therapy 
The hNIS is not only an imaging reporter gene. The extensive experience in the 
treatment of thyroid cancer provides sufficient evidence that the hNIS can also 
serve as a therapeutic transgene. 
The vectors that are currently available for cancer gene therapy have, so far, failed 
to transduce every single cell in a tumour. In mouse experiments intratumoural 
injection of a NIS-expressing adenovirus showed heterogeneity of expression, with 
areas of high level expression adjacent to regions of low expression (Groot-
Wassink et al.. 2004a). 
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The combination of hNIS as a transgene with the use of radioisotopes has the 
advantage that non-transduced cells can still be eradicated by the bystander effect 
caused by the radioactivity. 1311 and other isotopes transported by NIS like 188Re_ 
perrhenate and 211 At (astatin) kill non-transduced cells by radiation emission. These 
radioisotopes are used in clinical settings in the treatment of patients and the 
technology and experience are readily available. 
Dwyer et ai. (Dwyer et aI., 2005a, Dwyer et aI., 2005b, Dwyer et aI., 2006b, Dwyer 
et aI., 2006a) have extensively investigated the possibility of adenoviraI hNIS gene 
transfer, imaging and therapy in ovarian, breast and pancreatic cancer in preclinical 
mice models. Intravenous injection of a non-replicating adenovirus where a tumour 
specific promoter (MUC-l) drives the expression of hNIS did not yield an imaging 
signal or liver toxicity in comparison to the control virus where hNIS was driven 
by the CMV promoter demonstrating cancer-selective expression of the virus. 
Repetitive imaging with a gammacamera after injection of the virus in 
subcutaneous xenografts in nude mice allowed the investigators to determine the 
time of maximal iodine uptake. Treating the mice with 1311 showed a marked 
reduction in tumour size. 
The same authors have also carried out a study in large animals in preparation of a 
phase 1 clinical trial of prostate cancer using a non-replicating Ad-CMV -hNIS 
(Dwyer et aI., 2005c). The viral vector was injected directly into the prostate of 
male dogs. Serial imaging with SPECT ICT allowed the investigators to visualise 
transgene expression and to predict the dose of 1311 required to obtain a therapeutic 
effect. The dogs did not show side effects to other organs from the administered 
therapy. All these experiments were carried out with a non-replicating adenoviral 
vector. 
One of the most promising results for hNIS gene therapy was obtained by Faivre et 
ai. (Faivre et aI., 2004). They have created an animal model of liver cancer. Hepatic 
carcinomas were induced in immunocompetent Wistar rats by diethylnitrosamine 
administration in the drinking water. The adenoviral non-replicating CMV -rNIS 
vector was administered directly into the portal vein. Pretreating the rats with 
thyroxine inhibited thyroid uptake of iodine. They found a long-term retention of 
iodine in normal and cancerous liver (572 + 110% hours and 294 ± 50% hours) 
after transfer of the rNIS gene, which was mainly attributable to recirculation and 
reuptake in the transduced liver cells. Iodine was cleared rapidly from the 
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hepatocytes when NIS activity was blocked by perchlorate. They also showed that 
tumour growth was strongly inhibited and survival improved by 131 I therapy 
(40Gy) after rNIS gene transfer in hepatocarcinoma bearing rats. In some cases 
complete regression could be obtained. The authors did not observe any 131 I related 
liver damage in 2 months follow up in Wistar rats despite the high radiation dose 
suggesting that liver carcinoma cells are more sensitive to radiation than normal 
hepatocytes. These results suggest that intra-arterial NIS based gene therapy for 
hepatocellular carcinoma is an approach worth investigating in humans. 
7. Research strategy 
Richard Iggo has created a series of Wnt-specific replicating adenoviruses 
containing multiple Tcf binding sites in several adenoviral promoters (Fuerer and 
Iggo, 2002, Fuerer and Iggo, 2004, Homicsko et al., 2005). These viruses were 
evaluated in a series of in vitro experiments by Richard Iggo' s team. I received an 
aliquot of the plasmid vpKHl, encoding the Wnt-specific adenovirus KH 1 
containing Tcf binding sites in ElA, ElB and E4. I also received an aliquot of 
pMB20, encoding the wild-type adenovirus 5 genome. I incorporated the hNIS 
gene into these viruses. In order to accommodate such a large gene, space had to be 
created by deleting the E3-6.7k gene and E3-gpl9k gene, which has been shown to 
result in enhanced intratumoural gene expression and/or replication in 
immunocompetent tumour models when compared to the commonly deleted E3B 
genes (Wang et aI., 2003b). Replacing the E3-gpl9k with the hNIS resulted in 
viruses with 105% of the wild type genome size, which still allowed adequate 
packaging into virions. It was decided to use the yeast vector system for 
manipulation of the adenoviral genome following the experience of my supervisor 
with this technique (Vassaux et aI., 1997) (Vassaux and Huxley, 1997). 
Firstly, the constructed viruses were validated in vitro in different colonic cancer 
cell lines and in primary cultures of desmoid tumours. 
Secondly, the imaging of the propagation of virus inside a tumour in \'IVO was 
validated in subcutaneous xenografts in nude mice. 
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Finally, I explored the therapeutic potential of the hNIS by combining imaging 
with therapeutic radioiodine therapy in vivo in nude mice. 
Figure 1.11 shows a diagram of the constructed viruses. 
Figure 1.11: Overview of created viruses. AdWt :::: wild-type adenovirus, AdlP 1 :::: Wild-type 
adenovirus with hNIS replacing E3-6.7k and E3-gp19k, AdIP2 :::: Wnt-specific virus with Tcf-
responsive elements driving the expression of EIA, EIB and E4 and hNIS replacing E3-6.7k and 
E3-gpI9k, AdIP3 :::: wild-type adenovirus with and mUltiple cloning site (MCS) replacing E3-6.7k 
and E3-gp19k, AdlP4:::: Wnt specific adenovirus with Tcf-responsive elements driving expre Ion 
of E 1 A, E 1 Band E4 and MCS replacing E3-6.7k and E3-gp 19k. 
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CHAPTER 2: Materials and Methods 
1. Molecular Biology techniques 
1.1. Standard peR 
Polymerase chain reaction was used to amplify the desired sequences of the 
adenoviral genome which were needed for the construction of shuttle vectors. The 
strategy for the construction of shuttle vectors can be found in the figure below. 
Our aim is to replace the adenoviral E3-6.7k and E3-gp19k with hNIS. 
Figure2.1: A. Representation of the early transcripts of the adenoviral genome. 
ITR=Inverted Terminal Repeat. 'P=packaging signal. B. Detailed representation of 
the transcripts of the adenovirus E3 region. 6.7k and gp19k overlap with 3bp. C. The 
cloning strategy aims at replacing the adenoviral overlapping regions E3-6.7k and 
E3-gp 19k by hNIS. 
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Each peR was optimized with the Opti-Prime™ peR Optimization Kit 
(Stratagene, UK). peR reactions were set up in 50J-l1 volume containing lOng 
template DNA, IJ-l1 Master Mix Buffer (obtained from the Opti-Prime™ Kit), 1 mM 
dNTP' , Forward and Reverse primer (provided by Sigma-Geno i ) at a final 
concentration of 0.5 J-lM, 3U Taq DNA polymera e (Roche Diagno tic) and one of 
each of the 12 Opt i-Prime ™ buffer provided by the Opti-Prime ™ Kit. A c ntr 1 
lacking DNA was run in parallel. PCR was performed m a PTC-200 Peltier 
Thermal Cycler (MJ Research). 
The PCR products were confmned by electrophoresis analysis (see below) on a 
0.8% agarose gel (Invitrogen, Paisley, UK) and the Opti-Prime™ buffer leading to 
the best product was selected for future PCR reactions. 
The hNIS cDNA was provided by S.Jiang (Smanik et ai., 1996) and hNIS was 
cloned into a pShuttle based vector by Thomas Groot-Wassink (Groot-Wassink et 
aI., 2002) to obtain the plasmid pTGW10. This vector was used as the source for 
hNIS (nt 220-2151) amplification by PCR. A map of this vector can be found in the 
appendix. Primers used were: 
Forward: Xba1-hNIS: CTCT AGAGATGGAGGCCGTGGAGACCGGGGAACGG 
and 
Reverse: Xho 1-hNIS: CCTCGAGGTCAGAGGTTTGTCTCCTGCTGGTCTCG. 
The use of these primers introduced engineered restriction sites XballXho 1 into the 
PCR product to facilitate further sub-cloning into a shuttle vector. 
The settings were 5' at 94°C, 26 cycles: l' at 94°C, l' at 55°C, and 2' at 72 ° C and 
10' at 72 ° C to finish. 
The adenoviral regions E3-12.5k and E3-ADP were obtained and amplified by 
PCR from the plasmid MB20, a generous gift from Richard Iggo (St. Andrews 
University, Scotland). This plasmid contains the entire wild-type adenovirus-5 
genome, a Chloramphenicol resistance gene, and a Histamine gene. 
The reaction was optimized with the Opti-Prime PCR Optimization Kit 
(Stratagene, UK) according to the manufacturer's guidelines (see above). 
Primers for the E3-12.5k gene (nt27801-28533) were: Forward: SacII-12.5k: 
GCCGCGGCGATCAATTTATTCCTAACTTTGACGCand 
Reverse: Xba 1-12.5k: CTCT AGAGCTGCGCCTTTGGCCT AAT AC introducing 
engineered restriction sites SacII and Xbal respectively. 
The conditions used were: 5' at 94°C, 26 cycles of: 45" at 94°C, 45" at 58°C. I' at 
72°C and 10' at 72°C to finish. 
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The nucleotide sequence spanning E3-ADP (nt29355-29755) was amplified using 
Xho 1lKpn1-engineered primers. 
Xho 1-ADP: Forward: CCTCGAGGCAA TTGACTCT ATGTGGGAT ATGCTCC 
and 
Kpn1-ADP: Reverse: GGGT ACCCGAACATGTGTTTCAGTCCGTCCAA TC. 
The conditions used were: 5' at 94°C, 26 cycles of: 45" at 94°C, 45" at 58°C, 45" 
at 72°C and 10' at 72°C to finish. 
(Nucleotide numbers refer to the sequence location within the Ad5 genome and 
hNIS genome which can be consulted on the NCBI website: 
http://www.ncbi.nlm.nih.gov/entrezaccessionnumberforAd5isAC_OOOOO8.gi: 
56160529 and for hNIS is 087920, version 087920.1, gi: 2887404) 
1.2. Analysis by Agarose Gel Electrophoresis 
Gel Electrophoresis was used to confirm successful PCR, cloning and ligation. 
10 III of PCR product or restriction-digest was run on a 0.8%-1 % (w/v) agarose gel 
[0.8g-1g agarose in 100mI Ix Tris-Borate-EDTA (TBE) buffer with 10111 ethidium 
bromide (EtBr) at 0.5Ilg/ml] @ 160V in a tank containing 1 x TBE buffer. Samples 
were run alongside a lkb ONA stepladder (lnvitrogen™). Visualisation under UV 
light ensured that the PCR products were the expected size and of sufficient quality 
(buffer selection). 
1.3. Cloning 
1.3.1. Cloning of PCR products 
The selected PCR product, obtained from the hNIS amplification, was cloned into a 
commercial plasmid pcONA3.1N5-His© -TOPO® (Invitrogen TM, USA) (see 
appendix) with the TOPO-T A Cloning® kit (Invitrogen, USA) according to the 
manufacturers' protocol and plated on Luria-Bertani (LB) agar plates [LB broth 
supplemented with 1.5% (w/v) agar] (Cancer Research UK Research Services) 
containing Ampicillin at a concentration of 60llglml LB agar. 
66 
The selected PCR products of E3-12.5k and E3-ADP were cloned into a 
commercial plasmid pCR@T7/CT-TOPO (lnvitrogen™, USA) (see appendix) with 
a TOPO-T A@ Cloning Kit and plated on LB agar plates containing Ampicillin at a 
concentration of 60J..lg/ml LB agar. 
Plasmids thus obtained were called pIP1 (E3-12.5k-TOPO), pIP2 (E3-ADP-TOPO) 
and pIP3 (hNIS-TOPO). 
1.3.2 Sub-cloning by restriction digestion 
Consequently, the hNIS, E3-12.5k and E3-ADP were sub-cloned into the multi-
cloning site (MCS) of plasmid pGV1, a URA3 [Orotidine-5' -phosphate (OMP) 
decarboxylase] integrating shuttle vector, donated by Dr. Georges Vassaux, my 
supervisor. This vector sequence is based on pRS406 (NCBI Accession U03446, 
gi: 416317), in which the HindIII site within the MCS has been inactivated. The 
map of pGV 1 can be found in the appendix. 
The E3-12.5k was cloned in the MCS of pG V 1 by parallel Sac II and XbaI 
restriction-digestion of pIPl and pGVl. The plasmid obtained was called pIP4. The 
E3-ADP was subcloned into pIP4 by parallel restriction digestion of pIP2 and pIP4 
with XhoI and Kpnl. The plasmid obtained was called pIP5. hNIS was cloned into 
pIP5 by parallel restriction-digestion of pIP3 with EcoRV and XbaI and of pIPS 
with SmaI and Xbal. Digestion with SmaI and EcoRV enzymes leads to blunt ends, 
which can be joined with T4 Ligase. The restriction sites SmaI and EcoRV in the 
resulting construct however are lost for further use in later screening experiments. 
The resulting plasmid was called pIP7 (map below). 
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Figu~e2.2:. map. of plasmid plP7 obtained by sub-cloning of regions 12.5k, hNIS and ADP into the 
multi clonmg site (MCS) of plasmid pGV I. 
pIP7 Shuttle 
NotI 
XhoI NacJ 
Xbal XhoI· EcoRV 
EcoRI Sail Sacll .. 
TJ promoter T7 promoter 
Restriction enzymes and T4 Ligase were purchased from New England Biolab ®, 
Hitchin, UK and reactions carried out in buffers supplied by the manufacturer. 
Restriction enzyme digestions were set up in 20JlI volumes. Sample were dige ted 
with 2.5U of required restriction enzyme(s) in lOx buffer. 
lJlg of backbone DNA was digested at the same time as 5Jlg of the pIa mid 
containing the relevant insert. 
Digestion was carried out for 2 hours in a warm water bath at 37°C. 
Nucleotides were removed using a nucleotide removal kit (Qiagen, Crawley, U.K.) 
in accordance with the manufacturer's instructions and the DNA wa dige ted with 
the second enzyme if appropriate. 
The digestions were run on a 0.8% agarose (Invitrogen, Paisley, UK) gel and the 
bands required for further ligation steps were exci ed with a clean calpel under the 
guidance of ultraviolet light illumination in the dark room. The DNA wa purified 
from the gel with a QIAquick® Gel Extraction kit (Qiagen®) according t th 
manufacturer ' instruction . 
1.3.3. Alkaline Phosphatase treatment 
The dige ted ba kb ne pIa mid DNA wa m difi d y tn u ati n 
Alkalin Ph phata (SAP) (USB. Ohi ,USA in 1 x uffer. 
hrim 
SAP removes S' phosphates from plasmid and bacteriophage vectors that have been 
cut with a restriction enzyme. In subsequent ligation reactions, this treatment 
prevents self-ligation of the vector and thereby greatly facilitates ligation of other 
DNA fragments into the vector. 
Reactions were set up in 20J.11 reaction volumes and incubated at 3-r>C for 15 
minutes before further incubation at 6SoC for IS minutes in order to denature the 
modifying enzyme. Reactions were allowed to cool to room temperature before 
setting up ligation reactions. 
1.3.4. DNA ligation 
Ligation reactions were set up in 2SJ.11 volumes using 2U T4 DNA Ligase, 2.5 ~l 
lOx T4 Ligase buffer with differential ratio's of backbone to insert. 3~1 of the 
dephosphorylated backbone and 17~1 or SJ.11 of insert respectively were ligated 
together. Controls included unmodified backbone - no insert, dephosphorylated 
backbone - no insert and no backbone - insert only. Ligation reactions were 
incubated overnight at 16°C in a PTC-200 Peltier Thermal Cycler (MJ Research). 
1.4. Generation of chemically competent bacteria 
DH lOB E. Coli bacteria were made competent by CaCb treatment by usmg a 
variation of the method of Cohen et aI. (Cohen et aI., 1972). 
Glycerol stocks of DHIOB available in the laboratory were streaked onto Luria-
Bertani (LB) agar [LB broth supplemented with 1.5% (w/v) agar] (Cancer 
Research UK Research Services) plates. The following day a single colony was 
picked and inoculated into 5rnl of LB [1 % (w/v) tryptone, O.S% (w/v) yeast extract 
and 1 % sodium chloride] broth and grown over night in a 50rnl falcon tube at 37°C. 
The following day the culture was added to loomi of LB broth in a 11 flask and the 
bacteria were incubated at 37°C with vigorous shaking (300 cycles/minute in a 
rotary shaker) until a density of 108 bacteria/ml was reached. The cultured cells 
were then transferred into sterile 50ml ice-cold Falcon tubes and cooled to OOC by 
placing the tubes on ice for 10 min. The bacteria were then recovered by 
centrifugation at 4oo0rpm for 10 minutes at ..t.°C. Supernatant was discarded and 
each bacterial pellet was then gently resuspended in IOml of ice cold O. 1M CaCh 
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and stored on ice. Cells were recovered by centrifugation at 4000 rpm for 10 min at 
4°C. After discarding the supernatant each pellet corresponding to 50ml original 
culture was resuspended in 2ml of O.IM CaCho 200fli of the suspension of 
competent cells was added to a 1.5ml sterile Eppendorf tube ready for 
transformation. Long-term stocks were made by storing aliquots of 200fll of 
bacteria in a 20% (w/v) glycerol solution at -800C. 
1.5. Chemical transformation into competent bacteria 
5 fll of the overnight ligation reactions was used to transform one aliquot of 
competent DHI0B. DNA-extracts (method described below) obtained from the 
colonies selected after TOPO-cloning (no more than 50ng DNA in a volume of 
10fll or less) were also added to 200fll of competent cells. The contents of the tube 
were mixed and stored on ice for 30 minutes. The tubes were then transferred to a 
rack and placed in a water bath preheated to 42°C for exactly 90 seconds. 
Thereafter the tubes were rapidly transferred on ice and allowed to chill for 1-2 
minutes. 800fll of LB broth was then added and the bacteria were allowed to 
recover in a water bath at 37°C for 45 minutes. 200fll of transformed cells were 
then transferred to an LB agar plate containing the appropriate antibiotic and 
incubated over night at 37°C. 
1.6. Extraction of DNA from bacteria 
Colonies were chosen from the agar plates and added to 5ml LB containing the 
appropriate antibiotic selectable marker. After overnight incubation at 37°C in a 
shaking incubator the bacterial cultures were harvested by centrifugation at 13,000 
rpm and plasmid DNA purified from the pellet by standard protocol, usmg a 
QIAprep® Spin Miniprep Kit (Qiagen®). 
Constructs that were selected were inoculated In larger volumes of antibiotic 
selective LB and grown over night. A QIAprep@ Maxiprep Kit was used to purify 
these larger amounts of plasmid DNA according to the manufacturer's instructions. 
DNA concentrations of successful constructs were determined using a i\anodropCK) 
I . Inc S I ND-lOOO photospectophotometer (NanoDrop Teeno ogles). amp es were 
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assessed at 260nm versus a blank control of the elution buffer and DNA 
concentration was calculated from the formula: DNA concentration = OD260nm x 
50Jlg/ml. 
1.7. Glycerol stocks of bacterial plasmids 
Long-term stocks of bacterial plasmids were made and stored at -800C. A fresh 
colony was picked and incubated over night in 5ml of LB broth containing the 
appropriate antibiotic. The following morning 800Jll of LB broth containing the 
bacterial plasmids at the appropriate density (approximately 108 bacteria Iml) was 
mixed with 400JlI of 50% glycerol in water to obtain a final concentration of 20ge 
glycerol and stored in cryovial tubes at -800C until required. 
1.8. Sequencing and analysis of colonies 
The Cancer Research UK sequencing service was used to screen the DNA extracts 
from selected colonies after cloning and transformation of E3-12.5k and E3-ADP 
into TOPO cloning vectors. The primers used were T7 SeqlInvitrogen: Forward: 
TAATACGACTCACTATAGGG and V5 (Rev) SeqlInvitrogen: Reverse: 
ACCGAGGAGAGGGTTAGGGAT. The desired DNA sequence was selected by 
comparing each clone with the original DNA sequence by BLAST analysis using 
the DNA Strider™ 1.3ftl computer program. 
Analysis of hNIS clones was not performed by sequencing. The DNA extracts from 
the colonies obtained from the hNIS-TOPO cloning reaction were transfected into 
293 cells. After 24h an Iodine Uptake assay was performed and the most functional 
clone was selected (See in vitro manipulations below for further details). 
1.9. Homologous recombination in yeast 
Adenoviral genomes were modified by two-step homologous recombination III 
yeast (Gagnebin et aI., 1999). 
Co-transformation of the relevant URA3 integrating shuttk vector anJ the 
adenoviral genome into the yeast resulted in the first part of the gene replacement 
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event, called "pop-in". These intermediate constructs contain a duplication of the 
target sequence (figure 3.1). 
Removal of the selective requirement for URA3 resulted in a second spontaneous 
recombination event called "pop-out", which excised the integrated vector. 
Recombinants which had lost the URA3 integrating vector were selected on -HIS 
plates (Q-Bio-Gene, U.K.) supplemented with 5-Fluoro-orotic acid (5-FOA) at 
0.1 % (w/v). 5-FOA is converted into a toxic metabolite 5' -FLuoro-Uracil (5-FU) 
by the URA3 gene product (orotidine-5' -phosphate decarboxylase). 
1.9.1. Transformation in yeast 
The shuttle vector was co-transformed into yeast with plasmids pMB20 or vpKHl 
(both generous gifts from Richard Iggo, St. Andrews University). The pMB20 has 
been described earlier. The vpKH 1 plasmid is similar to the pMB20 but contains a 
Wnt-specific adenoviral genome instead of the wild-type Ad5 genome. Tcf-4 
binding sites are present in E1A, E1B and E4 of the viral genome (for complete 
description see (Homicsko et aI., 2005)). 
In a first step Saccharomyces cerevisiae YPH587 (ATCC 76628): genotype MAT 
alpha ura-3-S2 lys2-801 ade2-101 trp1-~200 leu2~1, provided by Richard Iggo (St. 
Andrews University, Scotland), was transformed with pMB20-Wild type Ad5 or 
vpKHl respectively using the Alkali-Cation Yeast transformation Kit (Q-Bio-
Gene, UK) following manufacturers' instructions. 
A fresh single colony of YPH587 was picked from YPD (YPD supplemented with 
1.7% agar) agar plates (Q-Bio-Gene, UK) and inoculated into l00mI YPD l2 cIr 
(w/v) peptone-Y, 1 % (w/v) yeast extract and 2% (w/v) dextrose] broth (Q-Bio-
Gene) and grown with aeration at 30°C for 12-24 hours. At the same time pMB20 
or vpKH 1 were linearised by Pac 1 restriction digestion over night. 2J.1g of plasmid 
DNA was digested in a final volume of 20J.11 at 37°C. Digestion was followed by an 
enzyme denaturing step at 6SoC for lSmin. Yeast cells were made competent by 
treatment with Lithium/Cesium Acetate Solution, according to the manufacturer's 
protocol. Transformation reactions were set up using four different concentrations 
of DNA from 0.1 J.1g to 1 J.1g in a maximum volume of 10J.1l. ON A was comhined 
with 5J.11 carrier DNA and 5J.11 Histamine Solution (provided by the manufacturer) 
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and mixed gently with lOO~1 of competent yeast cells. Transformation was 
performed by heat shock at 42°C for 10 minutes. Cells were plated onto synthetic 
defined dropout media, -HIS [0.17% (w/v) yeast nitrogen base, 0.5% (w/v) 
ammonium sulphate and 2% (w/v) dextrose supplemented with 1.7% agar] agar 
plates and incubated at 30°C for 48-72 hours, until colonies appeared. 
In a second step, a fresh colony of y-MB20 or yKHI was picked and inoculated 
into 100ml-HIS broth (Q-Bio-Gene) and incubated for 12-24 hours at 300 C with 
aeration. At the same time the relevant shuttle vector pIP5/pIP7 was linearised by 
Not1 restriction digestion over night. 2J.lg of plasmid DNA was digested in a final 
volume of 20~1 at 37°C. Digestion was followed by an enzyme denaturing step at 
65°C for 15min. Yeast cells were transformed the following day using the Alkali-
Cation Yeast Transformation kit (Q-Bio-Gene) as described above. Transformation 
reactions were set up as described above. Transformation was performed by heat 
shock at 42°C for 10min. Cells were plated onto synthetic dropout media -HIS -
URA [0.17% (w/v) yeast nitrogen base, 0.5% (w/v) ammonium sulphate and 2% 
dextrose supplemented with 1.7% (w/v) agar] agar plates and incubated at 30°C for 
48-72 hours, until colonies appeared. 
The yeast resulting from co-transfection of pMB20 and pIP7 was called yiP 1. 
The same reaction was repeated to transform vpKHl and pIP7 into YH587 and the 
resulting yeast was called yIP2. Co-transfection of pMB20 and plP5 was called 
yIP5 and co-transfection of vpKH 1 and pIP5 was called yIP6. 
1.9.2. Yeast DNA extraction 
Yeast DNA was extracted from overnight cultures following enzymatic digestion 
of the cell wall resulting in spheroplast formation. 
After transformation colonies were selected from the plates and grown in 10ml of 
selective media (provided by Q-Bio-Gene, UK) at 30°C over night. Each colony 
selected was recorded and numbered on a reference plate of the same media. 
The next day the yeast cells were spun down at 7500rpm for 5 to 10 minutes. The 
supernatant was discarded and the pellets washed with 20ml of YI solution [250ml 
of 2M sorbitol (final concentration 1 M), lOOml 0.5M ethylenediaminetetraacetic 
acid (EDT A) (final concentration 0.1 M) supplemented with dH20 to 500ml]. After 
10 minutes centrifugation at 7500rpm. the supernatant was discarded and the cells 
73 
spheroplasted by enzymatic digestion in 500fll yeast lytic enzyme solution (YI 
solution containing 2mglml of yeast lytic enzyme and 0.1 % p-mercapto-ethanol for 
60 minutes at 30°C. After 1 hour of incubation the spheroplasting process was 
observed under a microscope as cell lysis on addition of 1 drop of 10% Sodium 
Oodecyl Sulphate (SOS). Sferoplasts were pelleted by centrifugation for 5 minutes 
at 7500rpm and resuspended in 300fll of TE pH8 containing RNAse (50flVrnl) and 
transferred to an eppendorf tube. Sferoplasts were then lysed by adding 30fll of 
10% SOS to each tube and incubated for 1 hour at 65°C. Proteins, genomic DNA 
and debris were precipitated by adding IOOfll of 5M potassium acetate 
(CH3COOK) followed by centrifugation at maximum speed for 30 minutes at 4°C. 
The supernatant was transferred to a new tube and an equal volume of room 
temperature isopropanol (CH3CHOH) added. The DNA was recovered by spinning 
the tubes at maximum speed for 15 minutes at 4°C. The DNA pellet was gently 
washed with 1 ml of room temperature 70% ethanol (EtOH) and re-spun for 10 
minutes at 4°C maximum speed. The DNA was air-dried and resuspended in a 
suitable volume of distilled water. ONA concentrations were determined using a 
NanoOrop® NO-I000 spectrophotometer (NanoDrop Technologies Inc). 
1.9.3. Generation of electrically competent bacteria 
One colony of OH lOB EColi bacteria was picked from a freshly grown LB plate 
and inoculated into 10rnl of LB broth and grown over night in a 50ml Falcon tube. 
The following morning 2rnl of the starter culture was added to 400rnl of LB broth 
and transferred to a 21 flask. The cells were grown with gentle shaking at 37°C for 
2.5-5 hours until the optical density at 550nm reached 0.8. The cell suspension was 
divided into 8 x 50rnl disposable plastic tubes and left on ice for I hour, after which 
the cell pellets were recovered by centrifugation at 3000rpm for 10 min at -f°C. The 
supernatant was removed and four pellets were collected and transferred to a single 
50rnl Falcon tube, resuspended in 50ml of ice-cold WB [10% (w/v) ultrapure 
glycerol and 90% distilled water] solution. Subsequently both tubes were 
centrifuged at 3000rpm for 30min at 4°C, the supernatant removed and the cells 
resuspended in 50ml WB. This centrifugation was repeated and then each pellet 
was resuspended in 10ml WB and both pellets were pooled into one tube. Cells 
were kept on ice as much as possible. In a final centrifugation step at 3000rpm for 
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10min at 4°C the pellet of competent cells was recovered, the supernatant removed 
and the cells resuspended in 1.5ml of WB solution. 50lll of bacteria was used for 
each transformation reaction. The remaining bacteria were divided in 50lll aliquots 
in eppendorf tubes and stored at -800C until required. 
1.9.4. Transformation of electrically competent E.Coli with yeast DNA 
One tube of 50J,l1 electrically competent bacteria was thawed on ice and up to 5111 of 
yeast DNA extract was added. The mixture was transferred to a pre-chilled 2mm 
electroporation cuvette (Thermo Scientific) and electroporated using a BioRad 
GenePulser®n Electroporator, under the following conditions; 2.5kV, 200(2. 251lF. 
The electroporated bacteria were resuspended with 450111 of LB broth and 
incubated at 37°C for 30 minutes. 50111 - 100111 and 350111 of bacteria were plated 
onto LB agar plates containing the relevant antibiotic and incubated over night at 
37°C with aeration. The efficiency of home made electrically competent bacteria 
was inconsistent and therefore the yeast DNA extracts were predominantly 
transformed into commercially available electro-competent DHIOB E.Coli bacteria 
(ElectroMAX™, Invitrogen) according to the manufacturer's instructions to 
facilitate further PCR screening and confrrmation by restriction digestion 
fingerprinting. No more than loong of DNA in a final volume of llli was used to 
transform competent cells by electroporation using a BioRad GenePulser®II 
Electroporator, under the following conditions; 2.0kV, 200(1, 251lF. Cells were 
resuscitated in 1 ml SOC (Invitrogen TM) medium at 37°C for 1 hour. loolll of this 
suspension was plated onto LB agar plates containing Chloramphenicol (ChI) 
(25J,lg/ml) and incubated overnight at 37°C with aeration. 
1.9.5. DNA extraction for BAC low copy plasmids 
Colonies selected from plates were grown over night in 5-10ml of LB containing 
the appropriate antibiotic at 37°C. DNA was extracted according to a modified 
miniprep protocol (Qiagen@), which included a second alkaline lysis step to 
eliminate bacterial chromosomal DNA. 
The next morning, the bacteria were spun down at 5000rpm for 10 minutes at room 
temperature. The supernatant was discarded and the pellet re-suspended in 300~.tl of 
PI supplenlented with 50llg/ml RNAse A and transferred to a 1.5ml eppendorf tube 
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(PI, P2 and P3 were home made according to the recipe found in the Qiagen® 
MaxiPrep Kit handbook and autoc1aved). 300fll of normal alkaline lysis reagent P2 
was then added to the solution, the tube inverted 4-6 times and incubated at room 
temperature for 5 minutes. 300fll of pre-chilled alkaline lysis reagent P3 was then 
added and the solution incubated on ice for 30 minutes. The tubes were centrifuged 
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at maximum speed in a refrigerated Eppendorf tabletop centrifuge for 10 minutes at 
4°C. The supernatant was collected, transferred to a 2ml eppendorf tube and an 
equal volume of room temperature isopropanol was added. The tubes were then 
centrifuged for 10 minutes at maximum speed at room temperature. The 
supernatant was removed; the pellet resuspended gently in 50fll of distilled water 
and transferred to a sterile 1.5 ml eppendorf tube. 200fll of room temperature 70l7c 
ethanol was added and the tube was centrifuged at room temperature at maximum 
speed for 10 minutes. The supernatant was then discarded and the pe llet re-
suspended in 30 fll of Elution Buffer (EB) (obtained from Qiagen® miniprep kit). 
1.9.6. Screening of constructs 
The DNA extracts from the pop-in constructs were screened by analysing their 
restriction digestion fingerprint profile when compared against pMB20 or vpKH 1 
and pIP5 or pIP7, following digestion with XballXhol. Successful constructs were 
prepared for large-scale DNA extraction using the Large Con MaxiPrep Kit 
(Qiagen®). 
Successful integrative recombinant yeasts or "pop-in" were inoculated from their 
reference plate into 10ml of -HIS broth and incubated for 12-24 hours at 30°C with 
aeration. Following this incubation period, lOOfll of culture was plated onto -HIS 
5-FOA plates (described above) and incubated for 48-72 hours at 30°C to select for 
"pop-out" recombinants. Individual colonies were selected, referenced on -HIS 
plates and electroporated into commercially available electro-competent 
Electromax™DH10BTM E. Coli (Invitrogen™). BAC low copy DNA was extracted 
and successful constructs selected by analysing their restriction-digestion 
fingerprint profile (see above) and by PCR. Successful constructs were prepared 
for large-scale DNA extraction using the Large Con MaxiPrep Kit (Qiagen®). 
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Table 2. 1: Names of yeast plasmids produced: The yeast plasmids, the provenance and how they 
were produced. 
Table 2.2: Names of bacterial plasmids: The bacterial plasm ids and their structure. 
Names of bacterial plasm ids 
and their DNA-extracts 
plP1 12.Sk-TOPO 
_p1P2 ADP-TOPO 
_p1P3 hNIS-TOPO 
plP4 12.Sk-GV1 
_piPS 12.Sk-ADP-GV1 
_p1P6 faulty plasmid 
QIP7 12.Sk-hNIS-MCS-ADP-GV1 
plP8 MB20+hNIS 
plP9 KH1+hNIS 
QIP10 MB20-6gp19k+MCS 
plP11 KH1-6gp19k+MCS 
Table 2.3: Primers used for cloning and screening of clones: The primers, description and sequence. 
F, Forward; R, Reverse. 
Primer DescriQtion Seguence S' -3' 
P1 ADP-Xho1 F CCTCGAGGCAATTGACTCTATGTGGGATATGCTCC 
P2 ADP-Kpn1 R GGGTACCCGAACATGTGTTTCAGTCCGTCCAATC 
P3 12.S-Sacll F GCCGCGGCGATCAATTTATTCCTAACTTTGACGC 
P4 12.S-Xba1 CTCTAGAGCTGCGCCTTTGGCCTAATAC 
PS hNIS-Forward-Xba1 CTCTAGAGATCGAGGCCGTGGAGACCGGGGAACGG 
P6 hNIS-Reverse-Xho1 CCTCGAGGTCAGAGGTTTGTCTCCTGCTGGTCTCG 
P7 NIS-screen-R AGCCTTCATGCCGCCCACAGCCGTG 
P8 T7Seq/lnvitrogen TAATACGACTCACTATAGGG 
P9 VS(Rev)Seq/lnvitrogen ACCGAGGAGAGGGTTAGGGAT 
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2. In vitro work 
2.1. Mai ntenance of Cells 
Immortalised cell lines were obtained from Cancer Research UK Research Cell 
Services Department. Primary desmoid tumour cells were obtained from St. Marks 
Hospital, London, UK (Desmoid 5.2) and UZ-Ieuven, Belgium (Oesmoid 1-5), 
with the appropriate ethical approvals. 
Cells were maintained as adherent monolayers in sterile tissue culture flasks T75 or 
T175 containing the appropriate medium (both obtained from CR-UK Research 
cells services) supplemented with 10% foetal calf serum (FCS) (Sigma-Aldrich 
Chemie, GmbH, Germany) (immortal cell lines) or 20% FCS (primary cell lines). 
All FCS was heath inactivated (HI) by placing it in a water bath for 30min at 55QC, 
unless otherwise stated. The cells were incubated at 37°C in a humidified 
atmosphere of 95% air and 5%/10% carbon dioxide (C02) to allow cell attachment 
and growth. 
When approximately 70% confluent, cells were sub-cultured. The medium was 
aspirated and the cells were washed with 12ml (for T175) of Phosphate buffered 
saline (PBS). After aspiration of PBS, cells were incubated with 3ml of 0.083% v/v 
trypsin (CR-UK Media Services) in PBS at 37°C. When the cells were detached 
from the flask, trypsin was neutralised with 15ml of the appropriate medium 
containing 10% FCS and the cells resuspended by gentle pipeting. 2.5-4ml 
(depending on cell line) of the cell suspension was then added to a sterile Tl75 
flask containing 25rn1 of growth medium supplemented with 10% FCS and the 
cells were allowed to adhere at 37°C. 
To generate long-term stocks, cell suspensIons were centrifuged after trypsin 
neutralisation at lOOOg for 5 minutes. The supernatant was removed and the pellet 
was resuspended in 2ml of freezing medium consisting of 90% FCS supplemented 
with 10% dimethyl sulphoxide (OMSO; BOH, distributed by VWR, UK) and split 
into 2 x 1 ml in cryovials (Falcon), which were frozen at -80°C over night and the 
next day transferred into liquid nitrogen for long-term storage. Vials retrieved from 
long-term storage were defrosted on ice, transferred to a 37°C water bath and then 
re-suspended in the appropriate warm growth media and plated in culture tlask~. 
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All immortal cell lines were tested at regular intervals for mycoplasma 
contamination. 
2.2. Transient transfection of DNA into CYMR293 cells 
Screening of pIP3 (CMV -bNIS-TOPO) recombinants was performed by 
transfection with recombinant DNA of CYMR 293 cells and by subsequent Iodine 
Uptake Assay. Viral production of recombinant plasmids pIP8-li was also 
performed by transfection of CYMR293 cells and was carried out in a category 2 
tissue culture lab. 
The day prior to transformation, CYMR 293 cells were plated into 24-well plates 
for plasmids containing pIP3 clones and 6-well plates for plasmids containing the 
adenoviral genome (pIP8-11). 
2.2.1 Adenoviral genomes 
Adenoviral recombinant plasmids were digested overnight with Pac 1. 10/lg of 
plasmid DNA was digested at 37°C in a final volume of 50/lg, with 2U of Pac 1 to 
release a replication-competent Ad5 genome. The following day DNA the 36kbp 
fragment was purified using phenol-chloroform-isoamyl alcohol. IOlll (2/lg DNA) 
was removed and saved in an eppendorf for later use as a non-purified transfection. 
The remaining 81lg was purified by adding an equal volume (40~.tl) of 
phenol/chloroformlisoamyl alcohol followed by centrifugation at 13,OOOrpm for 5 
minutes at room temperature. The upper layer was collected as the purified fraction 
and 21lg of purified DNA was used to trans feet one of four wells in a 6-well plate 
containing 2xl05 CYMR 293 cells/well. 2/lg of DNA was mixed with lOO/ll 
OptiMEM™ (Invitrogen Ltd, Paisley, UK) and in parallel lOO/l1 of OptiMEM was 
mixed with 6J,l1 Lipofectamine (Invitrogen). A control was set up without DNA. 
The mixtures were incubated separately at room temperature for 45min after which 
the OptimemlLipofectamine and OptimemlDN A mixtures for each well were 
combined and incubated for another 30 minutes at room temperature. Following 
this 800111 Optimem was added to each mixture and each mixture added to one well 
of CYMR293 cells that were washed with 2ml Optimem. Cells were incubated for 
4h at 37°C under standard conditions after which the OptimemlDN A mixture was 
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aspirated replaced with 2-3ml of growth medium supplemented with 10% FCS. 
Cells were incubated for 10-11 days until detachment. The culture medium 
containing virus and cells was collected and stored in a 15ml falcon tube at -80°C 
until required for further expansion of the virus. 
2.2.2. topo-vectors 
The standard protocol was adjusted as follows for the CMV -hNIS plasmids. 2J.1g 
DNA of each clone was dissolved in Optimem ™ (Invitrogen, Paisley, UK) to a 
total volume of 125J.lL In a separate tube 6J.l1 of lipofectamine (Invitrogen. Paisley. 
UK) was added to 119J.ll of Optimem for each clone. Both tubes were incubated for 
45 minutes at room temperature. Each tube containing DNA was then mixed 
together with a tube containing lipofectamine and incubated for another 30 minutes 
at room temperature. During incubation the medium was aspirated from the 24-
well plate containing CYMR 293 cells at 5xl04 cells per well and Iml ofOptimem 
was added to each well. At the end of the 30 minutes incubation 600J.lI of Optimem 
was added to each tube. The Optimem was aspirated from the cells and 200J.11 of 
the mixture DNAl1ipofectamine/Optimem was then added to each well (four wells 
for each clone) and incubated for 4 hours at 37°C. After incubation the mixture 
was aspirated and 500J.l1 of E4 (DMEM, Dulbecco' s modification of Eagle's 
medium) medium supplemented with 10% FCS was added to each well. The 
following day, the medium was changed and fresh medium added to the cells. On 
the second day after transfection (after 48h), an Iodine uptake assay was performed. 
2.3. Iodine Uptake Assay 
Iodine uptake assays were performed to demonstrate the presence of functional 
hNIS in vectors and adenoviruses. Control plasmid was pTGWIO and control virus 
was AdIO, a non replicating (EIA deleted) CMV -Ad5 virus, previously produced 
in our laboratory by Thomas Groot-Wassink (Groot-Wassink et al.. 2(02). 
Cells were seeded in 24-well plates at 5-7.5 x 104 cells per well depending on cell 
type. The following day. cells were infected with recombinant adenovirus at 
different multiplicity of infection (see below) or transfected with recombinant 
plasmids, pIP3 clones and pTGW I 0 (see above). After 24-48 hours the growth 
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medium was removed and 500J.lI of growth medium containing 1251 (10JlI of llllivi 
Nal251 in 100ml medium) (purchased from Amersham Biosciences, UK). Controls 
wells were set up by adding perchlorate, a hNIS inhibitor to the 1251 -containing 
medium (lOJ.lI of 1M Perchlorate added to 100mI 1251 -medium). The source has a 
specific activity of 740MBq/mmol. The plate containing cells and radioactive 
media was incubated at 37°C for one hour, after which the radioactive media was 
removed and the cells washed with ice-cold PBS. Cells were subsequently lysed in 
500J.lI of 0.1 % sodium dodecyl sulphate (SDS). 400JlI of each well was added to 
3.6mI of Biodegradable Counting Scintillant (BCS®, Amersham Biosciences, UK 
Ltd) and counted in a LS6500 mUltipurpose scintillation counter (Becknlan-
Coulter). The readings were normalised against background noise as measured by 
counting 4ml of scintillation (BCS®) fluid and against a sample of the radioactive 
incubation medium. 
For each well the protein content was determined by adding 25, .. d of each well to a 
well of a 96-well plate (in duplicate) and performing a standard bicinchoninic acid 
(BCA™) Protein Assay (Pierce Biotechnology Inc., part of Perbio Science, 
Tettenhall, UK) according to the manual provided by the manufacturer. The 
radioactivity was described as cpm (counts per minute) /Jlg protein. 
2.4. Cell lysate protein concentration determination 
Colorimetric detection and quantitation of total protein content was performed with 
the BCA™ Protein Assay Kit (Pierce Biotechnology Inc). 
Preparation of diluted Albumin (BSA) Standards was performed according to the 
manufacturer's protocol. Bovine Serum Albumin 2mg/ml (v/w) was diluted m 
0.1 % SDS in order for standards to have the same diluent as the samples. 
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F~gure 2.3: Belo~ is a diagram representing the method for the preparation of standards. This 
dIagram was obtamed from the manufacturer's website: ww\v.piercenet.com. 
Preparation of Diluted Aloomin (BSA) Standards for BeA'" Assay 
and BCA'" Reducing Agenl-Compatibre Assay 
Diluti~n Scheme fa" S1andard Test Tute Protocol and Microplate Prradure (Working Range = 20-2,000 ~hnl) 
Vol.me Vllume aDd FilalBSA 
Vtal of Diluent Source of BSA Concentration 
A 0 300 Ul of stodt 2(((1 ~iml 
B 1l5lJl 375 lJl of stodt E(Ol9iml 
C 325lJl 325 lJl of stodt Hro~iml 
D 175lJl 175 W of'I'ia! B dilution 750 lJ!l"ml 
E 325lJl 32) lJl of ";al C di lulion 500 lJq.'ml 
F 325lJl 325 lJl 01 via E diluti on 250 u~'ml 
G 325lJl 325 ul 01 via F diluti on 125 ut1"ml 
H 400 lJl 100 Ul ,)f ',;al G ,jilulion .25 f)Jiml 
1 400 lJl 0 o Utl,ml = Blank 
http://www.piercenet.comlfilesI160 1325ProteinAssay.pdf 
25J.11 of each standard A-lor unknown sample replicate was added to a 96-well 
plate. Working Reagent (WR) was prepared by mixing 50 parts of BCA ™ reagent 
A with 1 part of BCA™ reagent B. 200J.11 of the WR was added to each well and 
the plate mixed thoroughly on a plate shaker for 30 seconds. The plate was then 
covered with tin foil and incubated for 30 minutes at 37°C. After allowing the plate 
to cool to room temperature the absorbance was measured at 560nm on a plate 
reader. The average 560nm absorbance measurement of the blank standard 
replicates was subtracted from all other individual standard and unknown sample 
replicates. A standard curve was prepared by plotting the average blank-corrected 
measurements for each BSA standard versus its concentration in J.1g/ml. The 
standard curve was used to determine the concentration of each unknown sample. 
2.5. Viral amplification 
CYMR 293 cells transfected with adenoviral plasmids were left in 6-well plates for 
approximately 10 to 11 days at which time cells were dying due to viral infection 
and were floating in the medium (= cytopathic effect (CPE)). The viral suspension 
(medium, virus and cells) from each well was collected separately and freeze-
thawed 3 times by transferring the tubes from the -80°C freezer to a 37°C water 
bath. After conclusion of the last cycle. the entire content of one tube was used to 
infect a I Oem diameter culture dish containing 5 x 105 CYMR 293 cells seeded the 
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previous day under standard conditions in E4 medium supplemented with lOCk 
FCS. Prior to infection the media was removed from the cells and replaced with 10-
ISm1 E4 supplemented with 2% FCS. After approximately 3-4 days CPE became 
evident and the cells and supernatant were collected and stored at -80QC until 
required. In preparation for further viral amplification the suspension was subjected 
to 3 cycles of freeze-thaw action as described before. 3-Sm1 of the cell suspension 
was used to infect a T17S flask containing CYMR 293 cells at 709('-80% 
confluency. Full CPE became evident after 48-72h and the cell suspension was 
again collected from the flasks and frozen at -80QC. The cell suspension was again 
subjected to three freeze-thaw cycles and 8-1Sml of the freeze-thawed suspension 
was then used to infect a CFI0™ cell factory (Fisher). 
Viruses based on AdS Wild-type were produced in CYMR293 cells and viruses 
based on the Wnt-specific AdS genome were produced in SW480 or SW620 
colonic cancer cells. 
Four T 17 S flasks at 70-80% confluency are required to seed a single CF 1 0 TM. The 
supernatant was removed from the flasks and the cells were washed with 12ml of 
warm PBS. The PBS was aspirated from the cells and Sml of trypsin was added to 
each flask. Once the cells had detached Sml of growth medium supplemented with 
10% FCS was added to each flask. The four flasks were pooled together into one 
T17S flask and 400ml of growth medium supplemented with 10% FCS was added 
to the flask. The CFIO™ was then unpacked and sterile tubing and a glass funnel 
were used to transfer the cells from the flask into the CFIOTM. 600ml of growth 
medium supplemented with 10% FCS was then used to flush the remaining cells 
from the tubing. The cell factory was then incubated under standard conditions for 
48-72 hours at 37QC. On the day of infection, the medium was removed from the 
cell factory and replaced with 400ml of growth medium supplemented with 2% 
FCS to which 8-ISml of the freeze-thawed viral suspension was added. The tubing 
was flushed with 600ml of growth medium supplemented with 2% FCS. 
After approximately 3-4 days CPE became evident and the cells suspension was 
collected from the CFI0 tower in two sterile SOOml centrifuge tubes and 
centrifuged at 2000 rpm for 10 minutes at 4°C. After the supernatant had been 
discarded the cell pellet was resuspended in ISml of ice cold PBS. transferred to a 
SOml tube and centrifuged at 1000 rpm for another 10 minutes. After aspiration of 
the supernatant the remaining cells were resuspended in 24ml of cold 1 Om~l Tris-
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HC1, pH 8, transferred to a single labelled sterile 50ml tube and stored at -800C 
until ready for Caesium Cloride (CsCl) banding. 
2.6. CsCI banding 
Each virus was purified by CsCl (Sigma) banding as described by He et al. (He et 
al., 1998) and (Graham and Prevec, 1995). 
The viral concentrate collected from the cell factory was defrosted at 37QC and then 
freeze-thawed three times by transferring the sample between liquid nitrogen and a 
37QC water bath. The virus suspension was spun for 10min at 6000rpm at room 
temperature and the supernatant removed and layered onto the CsCI for banding. 
The virus was collected by ultracentrifugation following two successive rounds of 
purification on a CsCl gradient. Subsequently the virus was dialysed to remove 
CsCI using the slide-a-Iyser system (Pierce Biotechnology Inc part of Perbio 
Science, Tettenhall, UK). Dialysis solution consisted of 10mM Tris-HCI pH7.4, 
ImM MgCh, 150mM NaCI and 10% glycerol (w/v). After dialysis the virus 
solutions were divided into 100f.l1 aliquots and stored at -800C in eppendorf tubes. 
Table 2.4: Representation of the viruses produced, which structure they contain and which plasmid 
they were produced from. 
viruses produced 
Name Structure Provenance 
AdWt AdS-Wild type Claudia Montiel-Equihua 
AdKHI AdS-Wnt Specific vpKH1 
AdIPI AdS-Wild type+hNIS plP8 
AdIP2 AdS-Wnt Specific+hNIS plP9 
AdIP3 AdS-Wild type-f16.7k-gp19k plP10 
AdIP4 AdS-Wnt Specific-f16.7k-gp19k plP11 
2.7. Viral yield determination 
The viral titre was determined by titration in CYMR 293 cells in 96-well plates in 
duplicate. Cells were seeded at 10.000 cells in 100~.tl of E4 medium supplemented 
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with 2% FCS per well and incubated under standard conditions at 37QC with 
aeration. The following day, ten-fold serial dilutions of virus were made (ranging 
from 10-5 to 10-12) in E4-2% FCS and l00~1 of diluted virus was added per well. 
For each dilution ten wells per 96-well plate were infected. Plates were incubated 
under standard conditions at 37°C for 10 days and then the titre was determined 
according to the Tissue Culture Infectious Dose 50 (TCID50) method of Reed-
Muench (Http://gbiogene.com!technicalJprotocols/gene-expressionlpdflm-
adeasy.pdt). The titre was calculated using the Karber statistical method T=10 1+d(S-
0.5) were d is 10giO of the dilution and S is the sum of ratios. TCID50 values are 
adjusted as they are 0.7 Log higher than standard plaque assay enabling viral titres 
to be expressed as PFU/ml. (i.e. lxlOx TCID50/ml is adjusted to lxlOx-O.7PFU/ml). 
The average of the duplicate titration was used as the definitive titre. 
2.8. Infection of cells with adenovirus 
Cell lines were seeded in 24-well plates in the appropriate medium at 50-75,000 
cells per well or 6-well plates at 200.000 cells per well and incubated under 
standard condition at 37QC. The following day viruses were diluted in FCS-free 
medium at different multiplicities of infection (MOl) (i.e. 50,000 PFU/50,OOO cells 
= MOl 1) to assess cell killing (see MTT assay below) or at the required MOl for 
other experiments (i.e. Western Blot). 500~1 (1 ml for 6-well plates) of diluted virus 
or FSC-free medium for controls was added per well and the cells incubated ad 
37°C under standard conditions for 30 minutes. 1.5rnl (2rnl for 6-well plates) of 
medium supplemented with 15% FCS was then added to each well so the final 
concentration of FCS would be 10% and the plates were incubated under standard 
conditions at 37QC until ready for further processing. 
2.9. Cell viability (MTT) assay 
MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromidej (sigma. 
UK) assays first described by Mosmann (Mosmann, 1983) were used to determine 
the cytotoxic effect of viruses on a panel of cell lines. 
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This assay is based on the ability of a mitochondrial dehydrogenase enzyme from 
viable cells to cleave the tetrazolium rings of the pale yellow MIT and form dark 
blue formazan crystals which can not permeate the cell membranes, thus resulting 
in its accumulation within healthy cells. Lysis of the cells by the addition of a 
detergent results in the liberation of the crystals which are solubilised. The number 
of surviving cells is directly proportional to the level of the formazan product 
created. The color can then be quantified using a simple colorimetric assay. 
4-6-8 days after infection, depending on the virus and cell line, MIT solution at 
Smg/ml (v/w) was added to the medium of cells to obtain a total concentration of 
10% (v/v) (e.g.1SOf..l1 in lSOml medium in each well of a 24-well plate). The plates 
were incubated at 37°C under standard conditions for two hours after which the 
supernatant was aspirated and 200f..l1 of DMSO was added to each well of a 24-well 
plate. The plates were left on a shaker for 15 minutes. SOlll of each well was 
transferred to a well of a 96-well plate containing l001l1 of DMSO (each well was 
performed in duplicate) and the plate was read at S60nm in an OPSYS MR (Dynex 
Technologies) micro-plate reader. The average 560nm absorbance measurement of 
non infected wells (medium without virus) was used as the reference value = 1000/0 
cells. CPE of each virus in each cell line was expressed as % of cells surviving as 
compared to the reference. 
2.10. Western Blot analysis of protein extracts 
The selective activity of Wnt-specific viruses in Wnt-positive colonic cancer cell 
lines as compared to Wnt-negative cancer cell lines was verified by detection of the 
adenoviral EIA protein in extracts from infected cells using the Western Blot 
technique developed by W. Burnette (Burnette, 1981). 
Cells were seeded under standard conditions and infected the next day with 
adenoviruses at different MOL 24-48 hours later cells were detached with trypsin, 
the trypsin neutralised with medium containing 10% FCS and the cells pelleted by 
centrifugation (Sminutes at l000rpm). Supernatant was aspirated~ the pellets 
resuspended in 300111 lysis buffer (1 o/c SDS) containing 1 x complete protease 
inhibitor (Roche Diagnostic GmbH, Lewes, UK) (1 tablet dissolved in 2ml dH:!O is 
86 
25x solution) and put on ice in eppendorf tubes. 25J.11 was used to detennine protein 
concentration using BCA protein assay (described above). 
20J.1g of protein was loaded onto a 12% SOS-PAGE (polyacrylamide gel 
electrophoresis) gel and was run at lOOV. The gel was then transferred onto a 
nitrocellulose membrane using semi-wet transfer at 15 V for 45 minutes. Transfer 
buffer consists of 10% lOx Tris-Olycine-electro-blotting buffer (CR-UK Research 
Services), 20% Methanol and 70% distilled water. 
The membrane was then blocked over night with 5% milk in PBS with gentle 
agitation on a rocking plate in the cold room at 4°C. The next day the membrane 
was washed with PBS 3 x 5 minutes on a shaker with gentle agitation at room 
temperature and mouse monoclonal anti EIA (Invitrogen or BO Phanningen) 
primary antibody added at a concentration of 111000 in 5% milk in PBS. After 
having rocked for 1.5 hours at room temperature the antibody was poured away 
and the membrane washed with 10mI of 0, 1% Tween20 (Sigma) in PBS (3 x 5 
minutes). The secondary antibody, peroxidase conjugated goat anti-mouse [gO 
(Oako Cytomation Inc, Ely, UK), was added at a concentration of 115000 in 5% 
milk in PBS for 1 hour, after which the membrane was washed with 0,1% tween20 
in PBS (3 x 10 minutes). The membrane was then developed by chemical 
luminescence (ECL ™ reagent from Amersham Biosciences Ltd, Little Chalfont, 
UK). 
A loading control was performed to ascertain that the same amount of protein was 
loaded in each well. 
The membrane was stripped by adding 10mI of stripping buffer (0.2M Olycin at 
pH 2.5, 0.05% Tween20 in PBS) and was put in the oven at 80°C for 30 minutes. 
The buffer was then removed, the membrane washed and blocked with 5% milk in 
PBS over night with gentle agitation in the cold room at 42C. The next day. the 
milk was removed and primary antibody goat monoclonal anti KU70 (Santa Cruz 
Biotechnology) was added at a concentration of 111000 in 50/0 milk in PBS. After 
having rocked for 1.5 hour at room temperature, the milk was poured away and the 
membrane washed 3 x 5 minutes with 10mi of 0.1 % Tween20 in PBS. The 
secondary antibody, donkey anti goat IgO (Santa Cruz Biotechnology) was then 
added at a concentration of 112000 in 5% milk in PBS and the membrane incubated 
for I hour after which the membrane was washed with 0, 17c twecn20 in PBS (3 x 
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10 minutes). The membrane was then developed by chemical luminescence 
(ECL TM reagent from Amersham Biosciences Ltd, Little Chalfont, UK). 
2.11. RT-peR 
Real-time PCR (RT-PCR) was carried out to amplify and simultaneously quantify 
the target molecule (EIA or hNlS). It enables both detection and quantification 
(absolute number of copies or relative amount compared to housekeeping genes) of 
a specific sequence in a sample. To quantify relative gene expression at a particular 
time RNA was extracted from cell homogenates. An additional step of reverse 
transcription was required to convert mRNA into cDNA. To determine the copy 
number of the target gene DNA was extracted from cell homogenates. 
Total RNA was purified from cells using Trizol® Reagent (Invitrogen TM) (see 
below). Total DNA was purified from cells using QIAamp® DNA Micro Kit 
(Qiagen) and from tissue using the DNeasy Tissue Kit (Qiagen) following the 
manufacturers guidelines. All RT -PCR was performed using SYBR green PCR 
Master Mix (Applied Biosystems). SYBR green is a fluorescent dye that 
intercalates with double stranded DNA amplicons generated during the PCR. When 
bound to dsDNA the intensity of fluorescent emissions increases. 
RT -PCR detects the accumulation of amplicon during the reaction. The 
fluorescence IS measured during the exponential phase of the reaction. 
Fluorescence IS plotted against cycle number on a logarithmic scale so an 
exponentially increasing quantity will give a straight line. The threshold is 
determined as the point at which the fluorescence level of a reaction exceeds 
background fluorescence. The cycle at which a sample reached this threshold is 
called the cycle threshold, Ct. The quantity of DNA doubles every cycle during the 
exponential phase so relative amounts of DNA can be calculated, e.g. a sample 
whose C
t 
is 4 cycles earlier than another's has 2~ = 16 times more template 
(http://www3.appliedbiosystems.comlcms/groups/mcb marketing/documents/gene 
raldocuments/cms 042484.pdD. 
The total amount of DNA in a sample was determined by absolute quantification 
by comparing the results to a standard curve produced by RT -PCR of serial 
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dilutions of a known amount of DNA of the amplified gene (plasmid or PCR-
product). Standards were prepared and stored at -20°C. 
To quantify gene expression from RNA samples, the measured amount of RNA 
from the gene of interest was divided by the amount of RNA from a housekeeping 
gene (I8s) measured in the same sample to normalise for possible variation in the 
amount and quality of RNA between samples. 
2.11.1. Reverse transcription 
Reverse transcription of total RNA extracts was carried out with TaqMan® Reverse 
Transcription Agent Kit (N808-0234) (Applied Biosystems). 2J.lg of total RNA. 
diluted in a total volume of 10.4J.lI with diethylpyrocarbonate (DEPC)-treated 
water, was added to a reaction mix containing 3J.lI TaqMan® RT buffer (lOx), 6.6J.lI 
MgCh (25mM), 6J.lI dNTP (2.5mM each), 1.5J.lI random hexamers (50J.lM), 0.6J.lI 
RNase inhibitor (20UI1) and 1.88J.lI Multiscibe Reverse transcriptase. All reagents 
were provided by the manufacturer. Conditions used were 10min @ 25°C, 60min 
@ 37°C, 5min @ 95°C and 4°C to finish. 
2.11.2. Quantitative peR 
SYBR® Green PCR Master Mix (Applied Biosystems) was used to perform all RT-
PCR. Samples obtained through reverse transcription of mRNA were normalised 
by amplifying 18S ribosomal RNA (rRNA) from diluted samples. 
In early experiments standard curves were borrowed from other researchers in our 
group. The standard curve for hNIS was made by serial dilution of a known 
concentration of plasmid pShuttle-TK-hNIS (previously made in our laboratory by 
Ms Korin Knight); the standards for E1A were obtained by serial dilution of 
pShuttle-hTERT-E1A (previously made in our laboratory by Andrew Merron, also 
called pAM 10) and the standards for 18s were produced from reverse transcription 
of standard Universal U-RNAs (Applied Biosystems). 
In subsequent experiments standard curves were produced by serial dilutions of 
PCR-products. PCR reactions were optimised with Opti-Prime™ PCR 
Optimization Kit (Stratagene. UK) as described above. 
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hNIS PCR-product was obtained from pIP3. Primers used were P5 and P6. 
Conditions were 5min @ 94°C, 27 cycles of lmin @ 94°C, lmin @ 55°C, 2min @ 
72°C and 10min 72°C). 
EIA-PCR product was obtained from pAMIO. Primers used were EIA-F and EIA-
R. Conditions were 10min @ 95°C, 40 cycles of 10sec @ 95°C, 15sec @ 580C. 
8sec @ 72°C and 5min @ 4°C to finish. 
18S-PCR product from reverse transcribed U-RNA. Primers used were 18S-F and 
18-R. Conditions were 2min @ 95°C, 10min @ 95°C, 40 cycles of 30sec @ 95°C, 
lmin @ 60°C and 5min @ 4°C to finish. 
PCR products were run on a 0.8% agarose gel to verify the quality and the correct 
size of the product. 
RT -PCR reactions were set up for standard curve dilutions, reverse transcribed 
products and purified DNA by adding the SYBR® green mix (2x final 
concentration) and primer mix (final concentrations of primers for hNIS and 18s 
were 300nM forward and 50nM reverse and 100nM forward and 100nM reverse 
for EIA). In each reaction 19.4J.lI of reverse transcribed product was used or 50ng 
of total genomic DNA for extracts from cell monolayer or 500ng for extracts from 
tissue diluted in DEPC water to a total volume of 19.4J.lI. 32.3J.lI of SYBR® Green 
mix and 12.9J.lI of primer mix was added to obtain a total volume of 64.6J.ll. 
Optimisation of primer concentrations for hNIS and 18s had previously been 
performed by Thomas Groot- Wassink. Optimisation for E 1 A primer 
concentrations was carried out using RT -PCR analysis on a primer matrix using 
E I A-PCR product with different concentration ratios of forward and reverse E 1 A 
pnmers. 
20J.lI of each sample was loaded in triplicate to a 96-well Optical Reaction plate 
(Applied Biosystems). Non-template (NTC) wells were added to determine 
potential template contamination. The plate was sealed with Optical Caps (Applied 
Biosystems) and quantitative RT-PCR performed on either ABI PRISM 7700 or 
ABI PRISM 7500 sequence detection systems (Applied Biosystems). Reaction 
conditions used for hNIS and 18s amplification were 2min @ 95°C, 10min @ 95°C. 
40 cycles of 30sec @ 95°C, 1 min @ 60°C. Cycling conditions for E I A on ABI 
PRISM 7700 were 10min @ 95°C. 40 cycles of 10sec @ 95°C. 15sec @ 58°C. 8s~c 
@ 72 ° C and on ABI PRISM 7500: 10min @ 95°C, 40 cycles of 10sec @ 95°C. 
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15sec @ 58°C, 33 sec @ 72°C. A primer-DNA dissociation stage was performed on 
each plate after template amplification under the following conditions: 15sec @ 
95°C, lmin @ 6()OC and 15sec @ 95°C. All RT-PCR analysis was carried out using 
sequence detection software (SDS) 7500 version V.l.3 (Applied Biosystems). The 
primers used for RT-PCR analysis can be found below (table). 
Table 2.5: Quantitative real-time PeR primers: primer names, description and sequence are shown 
for hNIS, E 1 A and 18S. F, forward; R, reverse. 
Primer Description Sequence 5'-3' 
P10 hNIS RT -PCR-F TCATGTTTGTGTTTCTACACTGAC 
P11 hNIS RT -PCR-R TGCTGAGGGTGCCACTGTAAG 
P12 E1A-F CCTGTGTCTAGAGAATGCAA 
P13 E1A-R ACAGCTCAAGTCCAAAGGTT 
P14 18S-F CGCCGCTAGAGGTGAAATTC 
P15 18S-R CATTCTTGGCAAATGCTTTCG 
2.12. Nucleic acid extraction from adenovirus infected cells 
2.12.1. Total RNA extraction 
Extraction of total RNA from cells was carried out usmg Trizol® Reagent 
(Invitrogen TM) according to the manufacturer's guidelines. Total RNA was then 
used to perform reverse transcription and RT -PCR for target genes to quantify 
relative gene expression at a specific time. 
Cells were seeded with a density of 2xl05 cells per well in 6-well plates (immortal 
cell lines) or 12-well plates (primary cells) with the appropriate medium [E4 
supplemented with 10% FCS for cell lines, RPMI-I640 (developed by Moore et. al. 
at Roswell Park Memorial Institute) 2% supplemented with 20% FCS for primary 
cells] and incubated under standard conditions at 37°C. The following day. cells 
were infected with the required adenovirus(es) as described before. Depending on 
the experiment total RNA extraction was performed 1-2-3-4-5 days post infection. 
The medium was aspirated from the cells and the cells washed with warm PBS. 
PBS was aspirated and under a fume hood 1 ml Trizol® was added to each well to 
lyse the cells. The total RNA was then recovered by following the manufacturer's 
protocol. Samples were stored at -20°C until required. 
91 
Extraction of total RNA from animal tissue was performed with the RN eas y Kit 
(Qiagen) according to the manufacturer's guidelines. Fresh samples were stored in 
RNAlater RNA Stabilization Reagent (Qiagen) at -200C until extraction was 
performed. 
RNA concentrations were determined USing a NanoDrop® ND-l000 
spectrophotometer (NanoDrop Technologies Inc). RNA quality was verified by gel 
electrophoresis (see below). 
2.12.2. Total DNA extraction 
Total DNA was extracted from cells using the QIAamp DNA Micro Kit (Qiagen). 
The protocol used was a modified version of the DNeasy tissue Kit (Qiagen) 
protocoL 
Cells were seeded and infected as described above for RNA-extraction. On the day 
of collection, the medium was aspirated and the cells washed with warm PBS. 
Cells were detached with 300J,l1 trypsin and the trypsin was neutralised by gently 
resuspending the cells in 1 ml of warm medium. Cells were transferred to a sterile 
eppendorf tube and centrifuged at room temperature for 5min at 300 x g. The 
medium was apirated and the cells resuspended in 200J,l1 PBS. 20J,l1 of proteinase K 
and 200J,l1 of Buffer AL (both provided in the kit) were added to the sample, mixed 
thoroughly by vortexing and incubated at 70°C for 10 minutes. 200J,l1 of ethanol 
(96-100%) was added to the sample and mixed thoroughly by vortexing. The tubes 
were briefly centrifuged to remove drops from the lids and the mixture of each tube 
was transferred to a QIAamp MinElute Column. Columns were spun for 1 min at 
room temperature at 8000rpm The column was then transferred to a clean 2ml 
collection tube (provided by the manufacturer) and the collection tube containing 
the flow-through discarded. 500J,l1 of buffer AWl was added to the column and the 
column spun at room temperature at 8000rpm for Imin. The column was 
transferred to a clean collection tube and the collection tube containing the tlow-
through discarded. 500J,l1 of buffer A W2 was added and the column spun at room 
temperature at 8000rpm for 1 min. The column was transferred to a clean collection 
tube and the collection tube containing the flow-through discarded. The columns 
were then spun at room temperature for 3nun at full speed to dry the membrane 
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completely. The QlAamp MinElute Column was transferred to a clean 1.5ml 
eppendorf tube and 20~1 of buffer AE was added to the centre of the membrane. 
incubated at room temperature for 5min and then spun at full speed for 1 min. This 
step was repeated so a final volume of 40~1 DNA was obtained for each sample. 
Total DNA was extracted from tissue using the DNeasy Tissue Kit (Qiagen) 
following the manufacturer's guidelines. 
DNA concentrations were determined uSIng a NanoDrop® ND-l ()()() 
spectrophotometer (NanoDrop Technologies Inc). 
2.13. Viral replication kinetics 
2.13.1. By titration 
In order to assess replication competence of the viruses produced, compliant cells 
were infected with virus at a low MOl so the cells could survive long enough in 
order for the virus to be able to replicate within. 
SW480/SW620 (Wnt-positive colonic cancer cells) cells were seeded in 6-well 
plates and incubated for 24 hours under standard conditions. The following 
morning the 6-well plates (3 wells per virus per day) were infected with 
Adenovirus (AdlPl and AdIP2) at MOl 0.01 as described above and incubated 
under standard conditions at 37QC. Cell homogenates from three individual wells 
for each virus were collected every day for 7 consecutive days by scraping the 
plates and transferred to a 15m1 sterile Falcon tube. The collected homogenates 
were stored at -80QC until required for titration. The viral titre of each cell 
homogenate was determined by TCID50 method in CYMR293 cells as described 
above. Cell homogenates were freeze-thawed three times before serial dilutions 
were made to infect 96-well plates for titration. 
2.13.2. By qPCR for EIA 
Viral replication was also evaluated by extracting total RNA (gene expression) and 
total DNA (copy number of genes) from infected cells at different time points and 
performing real time PCR for E 1 A. The methods employed are described above. It 
was assunled that an increase in gene expression or copy number signified 
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replication of virus. A non-replicating EIA-deleted VIruS (AdIO) was used as 
negative control. 
2.14. RNA gel 
The quality of RNA extracts was verified by running them on a I % agarose 
(w/v)/formaldehyde gel. The gel was made by mixing I % agarose with 1 x running 
buffer (RB) at pH7 [3-(N-Morpholino)propanesulfonic acid (MOPS) 25mM, 
anhydrous Na-Acetate (CH3COONa) 6.25mM, ethylene-diamine-tetraacetic acid 
(EDTA) 0.125mM pH8 in DEPC water] and 7.S% formaldehyde 37-40%. Samples 
were mixed with three volumes of sample buffer [1 x RB, SO% ultrapure 
formamide, 5.S% formaldehyde 37-40%, 20% Bromophenol Blue (lOmg/ml), 1 % 
Ethidium Bromide (lOmg/ml) in DE PC water]. The gel was run at 80Y in 1 x RB 
and the bands checked under UV light when opportune. 
2.15. Immunofluorescence of adenoviral proteins 
2.15.1. Immunocytochemistry 
Immunocytochemistry was used to determine whether the cells infected with 
Adenovirus-hNIS (AdIPl and AdIP2) were expressing the hNIS protein correctly 
within the cell membrane. Negative controls were non-infected cells and Wild-type 
AdS adenovirus (AdWt). The same method was employed to demonstrate the 
selectivity of the Wnt-hNIS adenovirus (AdIP2) for Wnt-positive cells. Negative 
controls were non-infected cells, a non Wnt-expressing cancer cell line and AdIP4. 
Cells were seeded onto microscope cover slips in 6-well plates and incubated over 
night under standard conditions at 37°C. Cover slips were prepared for use as 
follows: 30min wash in 60:40 ethanol:concentrated HCI, 3x 10min rinse with dH 20 
and stored in 70% ethanol. The following day, cells were infected with virus at 
MOll as described above and incubated for 24h at 37°C with aeration. The medium 
was removed, cells were washed with warm PBS and infected cover slips were 
then fixed with 2ml of 3-4% para-formaldehyde in PBS for lSmin at room 
temperature. The paraformaldehyde was then removed and the cells washed 2x 1 0 
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minutes with 2ml warm PBS. Cells were permeabilised with 0.1 % Triton® X-l00 
(a non-ionic surfactant) in PBS for 5 minutes at 4°C. Cells were then washed 2 x 10 
minutes with PBS after which the primary hNIS mouse antibody Abl FP5A 
(Neomarkers, Lab Vision Corporation) 1: 150 in 5OO~1 PBS was added to each well 
and incubated at room temperature with gentle shaking for 30 minutes. The 
primary antibody was then removed and the slides washed with PBS for 3 x 10 
minutes at room temperature. Secondary antibody, goat anti-mouse IgG (2mg/ml) 
488nm Alexa Fluor® Conjugate (Molecular Probes, Invitrogen), a dye which 
fluoresces around 488nm, was diluted 1: 1000 in 5 % heat inactivated goat serum in 
PBS and incubated for 30min in the dark before addition to the wells. Cells were 
incubated with secondary antibody for 30 minutes at room temperature with gentle 
shaking. Cells were washed for 3 x 10 minutes with PBS at room temperature after 
which cells were treated with 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen). a 
blue fluorescent dye that binds to double stranded DNA 1 :500 in PBS for 5 minutes 
at room temperature with gentle shaking. Cells were then washed for 2x 10 minutes 
with PBS after which the cover slips were removed from the wells, excess liquid 
removed and mounted on microscope slides with a drop of PermaFluor ™ (Thermo 
Scientific) mounting media. The slides were then stored in the dark at 4°C until the 
Laser Scanning Microscope (ZeissLSM510 Meta) became available. DAPI was 
scanned with laser diode 405 (blue) and revealed the nucleus of cells and Alexa 
Fluor® with Argonl2 laser (green), which revealed hNIS. 
2.15.2. AdGFP infection 
To determine whether desmoid cells could be infected with adenovirus, infection 
with a non-replicating Ad5 containing the gene for green fluorescent protein (GFP) 
was performed in conjunction with flow cytometry analysis for quantification. 
Infected cells express the GFP gene and auto-fluoresce. 
Desmoid cells were seeded in 6-well plates at 2xl05 cells per well in RPMl2% 
medium supplemented with 20% FCS and incubated at 37°C over night under 
standard conditions. The following day cells were infected with AdGFP (provided 
by Sandra Martinico) at different MOl and incubated for 48h at 37°C with aeration. 
Cells were visualised and auto-fluorescence of infected cells detected with an 
Olympus@ CKX-li microscope fitted with a fluorescence illuminator for GFP. Cells 
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were subsequently treated with trypsin and after neutralisation with gro\\th 
medium spun for 4min at room temperature at 1200rmp. Cells were resuspended in 
400JlI FACS Buffer [FCS 20% (v/v), 0.5mM EDT A pH8 in PBS] and stored on ice 
until required for flow cytometry analysis. 
2.16. Flow Cytometry analYSis 
Flow cytometry analysis was performed on a BD FacsCalibur System (BD 
Biosciences) for desmoids cells infected with AdGFP and desmoid cells stained 
with antibodies for CAR, Integrins and CEA and the results analysed with 
CELLQUESTPro software (BD Biosciences) provided with the machine. Green 
fluorescing cells were detected with FLl a blue argon laser (488nm) detecting 
fluorescein isothiocyanate (FITC) and GFP. 
Desmoid cells were seeded in 6-well plates at 2xl05 cells per well in RPMI2% 
medium supplemented with 20% FCS, incubated over-night and either infected 
with AdGFP as described above or stained with antibodies as described by Fuxe et 
ai. (Fuxe et aI., 2003). 
Cells for staining were collected by trypsinisation, spun down for 4 minutes at 
room temperature at 1200rpm, the medium removed and the cells washed with pre-
cold FACS Buffer. Cells were spun down, FACS buffer removed and the pellet 
incubated with primary monoclonal mouse antibody 1:500 in FACS buffer 
containing 5% normal goat serum (Dako Cytonation, Denmark) for 90min on ice. 
Every 15 minutes the each eppendorf tube was shaken gently. Cells were spun 
down for 3 minutes at room temperature at 2000rpm and the primary antibody 
washed away by three wash-spin cycles with pre-cold FACS buffer. After the last 
wash the pellet was incubated for 30 minutes at room temperature in the dark with 
secondary antibody goat anti-mouse FITC 1:30 in FACS buffer. The cells were 
spun down and the pellets washed by three wash-spin cycles. The final pellet was 
resuspended in 400f..tl FACS buffer and stored on ice until required. 
Primary antibodies used were CAR, CEA-CAM6 (both received from Dr. Y.Wang 
in our laboratory), Integrin Alpha-V (1 mg/ml) (abeam), Integrin Alpha V /Beta3 
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(Chemicon® International) and Integrin AlphaVlBetaS clone PIF6 (obtained from 
the Tumour Biology laboratory). 
2.17. Establishment of primary cultures of desmoid cells 
Desmoid tumour cells were obtained following surgical resection. The protocol 
was used in conjunction with the ethical approval from the Harrow or Leuven 
(Belgium) Research Ethical Committee. The tumours were macerated in small 
pieces with a scalpel and digested over night at 37°C in RPMI containing 209(' FBS 
(AutogenBioclear, Ltd, CaIne, UK), 100 unitslml penicillin, 1 OO~g/ml 
streptomycin, 0.2~g/ml Butyl-p-hydroxybenzoate supplemented with 1 mg/ml of 
Collagenase 0 ( Roche Diagnostic Gmbh, Lewes, UK). The digest was then 
filtered through a 100~1 nylon cell strainer and centrifuged twice at lOOOrpm. Cell 
pellets were washed twice with PBS, re-suspended in RPMI 20% FBS containing 
antibiotics (see above) and seeded. Primary cultures were maintained in a 50'( CO2 
atmosphere at 37°C. Erythrocytes and cell debris were washed away with PBS 24h 
later. Long term stocks of cells were made as described above and frozen at -80°C 
over night and in liquid nitrogen there after. Germ-line and somatic mutations were 
identified. 
Desmoid 1: ~-catenin mutation: substitution TIT for TCT resulting in a Ser to Phe 
change at codon 45. 
Desmoid 2: ~-catenin mutation: substitution of TIT for TCT resulting in a Ser to 
Phe change at codon 45. 
Desmoid 3: Mutations in APC or ~-catenin not detected. 
Desmoid 4: APC mutation: exon 15 c.3927 _3931del AAAGA 
(pGlu 1309 AspfsX4). 
Desmoid 5: APC mutation: exon 13 c.1495C>T (p.Arg499X). 
Desmoid 5.2: APC mutation: germline exon 6 c.646 C>T (p.R216X), somatic exon 
15H: c.4385delA. 
The above described collection of cells and identification of mutations was 
performed in Leuven for desmoids 1-5 and by Sandra Martinico in our lab for 
desmoid 5.2. Cryo-preserved samples were shipped to London from Leuven. 
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3. In vivo investigations 
All animal experiments were conducted with appropriate ethical approval and in 
accordance with the Guidance on the Operation of the Animals (Scientific 
Procedures) Act 1986 (House of Commons 1990). Heterozygous female Balb-c 
NuI- mice were used for the tolerability experiment, homozygous female Balb-c 
NulNu mice (Harlan) or homozygous female CD 1 NulNu mice (Charles River) 
were ordered for all other experiments. Mice were left to recover for one week after 
transport from the supplier before experiments were initiated. All mice were kept 
in individually ventilated cages and were only handled under sterile conditions in a 
safety cabinet. Mice were removed from the IVC cages and transported into the 
SPECT/CT room where they were kept behind a lead wall until the experiment was 
finished and mice were terminated. Mice were disposed off after the radioactive 
decay by passing them through a macerator. 
3.1. Tolerability experiment 
Heterozygous female Balb-c NuI- mice were injected intravenously via the tail vein 
with 109 PFU of virus in 100J-l1 in PBS or with PBS. Six mice were injected with 
AdlPl, four mice were injected with AdlP and four mice with PBS. After 3 and 6 
days respectively three mice were killed for AdlP 1 and two for AdIP2 and PBS and 
the livers were collected and split in half. One half was snap-frozen by dipping it 
for 5 minutes in isopentane and then for 5 minutes in liquid nitrogen and stored at -
800C until immunohistochemistry for hNIS and E 1 A was carried out on tissue 
sections (performed by the Institute of Cancer Pathology Services). The other half 
was stored in RNA later (Qiagen) at -20°C until RNA extraction (Qiagen RNeasy 
kit) and RT-qPCR. 
3.2. Generation of subcutaneous tumours 
Subcutaneous tumours were created by injection of 2x 106 HCT 116 cells suspended 
in l00pl PBS. Cells were seeded in T 175 flasks in E4 medium supplemented with 
10% FCS in the tissue culture facility and incubated under standard conditions until 
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the flasks were 80-90% confluent. On the day of injection, cells were trypsinised 
and the trypsin neutralised with growth medium. Cells were counted and the pellet 
was spun for 5min at lOOOrpm at room temperature. The medium was removed, the 
cells resuspended in an appropriate volume of PBS and transported on ice to the 
animal facility. The mice were injected subcutaneously with 100".11 containing 
2xl06 cells under sterile conditions in a biology safety cabinet. A Iml syringe (80, 
Plastipak™) and a 23G needle (BD, Microlance™3) were used. Tumour growth 
was determined by calliper measurement. After approximately 14 days tumours 
reached the required size of 5x5mm. 
3.3. Adenoviral intra-tumoural injections 
When the subcutaneous tumours reached the appropriate size, viruses were injected 
using Ultra-Fine™ Insulin Syringes (BO). Viruses were defrosted on ice and 
remained on ice for transfer and until injection. Viruses were diluted to a total 
volume of 100J-l1 in PBS and injected evenly in the centre of the tumour through 
one single entry point by moving the needle in all directions. If tumours were 
small, two doses of 50J-ll were injected with a 1 hour interval to assure the full dose 
was delivered inside the tumour. Doses used were 5 x 108 PFU and 1 x 109 PFU, 
depending on the experiment. All injections were carried out in a biological safety 
cabinet. 
3.4. Non-invasive imaging in vivo 
Imaging of mice was carried out with a four-headed multiplexing multi-pinhole 
single-photon emission computed tomography (SPECT), NanoSPECTICT™ in 
vivo animal imager (Bioscan Inc, Washington D.C.). Acquisition time depended on 
the specific radioactivity level measured in each mouse. 100,000 counts were 
required in order to obtain a good quality image. 
Mice were transferred to the scanning room and anaesthetised via intra-peritoneal 
injection (lP) injection for experiments until June 2007 and via gas anaesthesia for 
experiments thereafter. 
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IP injections: anaesthesia was induced by administration of 20-40)..11 of a Ketamine 
(lOOmglml):Xylazine (20mglml) 2: I mixture. When the anaesthesia was deep 
enough the mouse was positioned on its side and 18.5MBq (=500J.lCi) of 
Technetium 99m (Tc99m) (obtained from Barts Hospital, London) in a volume of 
lOOJ.11 was injected intra-venously (IV) via the tail vein. The mouse was then 
wrapped in cling film to keep her warm and positioned in a prone position on the 
bed of the NanoSPECTICT™ in vivo animal imager and a scan performed. When 
the scan was finished, the animal was transferred to an individual cage positioned 
under a heating lamp and left to recover before it was allowed to join its litter-
mates. 
Gas anaesthesia: Each mouse was first placed in a restrainer and 18.5MBq of 
Tc
99m 
in a volume of lOOJ.l1 was injected IV in the tail vein. The mouse was then 
moved to the ventilated chamber of an anaesthetic machine with a non-rebreathing 
circuit for induction. The gas-oxygen mixture for induction was: Halothane: dial 
setting 4, N20 600mllmin, O2 1 Vmin. The animal was then transferred to the bed of 
the imager and a nose cone applied. The maintenance anaesthesia was: Halothane: 
dial setting 2, N20 600mllmin, 02 I Vmin. After the scan was performed, the mouse 
was transferred to an individual cage heated with a warm lamp and allowed to 
recover. Once recovered the animal was allowed to join its litter-mates. 
Animal that were scanned on five successive days were kept in a lead-shielded 
cage until the next scan was performed. After the last scan the mouse was culled 
while still under influence of the anaesthetic. 
Animals that were scanned only once were culled while still under the influence of 
the anaesthetic and the tumour collected. Half of the tumour was kept at -20°C until 
DNA-extraction with a DNEasy Kit (Qiagen) and the other half was stored in 10% 
formaldehyde to be processed for immunohistochemistry (Pathology Services). 
After acquisition, the data obtained from the NanoSPECTICT™ in vivo animal 
imager were reconstructed using the HiSPECT software (Bioscan Inc., Washington 
D.C .. USA) and Interview XP® (Mediso Ltd., Budapest, Hungary) provided with 
the machine. Post-processing software used to fuse SPECT and CT images was 
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PMOD Biomedical Image Quantification Software verSion 2.65 (PMOD 
Technologies) and InVivoScope post-processing Suite (Bioscan Inc., Washington 
D.C., USA). 
3.5. Radiotherapy 
The therapeutic experiment including radiotherapy with 1311 was carried out in the 
Departamento de Bioquimica, Facultad de Ciencias Biosanitaria, Universidad de 
Francisco Vitoria, Madrid, Spain and repeated in INSERM, CIC-04 Biotherapies 
Hepatiques, U niversite de Nantes, France. 
Mice were injected with colon cancer cells HCT 116 to create subcutaneous 
tumours (method described above). When the tumours reached the appropriate size, 
the mice were given intra-tumoural injections of adenovirus as described above. 
Mice were fed levo-thyroxine (5mg/ml) in their drinking water in order to suppress 
thyroidal iodine uptake. After 48h, mice in the treatment arm were injected IP with 
3mCi (111MBq) 1311 according to the local institute radiation safety guidelines. 
Irradiated mice were kept separate from the control mice and were shielded with 
lead plates. They were kept in isolation until the radioiodine had sufficiently 
decayed. Tumour size was assessed by calliper measurements in two dimensions 
every other day. Mice were culled when tumour size reached the limit of 144mm2, 
which is the maximum allowed by the Home Office regulations. 
4. Statistical analysis 
All graphs were created and analysed with uSing GraphPad Prism 4 sofware 
(GraphPad, San Diego, C.A., USA). 
4.1. t-test 
The (-test was used was chosen for biological data when they were expected to 
follow an approximately Gaussian, bell-shaped distribution. A two-tailed p-value 
was chosen because it was assumed that for every of the two groups being 
compared either could have the largest mean. 
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4.2. Kaplan-Meier percentage remaining curves 
Percentage remaining curves presented were compared by generating a p-value 
testing the null- hypothesis that the intervention did not alter survival and therefore 
that the survival curves are identical in the populations. Each analysis asks whether 
intervention a alters survival compared to intervention b as well as asking whether 
intervention b changes survival compared to intervention a. Median survival is the 
time at which half the mice have died. 
4.3. ANOV A one way analysis 
Anova one way analysis of variance was used to test for differences between two 
or more treatment groups. 
Similarly, for the comparison of means of three or more treatment groups where 
the data was normally distributed, one way analysis of variance (ANOY A) was 
performed to test for significance in variation between these treatment groups. 
ANOY A utilizes positively skewed f distribution and works better in reducing the 
type I error (false positive) in multiple comparisons of means. 
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CHAPTER 3: Results 
1. Molecular biology 
1.1. Introduction 
The aim of this PhD project was to incorporate the cDNA of the human NIS into 
the genome of a Wnt-specific oncolytic adenovirus. This virus, AdKH 1, was 
donated by Dr. Richard Iggo and had previously been characterised and its 
specificity and selectivity determined (Fuerer and Iggo, 2(02). 
We chose to incorporate the hNIS cDNA into the E3 region of the adenoviral 
genome. Deleting E3-6.7k and E3-gp19k creates the necessary space to introduce 
the hNIS cDNA and has the additional benefit of increasing the antitumour activity 
in immuno-competent tumour models (Wang et aI., 2003b). 
We opted for homologous recombination in yeast by "pop-in"f'pop-out" 
replacement as the method of gene transfer for its high recombination efficiency 
(Rothstein, 1991) and because of the previous experience with this technique in our 
laboratory (Vassaux et al., 1997), (Vassaux and Huxley, 1997). 
Homologous recombination is very efficient in yeast when a DNA fragment 
containing free ends is introduced into these cells and if a homologous sequence is 
already present. To create these free ends in the shuttle vector, a unique restriction 
site is required and the homologous recombination will be directed at this exact 
site, leading to the integration of the whole shuttle vector in the targeted site. This 
event is selected by the presence of an URA-3 gene in the shuttle vector that will 
provide auxotrophy for uracil in the previously uracil-dependent yeast. In our case, 
a unique restriction site is present in the ADP sequence, allowing integration into 
the adenoviral genome already present in the yeast (see figure 3.1 A). 
The strategy of this system is to introduce a transgene (hNIS) into a region of 
interest (adenoviral E3 region). The transgene is cloned into a shuttle vector 
containing the URA-3 gene. When creating the shuttle vector, it was important to 
leave as much homology a" possible on both sides of the insertion. It was decided 
to flank hNIS by E3-12.5 and E3-ADP. The restriction site for targeting shOll Id be 
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between the insertion site (hNIS) and the shortest stretch of homology ADP to 
increase the probability that the pop-out event will occur in the longer tretch of 
homology (E3-12.5), resulting in successful replacement (Rothstein, 1991 . E3-
ADP contains the unique restriction site NotI. The adenoviral plasmid contain a 
HIS gene and can be linearised by PacI. 
5' 
I 
Wild type sequence 
hNIS 
Mutant sequence 
A. POP-IN 
Selection for URA+ 
Integration 
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Figure 3.1A: The yeast containing 
the adenoviral genome (either wild-
type or AdKH 1) i elected for 
growth on plate without histidine. 
This yeast i tran formed with the 
shuttle pIa mid Iineari ed in the 
ADP region. The re ulting 
recombinant are elected onto 
plates without uracil and Hi tidine. 
The mo t frequent event i a 
duplication containing the wild type 
and the mutant copy of the gene 
flanked by the pia mid equence . 
Thi i called "pop-in". 
Wild type sequence 
I Selection with 5-FOA Excision 
hNIS 
Mutant sequence 
Wild type sequence 
B. POP-OUT 
Figure 3.lB: In the "pop out' tep., 
the yeast are grown overnight in 
medium containinig uracil. Till 
removes the election pres ure for 
maintenance of the huttle pIa mid 
and in a small proportion of yea t an 
excision will occur. Becau e of the 
high efficiency of homologou 
recombination, this excision '{ ill 
occur preferentially by 
recombination noted 1 or 2 in the 
figure. These relatively rare e en 
will be selected onto plate 
containing 5-FOA, a compound 
transformed into a toxic agent by 
the product of the URA-3 gene. 
This will result in growth of two 
types of yeast clones of tructure 1 
or 2. The configuration 1 will be 
selected by diagnostic test . 
1.2. Construction of shuttle vectors 
E3-12.S and E3-ADP DNA was amplified by PCR from the plasmid pMB20 u ing 
the Opti-Prime PCR Optimisation Kit (Stratagene). The PCR products were cloned 
into the commercial plasmid pCR@T7/CT-TOPO (Invitrogen, USA) (see appendix 
for map). The resulting plasmids were called pIP 1 for E3-12.S-TOPO and pIP2 for 
E3-ADP-TOPO. Glycerol stocks were made of each bacteria clone containing the 
plasmids. 
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Figure3.2: On the left hand side an agarose gel showing the PCR product of E3-12.5 together with 
clone of E3-ADP-TOPO digested with Xba 1 and HindIII, which exci e the cloned product from 
the backbone vector. On the right hand side an agarose gel hawing the elected E3- L.5k-TOPO 
clones. Correct clones (2, 8, 11 , and 12) were sequenced and clone 12 contained the orre t 
sequence and was used for large-scale DNA purification. 
To facilitate molecular biology manipulations, the hNIS cDNA wa amplified by 
peR from the plasmid pTGWIO (Groot-Wassink et aI. , 2002) by Opti-Prime peR 
Optimisation Kit (Stratagene) and cloned into plasmid pcDNA3.lN5-Hi -TOPO 
(Invitrogen, USA). Functional clones were selected using an iodide uptake a ay 
after transfection into 293 mammalian cells. As a positive control pTGW 1 0 wa 
used and pIPl as a negative control. An iodine uptake a ay wa performed after 24 
hours and the clones showing the highest iodine uptake (1 and 21) were 
transformed into chemo-competent DHIOB bacteria. Large cale DNA purification 
(maxi Kit, Qiagen) was performed and glycerol stock were made. The pIa mid 
was called pIP3. 
Figure3.3: Example of agarose gel on which hNIS-TOPO clone were run. The clone containing 
the insert were used for transfection into CYMR293 cells and iodine uptake a ay. 
1 hNIS-Tapa clones digested WI th Xba1 
I 
Figure 3.4: Iodine Uptake Assay performed on CYMR293 cell tran feeted v:ith h TIS-TOPO 
clones. Clone 1 and Clone 21 have the highest iodine uptake and have been eleeted for large- ale 
--DNA purification. 
E 
a. 
u 
Iodine Uptake Assay 
_Iodine 
Dlodine + Perchlorate 
Subsequently pIP!, pIP2 and pIP3 were sub-cloned into the pGVl (for map ee 
appendix) to create the shuttle vector. 
(1) In the first step, a SacIIlXba I-digested fragment of pIP 1 containing the 
E3-!2.Sk gene was ligated into SacIIlXbal-dige ted pGVl backbone to create 
pIP4. Confrrmation digests were performed and a correct clone elected for large-
scale DNA purification to be used for the next cloning tep. Glycerol tock were 
made. 
Figure 3.5: Digestion of selected miniprep clones with XbaI, lineari es the huttle vector and hould 
only represent one band on the agarose gel of approximately 5kb (pOV I +E3-l2.5k). 
• l'oJ ...... .. - .... - .. ~a 
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Figure 3.6: A. Representation of pIP4 showing the restriction he. B. Further veriti arion of 
clones was performed by mUltiple restriction digestions. 
E3-12.5k 
\ 
PvuU(20S7. 
Sac! (2279) 
SQcU(a286) 
rreer 
(2) In a second sub-cloning step, a KpnIlXhoI fragment of pIP2 containing 
the E3-ADP gene was ligated into KpnIlXhoI-digested pIP4 to create pIPS. 
Restriction digestion was performed and the correct clone elected for large- cale 
DNA purification (Maxi Kit, Qiagen). Glycerol stocks were made. 
Figure 3.7: A. Representation of pIPS showing restriction ite. B. Dige tion of the elected clone 
with Not 1, which is a unique restriction site and linearise the vector, with SacII, which cut out the 
MCS and part of the inserted DNA fragment and uncut pIPS DNA to compare. 
-~V~:T 
-'t I Noll I Sacll I uncut I 
F1 Orl 
I'WllC>057) 
~/, __ -~ S<KI(>l7Y 
SGdJ <.»H l 
(3) A previous cloning attempt digesting the back bone with XhoIlXbaI 
failed so we opted to blunt both ends by digestion with blunting re tnctl n 
enzymes. An EcoRVlXbal fragment ofpIP3 containing the hNIS gene wa ligated 
into SmaIlXbal digested pIP5 to create pIP7. ConfIrmation digests were perform d 
and a clone was selected and large-scale DNA purification performed. Glycerol 
stocks were made. 
Figure 3.8: A. Map of pIP7 showing restriction sites and inserts, B. Re triction dige tion with 
multiple enzymes to confirm correct clones were selected. 
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1.3. Transformation in yeast 
The plasmids containing the adenoviral genome (pMB20 and vpKH 1) were 
transformed into yeast yPH587 using the Alkali-Cation Yeast Tran formation Kit 
(Q.Biogene). The yeasts were plated onto -HIS selective plate (adenoviral 
plasmids express the HIS-gene). Individual colonies were selected and glycer 
stocks were made. Yeasts were called yMB20 (Wild-Type Adenoviru -5 gen m 
and yKHl (Wnt-specific Adenovirus-5 genome). 
In a second step, pIP7 linearised to direct integration wa co-tran ~ t dint the 
yea t u ing the arne method and plated onto -HIS -URA plate (piP7 ntain: the 
URA-gene). The e intermediate con truct contain a dupli ati n f th tar,-"d 
equence and thi tep i called' p p-in '. T verify and Ie tine. '.\ 
wa xtracted from the individual y a t c I ill e M&M an [f [en e piatL:s 
were made. DNA was then transformed into commercial DHIOB electro-competent 
bacteria (ElectroMAX™) and plated onto LB agar plate contalllll1g 
Chloramphenicol (Chl) (l2.5flg/ml). Individual colonies were selected from the e 
plates and DNA extracted (see M&M). DNA was digested with re triction enzyme 
XballXhol and Notl and run on a 0.8% agarose gel. 
Clones containing the duplication pMB20/vpKHl and pIP7 were elected. 
Figure 3.9: A. Digestion with XbaIlXhoI: comparing restriction digestion profile of pIP7 and 
vpKHl with the individual clones. Backbone and insert of pIP7 are both pre ent in the ele ted 
clones. B. Digestion with Not!, a unique restriction site, which lineari es the huttle vector. 
Restriction digestion profiles are compared and should not differ. 
I piP? I c1one1 11 clone2 I vpKH1 11Kb Ladder I 
The selected clones were taken from their yeast reference plates and grown over 
night in -HIS broth. (This removes the selective pressure for URA-3). The 
following day cultures were plated onto -HIS plates containing 5-FOA (1 mg/ml) 
and the plates incubated at 30°C until colonies appeared. Individual colonie were 
selected and reference plates were made. DNA was extracted from individual 
clones and transformed into commercial electro-competent DHIOB bacteria, which 
were grown on ChI LB agar plates. DNA was extracted from individual bacterial 
colonies and digested with Xbal + XhoI and NotI and re triction dige tion pr fil 
of the clones compared those of pMB20 and vpKH 1. 
The elected clone were called pIP8 for wild type adenoviral-hNl pla 'mid 
(pMB20-hNIS) and pIP9 for Wnt-specific adenoviral-hNlS pl mi pKH 1-
hNIS). 
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Figure3.l0: A. Restriction digestion with Xbal-XhoI. Selected clone contain the mutation h 'I . 
but not the backbone of the shuttle vector. Re triction dige tion profile match the profii of parent 
adenoviral plasmids. B. Restriction digestion with NotI: Re triction dige tion profile of ele ted 
clones match the profiles of parent plasmids and do not contain the huttle ector. 
1Kb 
Ladder p~m20 pIP8 plP7 pKIII pIP9-4 pIP9-1 
3Os. 
2036 
\r~ 
I Xbal-Xhol 
1Kb 
------~--------~----~  
The same yeast transformation process was repeated with pIPS (hNIS-negative) a 
a shuttle vector. Adenoviral plasmids created with this vector contain a deletion of 
the E3-6.7k and E3-gpl9k, which lie between E3-12.S and E3-ADP. Pop-in" 
bacterial clones were screened by restriction-digestion with XballXho 1 and Not 1 
as described before and "pop-out" bacterial clones were creened by peR. Primer 
used were P3 and P2 (see M&M). The reaction was optimi ed with the Opti-Prime 
PeR-optimisation kit. The reaction conditions were the ame a for ADP-TOPO 
cloning (see M&M). The amplified samples were run on a gel and the clone with 
the deletion selected. Plasmids were called pIPlO for the wild type adenoviral 
plasmid with E3-~6.7k, ~gp19k (parent pMB20) and pIPll for the Wnt- pecific 
viral plasmid with E3-~6.7k, ~gp19k (parent vpKHl). 
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Figure3.1l: A. Restriction-digestion with Xbal-XhoI. Correct clone contain both ba kbone and 
insert of pIPS. B. PCR reaction: correct clones have a shorter PCR egment than the origm I wild 
type adenoviral plasmid corresponding to the deleted segement. 
1Kb 
LL_a_dd_ar~----,-_2 G ~ ~ 
1.4. Generation of adenoviruses 
The plasrnids vpKHI, pIP8, pIP9, pIPIO and pIPl1 were tran fee ted into 
CYMR293 cells. The viral amplification and purification protocol and the titrati n 
method are described in the M&M section. All viru e obtained were tored at -
80°C in 100f.ll aliquots. Viruses were called AdIP I (Wild type-hNIS), AdIP2 (Wnt-
specific adenovirus-hNIS), AdIP3 (Wild type-i16.7k, i1 gpI9k), AdIP4 (Wnt-
specific adenovirus- i16.7k, i1 gp 19k) and AdKH 1. 
An aliquot of wild type Adenovirus 5 was obtained from Claudia Montiel 
(Molecular Oncology Unit) and an aliquot of Adl0 (non-replicating adenoviru 
with CMV promoter driving hNIS) from Thomas Groot-Wa ink (Groot-Wa ink 
et aI., 2002). These aliquots were also amplified by direct infection of T 175 fl k 
containing CYMR293 cells. Cell homogenates from the e fla k were u ed to 
infect CFIO cell factories. The viruses were used a control in cell a ay . 
A few aliquot of AdLacZ, a non-replicating adenoviru where the CMV pr m ter 
drive the expre ion of the ~-galacto ida e gene were obtained fr m n ra 
Martinico in our laboratory. 
2. In vitro analysis of constructed viruses 
2.1. Comparison of the cytotoxic effects of the different 
viruses 
2.1.1. AdWt compared to AdIPl (AdWt-hNIS) and AdIP3 (AdWt-
A6. 7kAgp 19k) 
Cell survival assays were performed to assess the cytotoxic properties of the 
mutant viruses in comparison to the wild type virus. Assays were performed on a 
variety of cell lines in quadruplicate. The data presented are representative of three 
independent experiments. Statistical analysis was performed with the two-tailed 
unpaired t-test. Differences are significant when p<O.05. 
The viruses AdWt, AdIP I and AdIP3 were compared and it was evaluated whether 
the mutant viruses were able to kill cancer cells to the same extent as wild-type 
VlfUS. 
From these assays it was observed that insertion of the hNIS gene appears to 
compromise the cytotoxic effect of the adenovirus. In the cell lines represented, 
cell death is significantly less (p<O.OO 1 at MOl 1 in all cell lines except MCF-7) in 
the hNIS-containing virus pIPl as compared to the wild-type virus and the virus 
with the deletion in the E3 region (pIP3). Deletion of E3-~6. 7k, ~gp 19k does not 
seem to affect the cell-killing potential of the virus in colon cancer cell lines with 
Wnt activation. However, in other non-Wnt-activated cancer cell lines deletion of 
E3-6.7k and E3-gp19k affects the toxicity of the virus and makes it less powerful. 
We conclude that the insertion of hNIS or deletion of 6.7k and gp 19k seems to 
have an effect on the cytotoxic potential of the virus. 
Cell lines SW480 and SW620 are related human colorectal cancer cell lines. which 
were derived from the primary tumour and a lymph node metastasis repectively 
from the same patient. 
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Figure3.12: MIT assay for SW480 (a), SW620 (b), HCTl16 (c) colonic cancer cell infe ted \ 'ith 
AdWt, AdIPl and AdIP3. 100% corresponds to the value obtained in the non-infected control \\.ell . 
EC50 values are represented in a table with each graph. 
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Figure3.l3: MIT assay for HPAF (a) (pancreatic), SKBR3 (b) (brea t) HeLa (c (cervic 1 an er 
cells infected with AdWt, AdIPl and AdIP3. 100% corre pond to the value obtained in the n n-
infected control wells. EC50 values are represented in a table with each graph. 
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HT29 is a colonic cancer cell line and MCF-7 a brea t cancer cell line. Adenoviral 
infection increases the intensity of the MTT signal and appear to timulate ell 
growth at non-lethal multiplicities of infection. Other inve tigator ill our 
laboratory have described this before (Claudia Montiel-Equihua, PhD, 20 6 but to 
our knowledge the mechanism behind it has not yet been elucidated. It i beyond 
the scope of this thesis to investigate this further, but it could be that viral infection 
increases the metabolic activity in the infected cells and as a result lead to a higher 
MTT signal. The increased intensity measured may thus not be due to cell 
duplication or cell growth but merely reflect increased mitochondrial activity. If 
this were the case, viral infection may not lead to tumour growth in vivo but rather 
tumour swelling before cell death and tumour destruction occur . 
Infection of these cell lines with AdWt, AdIPl and AdIP3 at different MOl h w 
that insertion of the hNIS gene into the E3 region reduce the potency of the viru 
compared to wild type. In the breast cancer cell line the deletion in the E3 regi n 
also results in reduced efficacy. 
Figure 3.14: MTT assay for HT29 (a) (colonic) and MCF-7 (b) (brea t) cancer cell infected with 
AdWt, AdIPl and AdIP3. 100% corresponds to the value obtained in the non-infected contr 1 well ' . 
EC50 values have not been calculated due to the shape of each graph. 
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2.1.2. AdWt compared to AdIPl and AdIP2 
In a further series of MTT assays in non-permissive cell lines we verified \,: hether 
the insertion of hNIS into the Wnt-specific adenovirus affected the electi ity of 
the virus to replicate only in Wnt-activated cells. Assays were performed in 
quadruplicate and the data presented are representative of at least two independent 
experiments. HPAF is a pancreatic cancer cell line, MCF-7 and SKBR-3 are brea t 
cancer cell lines and HeLa is a cervical cancer cell line. 
AdIP2 kills cells significantly less than the wild-type viruses. In HP AF cell the 
Wnt-specific virus is 25 times less toxic while in SKBR-3 cells and MCF7 cell 
AdIP2 is more than IOO-fold less toxic than wild-type virus. AdIP2 i IOO-fold Ie 
toxic in HeLa cells. 
We observe that the insertion of hNIS preserves the electivity of the VlfU for 
Wnt-activated cell lines. 
Figure3.IS: MTT assay for HPAF (a) (pancreatic), HeLa (b) (cervical), SKBR3 (c) and MCF7 (d) 
(breast) cancer cells infected with AdWt, AdIPI and AdIP2. 100% corre pond to the va lue 
obtained in the non-infected control wells. ECSO value are repre ented in a table wi th each graph 
except for MCF-7 cells due to the shape of the graph . 
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2.1.3. AdWt compared to AdIPl and AdIP2 in Wnt activated cell lines 
In the next experiment we verified the potency of the Wnt-selective viru for Wnt-
permissive cell lines. We selected a panel of colonic cancer cell lines and one Wnt-
activated, non small cell lung cancer cell line (NSCLC), A549. 
Table 3.1 shows the genomic modifications in the different cell line that re ult in 
the activation of the Wnt signalling pathway. 
Table 3.1: Genetic profile of Wnt-activated cell lines. LOH = 10 of heterozygo ity, NL = normal. 
References: (Rowan et aI. , 2000) (Ikenoue et aI. , 2002). 
Wnt activated cell lines 
APe p-
catenin 
CAC02 mutation LOH wild type 
DLD1 mutation ? wild type 
HCT116 wild type NL mutation 
HT29 mutation NL wild type 
SW480 mutation LOH wild type 
SW620 mutation NL wild type 
A549 APC upregulated 
Dishevelled upregulated 
In col nic cancer cell line there i a varying effect of the lfU II . In 
SW4 0, AdIP2 i more potent than AdWt but in th r 01 an r 11 lin 
1 1 
AdIP2 is equally or less effective than AdWt. The cell lines SW480 and S\ 6 ... 
have high Tcf activity whereas the cell lines HCTl16 and HT29 have weak T f 
activity, which could explain why the viruses have a reduced cytotoxic effect. The 
same differences have been described by Fuerer et al. (Fuerer and Iggo 
the NSCLC cell line AdIP2 kills the cells but less effectively than AdWt. 
Figure 3.16: MIT assay for SW480 (a), SW620 (b), DLDl(c), HCTl16 (d), CAC02 (e and HT29 
(0 colonic cancer cell lines and A549 (g) NSCLC cell line infected with AdWt, AdIPl and dIP2 . 
lOO% corresponds to the value obtained in the non-infected control well . EC50 alue are 
represented in a table with each graph except for HT29 cells due to the hape of the graph. 
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We also verified the effect of hNIS mutation on the potency of the Wnt- electi e 
adenovirus. We therefore compared AdIP2 (hNIS) and AdIP4 (deletion E3-6, 7-
gpl9k) in permissive and non-permissive cell lines. MTT a ay were perform d in 
quadruplicate and repeated at least twice. 
In all colonic cancer cell lines presented, deletion of E3-6.7k and E -gp I k with ut 
in ertion of hNIS increa es the cytopathic effect of the viru . 
In HeLa and SKBR3 cell the AdIP4 viru i Ie potent th n the lfU 
hNIS. 
nt InIn ...., 
Figure 3.17: MIT assay for SW480 (a), SW620 (b), HCTl16 c) and HT29 (d) coloni can er ell 
lines and HPAF (e) (pancreatic), HeLa (f) (cervical), SKBRJ (g) and MeF7 h) brea t an er ell 
lines infected with AdIP2 and AdIP4. 100% corresponds to the value obtained in the non-infe ted 
control wells. EC50 values are represented in a table with each graph except for lIT ~9 HeLa and 
MCF cell lines due to the shape of the curve. 
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2.1.5. Comparing AdIP2 and AdIP4 to the original Wnt-specific virus 
AdKHl 
Deleting the E3-6.7k and E3-gp19k makes the virus ignificantly more potent than 
the original Wnt-specific virus without changes in the E3 region. In erting hNIS 
into the E3 region reduces the cytotoxic effect of the Wnt viru in \. itr In 
permissive cell lines. 
1._2 
Figure 3.18: MIT assay for SW480 (a) and SW620 (b) I . '. 
AdKH1, AdIP2 and AdIP4 1 OO~ co onte. ean~er eell lme mfe red \\ ith 
• 0 corresponds to the value obtamed 10 the non-infe red ntrol 
wells. EC50 values are represented in a table with each graph. 
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2.3. The expression and functionality of the hNIS protein 
To evaluate hNIS expressIon In infected celis, SW620 and HeLa cell were 
infected with AdIPI, AdIP2, AdIP4 or AdiO at MOllO. At 24h after infection, 
celis were stained for the presence of the hNIS protein. An hNIS-specific ignal 
was observed at the periphery of the infected cells, suggesting that the hNIS i 
correctly transported to the cell membrane (figure 3.19). The Wnt- elective viru 
AdIP2 does not show hNIS expression in HeLa celis, which do not have an active 
Wnt-signalling pathway. A signal is absent in cells infected with AdIP4 which doe 
not have the hNIS (negative control). AdiO is a non-replicating adenoviru where 
the CMV promoter drives hNIS (positive control). 
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Figure 3.19: Immunocytochemistry DAPI (staining the nucleus blue) and hNIS (green) in HeLa 
cells (top) and SW620 cells (bottom) infected with AdIO, AdIPl , AdIP2 or AdIP4. 
To test the functionality of hNIS, HeLa and SW480 cells were infected at different 
MOl with AdWt, AdIPl, AdlP2 and AdiO. 1125 uptake was monitored 48h after 
infection in the presence and absence of the hNIS inhibitor sodium perchlorate. A 
dose-dependent perchlorate sensitive 1125 uptake was seen for all hNIS-expre mg 
vrruses. 
Figure 3.20: Iodine uptake for HeLa cells (left) after infection with AdIO (a), AdIPl (b) and AdIP2 
(c) at different MOl and Iodine Uptake for SW480 cells (right) 48h after infection with AdlO (a , 
AdIPl (b) and AdlP2 (c). I = Iodine, P = Perchlorate, a competitive inhibitor of hNIS. 
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The amplitude of the uptake was similar for AdlO (CMV promoter driving hNIS 
expression) and AdIP2. This demonstrates that hNIS expre ion driven by the 
endogenous adenovirus E3 promoter can provide high level of tran gene 
expresslon. 
Reduction of iodine uptake at MOl 100 with viruses AdlO and AdIP2 i due to cell 
toxicity. After 48h cells have started dying and no longer take up iodine. 
2.4. Viral replication 
Viral replication was fIrst assessed by titration in CYMR293 cell of cell 
homogenates collected at different time points after infection. By 48 h ur th 
amount of virus produced in the cells had exceeded the initial input d e f 0.1 pfu 
/cell. Both the wild-type viruses (AdWt and AdlPl) increa e 100-~ Id betw n_4 
and 48 hour. The Wnt- pecifIc viru es increa e Ie than 50-fold, whi h m 
ignify that the Tcf promoter are weaker than the wild-type pr m t r in thi 
colon cancer cell line with weak Tcf activity. Viru e that hav in crti n f the 
hNIS gene in the E3 region (AdIP 1 and AdIP2) repli ate t 1 \ er titr than wild-
typ ad noviru , which might be due to th ize f th tr n b n . 
Figure 3.21: Graph showing the titres of AdWt, AdIPI, AdIP2 and AdIP4 cell hom gen te 
successive days. Cells were infected on day 0 with 0.1 PFU per cell (dotted line. 
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Even in cells with a high Tcf activity, the AdIP2 virus doe not replicate more than 
approximately 50-fold between 24 and 48 hours (figure 3.22). 
Figure 3.22: Virus production in SW620 cells after infection with AdWt and AdIP2 at input do of 
0.0 I pfu / cell (dotted line). 
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The ElA adenoviral gene i tran cribed early and i a k y m diat r f viral 
replication. The kinetic of the ElA gen w re det rmined by quantitativ re' \-
time peR. 
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In a ftrst experiment, total RNA (tRNA) was extracted from cells infected with 
different viruses. Total RNA was reverse-transcribed and quantitati e real-time 
PCR performed. Control virus was AdIO which does not replicate. The arne 
experiment was repeated but instead of total RNA, total DNA tD A \ a 
extracted. 
Figure 3.23: Left: real-time quantitative PCR for EtA on total RNA extract from cell. Right: re \-
time quantitati ve PCR for E 1 A on total DNA extracts from cells. The E 1 A value are plotted at da 
1 and day 3. In all cases except the non-replicating control virus there is an increa e in the am unt 
of ElA at day 3 compared to day 1. 
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In both t-RNA and t-DNA extracts there is an increa e in ElA for all oncolytic 
viruses tested on day 3 compared to day 1, indicating that viral replication en ue . 
There is no increase in the control virus which is a non-replicating viru . 
In the next experiment we evaluated the viral replication from day to day. SW4 
cells were infected at MOl 0.01 and total DNA extracted every day. SW480 cell 
are very sensitive to viral infection and even at MOl 0.01 cell are dying, e peci lly 
cells infected with AdIP2. 
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Figure 3.24: Real-time quantitative PCR for DNA extract from SW480 cell infected \\i th Ad\\ t 
and AdIP2. 
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The experiment was repeated and HCT1l6 cells were infected with AdIP2 at MOl 
0.1. DNA was extracted from cell homogenates daily and quantitative real-time 
PCR performed for ElA and hNIS. The amount of viral gene DNA relative to t tal 
DNA continues to increase up to day 5 since there i no cellly i . It wa important 
to perform this experiment since HCT 116 cells will be used in in vivo experiment 
and the viral dose administered to tumours may not be lethal to all cell within a 
tumour. 
Figure 3.25: Quantitative real-time PCR for ElA (a) and hNIS (b) on total DNA extracted fr m 
HCT 116 cells infected with AdIPZ at MOl 0.1. 
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2.5. Selectivity of Wnt-specific viruses for Wnt activated cell 
lines 
To verify whether in ertion of hNIS in the E3 regi n f th Wnt- ele tiVl; viru 
do not have a detrimental effect on the electi ity f the lru a We t rn B 1 l \ t 
P r~ rm d to detect the expre ion f th aden viral E 1 pr t in aftl;r f \ nt-
activated and Wnt-negative cell lines. High expres ion of ElA iral protein \\ 
detected ill SW480 cells infected with AdIP2 while no EIA expre 1 n w 
detected ill Wnt-negative HeLa cells up to at least MOllO figure A . E 1 A 
expression in SW480 cells is stronger than in control 293 cells. 
The experiment was repeated in HeLa cells alone and AdIP2 viru wa compared 
to AdWt virus (figure B). A small amount of EIA is expressed at MOIl 00 in cell 
infected with AdIP2, which corresponds to the cell killing effect seen in the MTI 
assays (figure 3.15). No expression of the late adenoviral gene Hexon i detected in 
HeLa cells infected with AdIP2. 
The experiment was repeated in the cell line wi38, which is derived from n rmal 
human embryonic lung tissue and the cells are fibroblast-like. There i me 
expression of ElA at MOl 100 in cells infected with AdIP2 but much weaker than 
expression in cells infected with wild-type virus. 
Figure 3.26: A. Western Blot for E LA and KU70 on HeLa and SW480 cell infected with AdIP2 at 
different MOL B. Western Blot for Hexon, KU70 and E I A on HeLa cell infected with AdWt and 
AdIP2. C. Western blot for EtA and KU70 in wi38 normal human fibrobla t . 
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3. In vitro analysis of the effect of constructed viruses on 
primary cells 
3.1. Evaluation of cell killing potential 
To determine the effect of adenoviral infection on primary de moid tumour cell , 
cells from sporadic (Desmoid 1-3) or FAP-related (De moid 4, 5, 5.2 de m id 
tumours were infected at different MOl with AdlP2 or AdKHl. Primary de m id 
cells were obtained from St. Mark's Hospital (Desmoid 5.2) and the UZ 
Gasthuisberg, Leuven, Belgium (Desmoid 1-5). The effect of adenoviru e on the 
cells was assessed by performing MTT assays. Each as ay wa performed in 
triplicate. 
Figure 3.27: Cell survival assays peformed after infection of primary de moid cell with dIP2 and 
AdKHl. Desl (a), Des 2 (b), Des 3(c), Des 4 (d), Des 5 (e) and De 5.2 (t). I ~ repre ent the 
value obtained in non-infected control wells. The dotted line repre ent 50~ cell death. 
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Different levels of sensitivity to oncolytic or wild-type adenoviral treatment n t 
shown) were observed in the desmoids. The stronge t effect wa n ticed in 
desmoid 2 (sporadic) > desmoid 5, desmoid 5.2 (familial) > de moid 3 ( poradic > 
desmoid 1 (sporadic), desmoid 4 (familial). Statistical analy i howed a hiohly 
significant difference (p<O.OOOl) between uninfected cell and cell infected with 
AdKHl and AdIP2 at MOl 100 for desmoids 2, 3, 5 and 5.2. The e f ult 
demonstrate that the sensitivity to oncolytic adenoviral treatment i not felat d t 
the type of mutation in the Wnt signalling pathway, or the poradic Of familial 
nature of the desmoid tumours. 
3.2. Evaluation of infectivity of primary cells 
The infectability of primary cells extracted from the different de moid tumour wa 
determined by infection with a replication-deficient adenoviru encoding the green 
fluorescent protein (GFP) and mea urement of GFP-po itive cell by f1 w 
cytometry analysis (figure 3.28). 
Figure 3.28: Flow cytometry analysis of GFP positive cell . The infecti vity corre pond t the 
cytopathic effect seen in MIT as ays. Ec50 values are pre ented in the graph . 
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Figure 3.29: Desmoid cells infected with AdGFP at MOr 100 (J1 f . . ell 
, 7C 0 po Itl ve 
flow cytometry (left y-axis and left bar) compared to the amount of dead cell 
death assay (right y-axis and right bar). 
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The range of infectability is similar to that obtained for the en itivity t aden irai 
infection. 
3.3. Evaluation of viral replication in desmoids cells 
To determine whether the reduced cell viability ob erved upon adenoviral in~ ti n 
of cells from desmoids 2, 3, 5 and 5.2 wa as ociated with viral replication, DNA 
from cells infected with AdIP2 was collected one day or four day after infecti n. 
This DNA was subjected to quantitative peR to titrate the amount of aden viral 
ElA DNA compared to total cell DNA. In all case amplification of the aden viral 
genome was observed between day 1 and day 4 ugge ting replicati n [ th 
oncolytic virus in these cells (figure 3.30). 
Figure3.30: qPCR for ElA in DNA extracts from primary de moid cell . De 1 wa infe t d at M 
lO, all other desmoids at MOr 5 becau e at MOr lO cell death wa apparent after 4 da s. 
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3.4. Evaluation of a panel of known adenoviral receptors on 
cell membranes 
I wanted to verify whether there was a correlation between the infectability f the 
cells and the expression of CAR receptor and integrins on the urface of the ell. 
The coxsackie and adenovirus receptor (CAR) has been hown to act a a primary 
receptor to adenovirus and to play a critical role in viral entry into th 11. 
Surprisingly, CAR staining was negative in all desmoid cell ample. Thi III 
sharp contrast to the highly positive A549 cells (97.16%) used a a po itive ntr 1 
and known to express high levels of CAR. 
Integrins playa role in the intemalisation of adenoviru and gene deli ery to th 
cell. The main integrins that playa role in adenoviral infection are avp3 and a pS. 
Figure 3.31: Desmoid cells were stained with antibodie agajn t adenoviral CAR-receptor, integrin~ 
and CEA-Cam6, which are all known to influence adenoviral uptake into cell . The p rentage f 
cells positive for each receptor was measured with flow cytometry. 
CEA 1.17 1.04 1.01 0.81 0.73 O. 
AlphaV 61.17 64.73 80.21 99.75 25.04 94.25 
Alpha VBeta3 39.82 2.94 1.22 56.09 0.97 2.3 
Alpha VBeta5 57.35 20.10 2.14 1.85 3.22 9.66 
There does not appear to be a correlation between the infectability of cell and th 
expression of CAR and/or integrins on the surface of the cell membrane ugge tin~ 
that a CAR- and integrin-independent mechanism i re pon ible for ntry f th 
virus into the cells. 
3.5. Additional toxic effect of the hNIS transgene 
In cell from de moid 2, 5 and 5.2 infected at MOll th iti 
1 h h n ali" VlfU tati tically more efficient (p<O. ) t an t 
h f h I in th iral gen Ill' Vlru (figure 3.27). T determine wh th r t pre n 
and it pr to ic fi r d m id ell., indep n ~ntl fr m the n I)li 
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action of the VITUS, primary cells were infected at MOl 100 with a replicati n-
deficient recombinant adenovirus encoding either the ~-galacto ida e oene 
(AdLacZ) or hNIS under the control of the immediate early CMV pr m ter 
(AdlO). The toxicity of AdiO is not observed with AdLacZ ugge ting a toxic 
effect of the hNIS gene product in desmoid tumour cells (Figure 3.33 . 
Figure 3.32: Effect of replication incompetent adenoviruses AdlO and AdLacZ on de moid tum ur 
cell survival. Desmoid tumour cells were infected at MOl 100 with replication in ompetent 
adenoviruses encoding lacZ or hNlS. The number of surviving cells wa as e ed after 6 da u ing 
MTT assay. 100% corresponds to the number of cells in control non infected well. Stati ti al 
analysis was performed using a two-tailed student t-test. P values are < 0.0001 in all the nditi n 
compared. 
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4. In vivo analysis of constructed viruses 
4.1. Toxicity of the virus 
Heterozygous balb-c nude (NuJ-) mice were injected intravenous with PBS. AdlPl 
or AdIP2. Livers were collected on day 1 and day 5 and half of the tissue was 
stored in "RNA later" and the other half was snap-frozen and sent to the pathology 
unit where H&E staining and immunohistochemistry for E 1 A were performed. 
Although the sample size of this experiment (two-three mice per group) is not large 
enough to perform statistical analysis, the results are intriguing. Repeating this 
experiment would also pose ethical problems as one of the viruses is evidently 
toxic for the mice. 
All animals injected with AdIP2 remained healthy throughout the study. Mice 
injected with AdIPl had either died or were seriously ill by day five. H&E staining 
showed a normal liver architecture for all animals injected with AdIP2. although 
there is evidence of a mild inflammatory infiltrate. The liver architecture of mice 
injected with AdIPl was seriously damaged and even destroyed (diffuse necrosis) 
and there is massive infiltration of inflammatory cells. Staining for E 1 A showed a 
few positive cells in the liver of mice injected with AdIP2. The livers of mice 
injected with AdIPl showed massive, diffuse staining for EIA. Real time peR for 
EIA was performed on the DNA extracts from liver tissue. The amount ofEIA 
present in mouse liver for each condition correlates with the amount seen in 
immunohistochemistry. These results are comparable to the ones seen by 
Homicsko et aI. after IV injection of Wnt-specific viruses compared to Wild-type 
virus (Homicsko et aI., 2005). 
1 ~ -- ) 
Figure 3.33a: Irnmuno-histochemistry of liver tissue for ElA (top) compared to H&E raining 
(bottom) for mice injected with PBS, AdIPl and AdlP2 at 48h. The arrow point out cell raining 
for E LAo Arrows = cells staining positive for ElA. 
1 6 
Figure 3.33b: Immuno-histochemistry of liver tis ue for E lA (top compared to H&E t 'ning 
(bottom) for mice injected with PBS, AdIPl and AdlP2 at l20h, The arrow point ou[ ell (inrn.:> 
for E lAo Arrows = cells staining positive for EIA. 
1 7 
Figure 3.33c: Real-time peR for ElA on the DNA extracted firom the [. f '" d . 1 er 0 mIce tnJe (e \\ Ith 
PBS, AdIPl and AdIP2. Next to the graph are the exact quantitie with tandard de iatl n. 
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4.2. Molecular imaging 
I PBS = 4 51 e-C05+1- 0 OOlD)OO I 
I AdIPl-48h = 011 +1- 0 003 I 
I AdIP2-48h = 0 OO(B)+I- 0 OlD) 13 I 
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I AdIP2-5 = 0.00021 +1- 0.cm016 I 
Subcutaneous xenografts of the colonic cancer cell line HCT 116 in nude mice w r 
injected with adenovirus at a dose of 5 x 108 PFU on two con ecutive day . Mi 
were anaesthetised and scanned on day 1 and day 5. 
Figure 3.34 shows representative images of hNIS expre ion 24h after th la t 
injection of virus. A signal is detected in the thyroid and the tomach a a re ult of 
endogenous expression of hNIS and in the tumour. No ignal wa ob erved in the 
liver after intratumoural injection of virus. Five day after viru admini trati n 
(figure 3.34b) the tumours did not accumulate 99-mrrc, ugge ting an ab ence of 
hNIS expression. To confirm these data, tumour were collected and 
immunohistochernically stained with anti-hNIS antibody. Figure 3.34c h w 
intense brown staining in the tumour at day 1, which had completely di app ar d at 
day 5 (figure 3.34d). 
13 
Figure 3.34: hNIS expression in vivo. (a) and (b) nano-SPECT/CT fu ed image of mi e with 
subcutaneous HCTl16 tumours (arrows) were intratumorally injected with 5x 10 PFU AdIPI n 
two consecutive days. A total of 18.5 MBq of 99-mTc was injected i.v. for canning n da} I a) 
and day 5 (b). (c) and (d) corresponding hNIS immunohistochemistry of tumour (x_O from a) nd 
(b) respectively. 
Tumours were excised after scanning and stained with hNIS- pecific antibody. Strong hNIS taining 
at day 1 (c) has decreased to non-specific background staining at day 5 (d). The data pre ented are 
representative of three animals at each time point. hNIS, human sodium iodide ymporter; SPECT. 
single photon emission computed tomography. 
1 
In addition real-time quantitative PCR on total RNA extra t from tum ur ~ 
(experiment performed by Andrew Merron) howed a ignal t da ' 1 th t 
dramatically decreased by day 5 (figure 3.36). 
Figure 3.35: Quantitative real-time PeR on total RNA extract from tumour infected \\;th dIP I 
and AdIP2 at day 1 and day 5. The amount of hNIS total RNA i decrea ed at day 5. 
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These data confrrm that it is possible to image gene expre ion after aden iral 
gene transfer of hNIS with SPECT/CT imaging. 
In a next serIes of experiments we wanted to image adenoviral pread within 
subcutaneous xenografts in nude mice. A single dose of 5 x 10 PFU wa injected 
into each of the subcutaneous HCT116 xenograft. The arne animal were imao d 
daily, starting 24h after infection. To obtain a greater re olution and a tran g n 
expression was exclusively localised in the tumour ( ee previou experiment), th 
scans were focused on the tumour region. Radiotracer uptake reflecting expre i n 
of hNIS transgene can be seen spreading through the tumour for both iru 
AdIP 1 and AdIP2. The peak of transgene expression a een by 99-mTc uptak w 
detected after 48h for both viruses (figure 3.36 and 3.37). No ignal wa d t 
on scans performed after 8 days (not shown). 
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Figure 3.36: Successive scans of subcutaneous xenografts injected with a ingle do e of 5 10 PF 
AdIPl. The maximal signal is detected 48h after infection of the tumour. 
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Figure 3:37: Successive scans of subcutaneous xenografts inJ'ected with '0-1 d f 5 ' AdIP2 Th '1' 1 . a me> e 0 e 0 x 10 PFU VlfUS. e max un a SIgna IS detected 48h after infection of the tu mour. 
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These data confirm that viral propagation can be imaged in vivo by SPECT/CT. 
Next we wanted to find out whether quantitative information could be obtained 
from these scans. A region of interest (RGI) was determined and the amount of 
radioactivity in MBq calculated. The activity measured in the tumour wa 
standardised by dividing it by the amount of activity measured in the background t 
account for the differences in the administered dose. 
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Figure 3.38: Determination of the region of interest in the t ( umour green and the background 
(blue). The software calculates the amount of radioactivity in MB . th ~ q pre ent In e ROI and al 0 the 
1 . 3 
vo ume In mm (see screen snapshot quantifications). cr = computed tomograph , 1 = ~lR = 
Nuclear Magnetic Resonance. 
Comment Mod Voxels volume Sum Mean StdDev Mil Mal( [mm3 ) QiU!MBq) QiU/kSq) QiU/kBq) SldErr (HU/kBq) QiU/kBq) 
1 40448 323.584 49582.2 1.22583 0.544418 0.00270697 0 2.88911 
2 40448 323.584 0.190512 0 .00471004 0.00462359 2.29896e-OS 0 0.0397915 
These data confum that the maximum amount of activity can be een in the tum ur 
48 hours after injection (figure 3.39). We can therefore conclude that SPEeT/CT i . 
able to image viral replication and that quantitative informati n of iral g n 
expression can be obtained from the image. 
14 
Figure 3.39: Relative intensity of radioactivity as expre ed by di iding in ten ity in the tum ur p r 
mm
3 by the intensity in the background per mm3. 
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4.3. Viral replication in vivo 
Subcutaneous HCT 116 tumours were created in nude mice and tumour inject d 
with AdIP2. Scans were obtained at different time point and mice acrificed after 
scanning. The tumours were collected and total DNA extracted from half of the 
tumour. The other half was fixed in formaldehyde. Quantitative real-time PCR wa 
performed on DNA extracts for EIA and hNIS to determine viral DNA and 
transgene content. Immunohistochemistry for ElA and hNIS wa performed on 
forrnalin- fixed tissue. 
Figure 3.40: SPECT/CT fused image of mouse with HCTl16 tumour in the left flank, , anned 24 
hours (a), 48h (b), 72h (c), 96h (d) and 120h (e) after intratumoural injection of 5 x 10 PFU AdIP2. 
A total of 18.5 MBq of 99mTc was injected intravenously approximately 20min before annm g. 
Below each scan are the corresponding pathological lides (lOx) with H&E taining, E I A and h I 
immunohistochemical staining. The data presented are repre entative of even animal at ea h time 
point. 
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The intense brown staining is mostly nuclear for ElA and at the pIa rna membrane 
for hNIS. The maximum intensity in the scans is after 48 hour of intra-tum ural 
injection as seen before. The intense staining in the pathological lide remain 
present until the fifth day. The amount of positive cells is reduced by the fifth day. 
Figure 3.41: A. qPCR for E1A of DNA extracts from tumours infected with AdIP2. B. q-PCR for 
hNIS of DNA extracts from tumours infected with AdlP2. 
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The amount of ElA and hNIS in the tumour continues to ri e until the fourth day 
and to decline from the fifth day onward. 
4.4. Therapeutic experiment virus alone 
In a first experiment we wanted to evaluate whether there i a difference in vivo 
between each of the wnt-specific viruses. Subcutaneous tumour were created in 
nude mice with HCTll6 tumour cells. When the tumour reached a ize of 
approximately 5 x 5 mrn2, they were injected with either 100J.ll PBS,S x 10 PFU 
of either virus in 100 I.d in PBS on three consecutive day. Tumour were m a ur d 
every other day for 100 days. Mice were killed when the tumour reached a f 
approximately 144mm2. The data were plotted a a"~ remaining' cur an 
Kaplan-Meier analy i performed. 
IS 
Figure 3.42: "percentage remaining" curve. 100% corresponds to all mice ali e, 0% = all mice dead. 
Total number is 6 mice per group. Arrow = intratumoural injection of virus on day 15, 16 and 1 
Day 0 = day of injection of 2 x 106 HCT1I6 cells. 
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Kaplan-Meier statistical analysis show that there is a significant difference between 
non-treated and AdIP2 (p = 0.0014) and treatment with AdIP4 and AdIP2 (p= 
0.0055). The difference between non-treated and treated with AdIP4 i not 
significant (p = 0.058). The Wnt-specific adenovirus containing hNIS appear to be 
better than the gpl9k-deleted mutant in vivo in xenografts in nude mice. 
Figure 3.43: Tumour size plotted over time for therapeutic groups (0 = initial ize at the time of 
injection). Injection of PBS or viruses was effectuated at day 14. All non-treated mice (PBS) were 
dead at day 44. All AdIP4 treated mice were dead at day 50. The last Ad1P2·treated mou e wa 
killed at day 113. 
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Figure 3.43 shows the tumour SIze plotted again t time m day for all thr e 
treatment groups. Statistical analysis with ANOY A one-way non-linear r gre I n 
conftrms a statistically significant difference (p<O.OOO 1) between treatm nt gr up . 
Comparing the individual treatment with an unpaired t-te t analy i d n t ~ho\ 
a ignificant difference between non-treated and dIP4 but , h \ ignifi ant 
151 
difference (p<O.OOOl) between non-treated and treatment with AdIP2 and between 
treatment with AdIP4 and AdIP2 (p = 0.0002). This confIrms the dat obtained 
from the survival curve. 
4.5. Therapeutic experiment virus and Iodine 
In the next experiment we want to correlate the data obtained from the irnaaina b b 
with radiotherapy by administration of 1311. 
From the imaging experiments we learned that the time point of maximal iral 
replication and transgene expression was 48 hours. Subcutaneou tumour were 
created in nude mice with HCTl16 colonic cancer cells. When the tumour reached 
a size of approximately 5 x 5mm2 they were injected with one do e of either PBS 
(100 Jll), AdIP2 or AdIP4 (lxl09 PFU in 100 Jll in PBS). After 48 hour a ingle 
dose of 3mCi 1311 was injected intraperitoneally. Tumour ize wa mea ured very 
other day. Due to logistical circumstances (the host institution wa unable to hou e 
the mice for longer), mice had to be culled after 8 days. In thi pilot experiment 
there appears to be a difference between treatment with viru alone and treatment 
with AdIP2 and radioiodine. Statistical analysis performed with one-way non-
linear ANOV A analysis shows the difference is not ignificant between group. 
Statistical analysis with unpaired t-test does not how a ignificant differ nee 
between any of the treatment groups. 
Figure 3.44: Pilot experiment: tumour size plotted again t time for the 8 day po t-radiotherap . 
There is no statistical difference between treatment groups. 
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A second therapeutic experiment was performed in France. Due to poor h gieni 
conditions in the host institution which compromised the health of the experimental 
animals as well as different housing facilities for radiotherapy-treated and ontr 1 
mice no defmite conclusions can be drawn form these re ult but they are included 
here for completeness. 
Figure 3.45: Mice treated with either PBS, AdIP2, AdIP2 + iodine, AdIP4 and AdIP4 + iodine. 
Tumour size in mm2 is plotted against time for each treatment. 
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Statistical analysis with ANOV A one-way, linear analy is how that there i a 
statistically significant difference between treatment group. Due to the fact that 
irradiated mice were kept in a separate animal house, group with viru alone can 
not be compared to groups with virus and radiotherapy for tati tical analy i . 
Statistical analysis with unpaired t-test shows a significant difference between 
PBS-treated and treatment with AdIP2 (p = 0.0002) and between PBS-treated and 
AdIP4 (p = 0.01). The same difference exists between treatment with PBS and 
AdIP2+iodine (p = 0.002) and PBS and AdIP4+iodine (p = 0.05). All we can 
conclude is that treatment with AdIP2 appears to be better than treatment with 
AdIP4 (p = 0.0003) and treatment with AdIP2 and radioiodine i better than 
treatment with AdIP4 and iodine (p = 0.0001). 
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CHAPTER 4: Discussion 
1. Characterisation of the viruses 
The hNIS transgene was successfully cloned into the E3 region of replicating 
adenoviruses. The endogenous gene expression machinery (promoter. 
polyadenylation and splicing signals) was used to express the foreign gene. The 
maximum viral genome size that can be packaged is limited to 105% of the wild 
type adenoviral genome (Bett et aI., 1993). The hNIS gene has a size of 
approximately 2kb and therefore it was necessary to delete adenoviral genes to 
create the necessary space. The endogenous genes E3-6.7k and E3-gp 19k were 
deleted together as they are adjacent in the adenoviral genome, are encoded by the 
same mRNA and have overlapping open reading frames. The gp 19k protein 
complexes with the MHC class I molecules and inhibits their transport to the cell 
surface, preventing the detection of the infected cell by the immune system and 
thus preventing its destruction and clearance by adenovirus-specific cytotoxic T 
lymphocytes (CTLs). Malignant transformation of cells is often associated with 
altered HLA class I expression and/or function (Hicklin et aI., 1999). The function 
of the gp 19k gene may thus be dispensable in tumour cells. The E3-6. 7k-gp 19k 
region is non essential for viral replication in vitro and in vivo (Ono et aI., 2005) 
(Wang et aI., 2003b). It has been demonstrated that when substituting E3-6.7k and 
E3-gp 19k for another gene, transgene expression mimics the substituted 
endogenous gene (Hawkins et aI., 2001). Immunocytochemistry has demonstrated 
that the hNIS transgene is expressed and correctly presented at the cell membrane 
in infected cells (figure 3.19) and iodine uptake assays have conftrmed that the 
level of gene expression is comparable to the level seen after infection of cells with 
a non-replicating virus where the CMV promoter drives gene expression (figure 
3.20). 
Hawkins et al have also demonstrated that the expression of the surrounding EJ 
genes can be maintained when substituting E3-6.7k and E3-gp 19k for another gem~ 
(Hawkins et aI., 2001) however, we have not verified this point experimentally. In 
my constructs the E3-ADP remains intact, this is important since in the late stages 
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of adenoviral infection it IS responsible for cell lysis and the release of \"iral 
progeny. 
The viruses with the insert hNIS exhibit a reduced potency in cell toxicity assays 
when compared to wild type adenovirus (figures 3.12,3.13, 3.14, 3.15. 3.16). This 
could be due to the critical size of the viral genome after insertion of the transgene. 
It has been demonstrated that larger inserts reduce replication efficacy. which may 
in its tum result in lower cytotoxic effect (Bett et al., 1993). Replication assays 
performed by infection of 293 cells have confrrmed that the titres obtained with 
these viruses are lower than the ones obtained with wild type virus (figure 3.21, 
3.22). 
Another reason could be that insertion of the transgene reduces the expression of 
the surrounding E3 genes and the virus's ability to induce CPE (Hawkins et aL. 
2001). However in all the viruses constructed the E3 y-Ieader sequence has been 
maintained. Hawkins et al. demonstrated that while the y-Ieader sequence is not 
coding it is spliced onto the E3-ADP mRNA. Deletion of this sequence resulted in 
weaker expression of ADP and reduced ability of the virus to induce CPE. 
Deleting the E3-6.7k and E3-gp 19k has no effect on the efficacy of the wild-type 
virus in colonic cancer cell lines (figure 3.12, 3.14a) in vitro but a reduced efficacy 
can be seen in other cancer cell lines (figure 3.13, 3.14b). This observation has not 
been further investigated. 
The majority of colonic cancers have activation of the Wnt signalling pathway. The 
group of Richard Iggo has created and tested a series of Wnt-specific replicating 
adenoviruses. The vKHI virus with EIA, EIB and E4 under the control of Tcf is 
specific for Wnt-activated cell lines leaving normal cells intact (Homicsko et al.. 
2005). 
Substituting E3-6.7k and E3-gp 19k for hNIS in this virus has resulted in a virus 
that is as powerful as wild-type virus in cell death assays in colonic cancer cell 
lines with high Tcf activity (figure 3.16a-c) but slightly less active in colonic 
cancer cell lines with low Tcf activity (figure 3.16d and 3.160. I han? clearly 
demonstrated that hNIS insertion does not affect this selectivity. The virw, is at 
least lOOx less toxic than wild-type virus in non-\\'nt activated cancer cell lines 
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(figure 3.15) and normal embryonic lung fibroblasts (figure not shown) in cell 
death assays. Western Blot analysis for EIA and Hexon has confrrmed these results 
(figure 3.26). While expression of EIA and Hexon in HeLa cells 48h after infection 
is high for cells infected with wild-type virus, expression of E 1 A protein is very 
weak for the Wnt-hNIS virus and expression of Hexon protein is absent (figure 
3.26A-B). The results obtained in normal lung fibroblast were similar (figure 
3.26C). 
Deleting E3-6.7k and E3-gpl9k in this virus enhances the cytotoxic effect of the 
virus in colonic cancer cell lines when compared to the hNIS-substituted virus 
(figure 3.17a-d) but also compared to the parent virus (figure 3.18). Viral 
replication assays have shown that the titres obtained with this virus are 
comparable to titres obtained with wild-type virus but titres of the hNIS substituted 
virus remain lower (figure 3.21). As stated above, the size of the transgene could be 
responsible for the reduced replication and reduced CPE. 
The enhanced efficacy of the deleted virus compared to the parent virus has been 
described before by Wang et al. (Wang et aI., 2003b) although the mechanism 
behind it remains unclear. 
In non-Wnt-activated cell lines the deleted virus is less active than the hNIS-
substituted virus (figure 3.17f,g). Possibly high levels of hNIS transgene expression 
are toxic to cells. In primary cells infection with a non-replicating virus where 
CMV drives the expression of hNIS is lethal to cells at MOl 100 (figure 3.32). 
Infection of the same cells with a non-replicating virus where CMV drives the 
expression of the ~-galactosidase gene is not lethal. 
2. Effect of the viruses on primary desmoids tumour cells 
Ideally we would have preferred to work on fresh colorectal cancer tissue rather 
than only desmoid tumours. Unfortunately it was not possible to access such a 
tissue and therefore desmoids tumours were a practical alternative. 
Constitutive activation of the Wnt-signalling pathway is a hallmark of sporadic and 
familial desmoid tumours (Tejpar et al., 2(05). Normal tissues where the \\'nt 
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pathway is active are stem cells in the skin, haematopoietic system and intestine 
and neurons in several regions in the brain, including subventricular zone. cortex 
and hypocampus (Homicsko et aI., 2005). Therapeutic strategies targeting the Wnt-
signalling pathway are expected to provide therapeutic benefits with minimal side 
effects in patients with this pathology. Selectively replicating oncolytic 
adenoviruses represent a novel class of therapeutic agents. Preclinical and clinical 
studies have demonstrated that these agents are safe and that they can be used in 
conjunction with classical cancer treatments such as chemotherapy and 
radiotherapy (Khuri et aI., 2000, Alonso et aI., 2007, Cheong et al .. 2008). A 
limitation of adenoviral vectors is that after systemic administration the majority of 
the virus is sequestered in the liver and only a minimal proportion of the injected 
dose reaches the tumour. Considering the size and location of tumours and the lack 
of metastasis in patients with desmoids local intratumoural injection of oncolytic 
adenovirus represents a practical approach that could be implemented in 
conjunction with chemo- and/or radiotherapy. 
Our data clearly demonstrate that primary cells from some desmoid tumours allow 
replication (figure 3.30) and are sensitive to the action of oncolytic adenoviruses 
(figure 3.27). However, in two cases the cells were completely refractory (figure 
3.27a and 3.27d). The difference between these cells and the responding cells is the 
infectability as demonstrated by infection of cell samples with a non-replicating 
virus expressing GFP (figure 3.28). Analysis of the expression of the key 
molecules involved in adenovirus infection (CAR and the integrins av~3 and av~5) 
proved puzzling (figure 3.31). Low or no CAR expression has already been 
reported in desmoids (Gu et aI., 2004) and we conftrm that CAR was absent in all 
the cellular samples tested whether responding to adenoviral treatment or not. 
These data suggest that an alternative CAR-independent mechanism is responsible 
for viral entry in the cell. Integrins are present on the surface of all cell samples 
when tested with av antibody but the highest level of u.v~3 and u.v~5 was observed 
in non-responding cells. Other mechanisms of infection may be involved (Nicklin 
et aI., 2005) in these cells and further studies will be required to elucidate these 
mechanisms. Mechanisms that have been suggested involve heparan sulphate 
proteoglycans (Dechecchi et aI., 200 1) or coagulation factors (Waddington et al.. 
2007. Waddington et a1.. 2(08). 
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In these primary desmoid cells there appears to be a direct effect of the hNIS 
trans gene on the viability of cells (figure 3.32). This is the frrst time that such an 
effect has been reported. 
This thesis demonstrated that gene therapy for desmoid tumours is feasible and that 
the success of treatment is dependent on the infectivity of the cells. In a clinical 
setting, direct injection of the oncolytic virus into the tumour under radiological 
guidance could be envisaged. Even a relatively modest effect could have an 
important clinical implication by making a previously unresectable intra-abdominal 
tumour amenable to surgery. Imaging of hNIS gene transfer could be performed to 
visualise viral spread and additional radiotherapy could extend the effect of the 
viral therapy (described below). Although it has been suggested that desmoid 
tumours are relatively radioresistant, there is evidence in the literature, as reviewed 
by Tolan et aI. (Tolan et aI., 2007) and Sakorafas et aI. (Sakorafas et aI., 2007) to 
suggest that these tumours can respond to external bean tadiotherapy, which 
supports the use of localised radiotherapy by hNIS gene transfer. 
3. Effect of the oncolytic viruses in vivo 
In vivo intravenous administration of wild-type replicating adenovirus 5 is lethal in 
mice after IV injection of 1010 particles (Homicsko et al., 2005) and acute hepatic 
necrosis was also seen after injection of 109 PFU of wild-type adenovirus 
expressing hNIS as confrrmed by pathology (figure 3.33a-b). The acute hepato-
toxicity that was seen is probably related to the expression of adenoviral E 1 A in the 
liver cells (Engler et aI., 2004) since adenoviruses fail to replicate efficiently in 
mouse cells. Immunohistochemistry of livers infected with AdIP 1 showed massive 
E 1 A expression and this was confrrmed by real time peR for E 1 A on ON A 
extracted from mouse livers (figure 3.33c). Intravenous injection of Tcf viruses is 
well tolerated in nude mice (Homicsko et aI., 2005) and this was no different for 
intravenous injection of the hNIS expressing Tcf virus. Histology showed an intact 
liver architecture and mild inflammatory infiltration at 48h which increased after 
120h. This inflammation subsides after 20 days (Homicsko et aI., 200S) but in our 
small scale experiment. mice were not kept for such a long period of time. Very 
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few cells stain positive for E I A when immunohistochemistry is performed and this 
was confrrmed with real time PCR on liver extracts. Normal liver cells do not have 
the Wnt signalling pathway active and reduction in toxicity is probably due to Tcf 
regulation of early viral promoters. Although this experiment together with th~ 
experiments performed by Homicsko et al. suggest that intravenous administration 
of Tcf-regulated adenoviruses would be safe, only a minimal proportion of the 
injected dose reaches the tumours (Homicsko et aI., 2005). Intratumoural injections 
of virus are therefore advised. 
In VlVO, the hNIS-encoding VlfUses AdIP 1 and AdIP2 demonstrate functional 
trans gene expression (figure 3.34) and the kinetics of viral replication can be 
monitored by molecular imaging using SPECT/CT (figure 3.36 and 3.37). A signal 
can be detected 24h after intratumoural injection of virus. which increases to a 
maximum after 48 hours and then sharply reduces thereafter. Measurements of 
radioactivity normalised against background confirmed maximum activity 48 hours 
after infection (figure 3.38 and 3.39). The sequence of events after injection of 
virus into the tumour is ftrstly internalisation into the cell, followed by transcription 
of viral DNA and viral replication and possibly packaging of viral progeny in 
virions that will infect neighbouring cells upon cell lysis and release. An imaging 
signal can be detected when hNIS protein is being produced and translocated to the 
cell membrane where it can take up radiotracer. Real-time PCR for hNIS and E 1 A 
on DNA extracted from tumour samples (figure 3.41) shows an increase of 
transgene expression up to day four. Positive staining for EIA and hNIS antibody 
is present in immunohistochemistry up to day 4 and only reduces at day 5. A 
possible explanation for the discrepancy between the maximum imaging signal and 
the qPCR data is that although viral replication continues and hNIS is still being 
produced in the tumour after 48h, radio tracer is no longer taken up by the ce lIs due 
to cell death. The marked necrosis that can be seen from day 3 onwards in the 
pathology slides of tumours supports this theory. 
Surprisingly, viral spread stops as early as four days post-infection and no 
significant signal can be detected. At this point the remaining life cells in the 
tumour may be inaccessible to the virus due to surrounding necrosis. Possibly 
reducing the viral load and preventing early necrosis may allow the virus to spread 
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further in the tumour. Dno et al. inserted the EGFP gene in the E3 region of a 
replicating wild-type adenovirus 5 and were able to monitor viral replication 
through EGFP expression with fluorescence-based optical imaging. The signal 
increased during the fIrst week and reduced thereafter. A signal was visible up to 
day 19 post-infection. The viral dose injected was comparable (lOlOvp) but the 
tumour size on injection was at least twice as large. The slight discrepancy between 
my data and these observations may be due to the difference in reporter gene. 
EGFP may have a longer half life than hNIS. In addition, to be detectable by 
SPECT imaging, hNIS has to be expressed in a cell that maintains its ability to 
accumulate iodide. Therefore, it is likely that a tumour positive for hNIS 
immunohistochemistry may not be detectable by SPECT if hNIS is present on dead 
or apoptotic cells. 
Animal models are important to evaluate and approve new anti cancer-therapies. 
The human adenovirus infects murine cells, viral proteins are synthesized and viral 
DNA replicates but the production of new infectious viral particles is limited. This 
leads to difficulties in interpreting the results of nude mice human xenograft 
tumour models. Another hurdle is that although the tumour cells are human, the 
supporting cells (e.g. stromal and vascular cells) are murine. This is likely to alter 
the dynamics of viral spread in the tumour. Last but not least, nude mice are 
immunocompromised. Most humans have been exposed to adenovirus and have 
antibodies to various human adenovirus serotypes. It has been reported, however, 
that neutralising antibodies predominantly playa role after intravenous but not after 
intratumoural injection of virus (Bramson et al., 1997). The immunity may have an 
effect on the elimination of virus and virus infected cells. However specific 
cytotoxic T-cell responses develop after a week or more, which should allow 
sufficient time for initial viral propagation. Immunity may also playa role in viral 
toxicity as was demonstrated by the Gelsinger case (Lehrman, 1999) as described 
in the introduction (p48). 
In a clinical setting therefore, one would hope that the virus spread continues for 
longer than 48 hours to avoid repeated administration of virus. Although clinical 
trials have provided evidence that repeated administration is feasible (Fujiwara et 
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aI., 2006a) one has to be aware of the possibility of inducing an immune response. 
which could reduce the efficacy of the virus. 
One clinical trial conducted in patients with hepatocellular carcmoma has 
confrrmed that it is possible to monitor gene expression in vivo with PET imaging 
in humans (Penuelas et aI., 2005b). The viruses that have been constructed for this 
thesis could behave differently when injected in human subjects. It would be 
feasible to monitor gene expression by PET or SPECT with or without CT to 
determine the time of maximal gene expression. Our mouse experiments have 
highlighted that it is very important in oncolytic virotherapy to determine the 
optimal viral dose. The administered dose should be high enough to obtain 
maximal viral spread and transgene expression but should not be too high in order 
to prevent early elimination of the cells by oncolysis which would prevent further 
viral spread in necrotic tumour tissue and make additional radioiodine therapy less 
effective. 
In vivo experiments conducted on mice have highlighted the possibility of an added 
effect of the hNIS gene in the Wnt-specific virus and injection of radioiodine could 
extend the effect of the viral therapy to the surrounding cells thus maximising the 
effect of oncolytic viral therapy. 
Since the completion of this work, further in VIVO experiments have been 
successfully conducted by my supervisor in France leading to the submission of a 
manuscript. The therapeutic experiment as described in figure 3.45 was repeated in 
duplicate as follows: Balb-c nude mice were injected with HCT 116 cells 
~ 
subcutaneously (2xl06 cells). When the tumours reached an average size of lcm-, 
tumours were injected with 109 PFU of AdlP2 or AdIP4. Fourty-eight hours later. a 
single dose of 131 I (1.5mCi) was administered intra-peritoneally. The data below 
represent nleans +/- SEM of the tumour measurement, with 6 animals per group. 
Two-way ANOY A statistical analysis was performed. 
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Figure 4.1: Comparison of viro-radiotherapy induced by AdIP2 and AdIP4. 
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These data show that a single injection of a therapeutic dose of radioiodine 4 h 
after a single injection of AdIP2 resulted in a significant deere a e in tumour ize 
that is not obtained with the hNIS-negative AdIP4. These data demon trate that 
hNIS-mediated viro-radiotherapy is relevant to oncolytic adenoviru e . 
4. Future developments 
Endogenous expression of hNIS in differentiated thyroid carcmoma ha led to 
extensive utilisation of radioiodine for the diagno is and treatment of thi 
pathology. Based on this experience, ectopic expression of hNIS in extrathyroidal 
cancers and subsequent treatment with radioiodine could provide a powerful new 
gene therapy strategy. The thyroid could be protected by admini tering thyroid 
hormone prior to treatment with radioiodine. The thyroid i the only organ which 
stores iodine in the colloid where it is used for the production of thyroid hormone. 
In other organs which express the hNIS, like the gastric muco a alivary gland 
adrenal glands and lactating breast, iodine is not stored and i dependent on the 
concentration of iodine in the extracellular fluid. The uptake of iodine in the 
thyroid is regulated by thyroid-stimulating hormone (TSH) al 0 called 
thyrotrophin. When the amount of thyroxine in the blood increa e TSH in th 
circulation decrea es and the iodine uptake in the thyroid i down-regulated by 
recycling the hNIS from the cell membrane into the cell (Dohan and Carra 
2003). Other factor that down-regulate TSH are ex hormone, 
omato tatin, IL-la, TNF-a IFN-y and protein kina e C. It ha be n h wn 10 
animal tudie that admini tering iodine (Nal) ix day pri r t r di i din 
tr atm nt gr atly reduce radioiodine uptake in the thyr id (F IT ir t al.,... 5. 
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Pre-treatment with thyroid hormone or even sodium iodide could therefore be used 
to down-regulate the expression of hNIS in the thyroid and consequently 
suppressing the uptake of 1311 in the thyroid thus protecting the thyroid from 
radiation damage. 
But, even if radioiodine uptake in the thyroid would cause damage to the gland, 
patients could be easily and inexpensively treated by routine thyroid hormone 
replacement therapy and the lost thyroid function might then be a small price to 
pay in the treatment of cancer. 
The extensive expenence (more than 50 years) with radioiodine treatment for 
thyroid disease and cancer provides evidence that damage to extra-thyroidal tissues 
that express the hNIS remains limited. Possible side effects to radioiodine 
treatment depend on the administered dose and include nausea and vomiting 
(although very rare), dry mouth, temporary change in taste (in up to 60% of 
patients, typically lasting several weeks), salivary gland swelling and pain, drop in 
blood counts and other effects related to the radiation (Alexander et ai., 1998). The 
most common long-term side-effects are due to radiation damage to the salivary 
glands. Several drugs have been reported that could provide protection for the 
salivary glands. They include Amifostine, Pilocarpine and/or Lidocaine (Hakim et 
ai.,2005). 
The combination of oncolytic adenoviruses and hNIS could overcome the limited 
efficacy of oncolytic adenoviruses alone. In an ideal clinical situation (figure 4.1), 
the adenovirus would then be delivered to the tumour where it would penetrate the 
tumour cells and replicate. In a next step, cell lysis and the release of progeny 
would allow for the virus to propagate in the tumour. Due to the presence of hNIS, 
patients could be monitored by SPECT or PET imaging and viral propagation in 
the tumour closely followed. The time-point of maximal propagation could be 
determined and dosimetry performed to calculate the ideal dose that would be 
required to obtain a maximum biological effect. Once this information is 
established, phase 1 clinical trials could be initiated and patients could be treated 
with a combination of virus and radioiodine. The efficacy of this treatnlent could 
then be compared to other more conventional therapies. 
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Figure 4.2: Overview of how oncolytic adenoviral therapy could be u ed in a clinical ituati n. 
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Although adenoviral vectors are highly potent gene delivery vehicle , can be 
produced to high titres, are able to infect both dividing and quiescent cell, do not 
integrate in the host genome and are stable, a few important hurdle till need to b 
overcome. 
Firstly, there is the problem of delivery. Intravenous administration of adenoviru e 
results in high liver transduction and relatively little virus reache the target ti ue. 
In the liver the macrophages or Kupffer cells interact with the viru and activate a 
strong immune response. Studies have suggested that the activation of the innate 
immune response can be largely attributed to the capsid protein. Another 
important factor in gene delivery is the fact that most people have been previou ly 
exposed to adenoviru es and may have circulating anti-adenoviru antibodi . 
Oncolytic adenoviru es although they do not replicate in normal cell. an till 
infect a wide variety of cell ince the two mo t important recept r . CAR and 
integrin are expre ed on many different cell type . Circulating ad n Lru , ar 
al 0 able to interact with coagulation factor, platelet and pIa rna pr t in ' III th 
cir ulation, which further reduce the amount delivered t th tar t ti~ Ue 
(Kr pp 1 and K chanek, 200 ). Chemical m dific ti n f ad n lru v 
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synthetic polymers could reduce innate and adaptive immune responses and 
subsequent liver toxicity CKreppel and Kochanek, 2(08). PEGylation of viral 
particles can overcome neutralisation by anti-adenoviral antibodies and 
significantly reduces neutrophil infiltration of liver cells after gene transfer due to 
reduced sequestration by Kupffer cells, which are responsible for initiating an 
immune response and has been shown to prevent interaction of the viral capsid 
with platelets. It has also been suggested to administer glucocorticoids before 
treatment with adenovirus to ablate further the innate immune response. However. 
although PEGylation reduces liver toxicity, it also results in ablation of the CAR 
tropism of adenoviruses, which could prevent delivery to tumour cells. 
Experiments revealed that the RGD motif in the penton base protein was still 
partially accessible even after heavy PEGylation which would allow for binding to 
integrins. Another strategy would be to combine PEGylation with ligands coupled 
to the vector surface. Another possibility would be to genetically modify the capsid 
proteins to prevent binding to CAR, which could be used in combination with 
chemical modification. 
An entirely different strategy to allow for intravenous administration and target 
delivery of adenoviral vectors would be to incorporate adenoviral DNA into 
synthetic vectors. A wide variety of synthetic vectors have been developed that are 
able to deliver genetic constructs to cancerous tissues (Wolff and Rozema, 20(8). 
In our laboratory Dr. Ed Chisholm and Jerome Burnet have successfully attached 
the adenoviral plasmid containing AdIP 1 to polypropylenimine dendrimers. 
Polypropylenimine dendrimer generation 3 are small molecules that when mixed 
with plasmid DNA form nanoparticulate complexes which when intravenously 
administered are able to deliver the plasmid DNA to tumour xenografts in mice 
CDufes et al., 2005). Furthermore, these dendrimers appear to possess an intrinsic 
antitumour activity which acts together with the delivered DNA to provide a 
stronger effect than can be obtained with either component alone (Dufes et al.. 
2005). Animal experiments performed in our laboratory have demonstrated that the 
intravenously administered adenoviral DNA (AdIP 1) attached to the dendrimers 
was delivered exclusively to xenografts in nude mice as seen by SPECT/CT 
imaging. These data have not yet been published. Dufes et al. have abo 
demonstrated that it is possible to use tissue specific promoters like the telomera.-..c 
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promoter to further increase the specificity of these delivery vectors (Dufes et al.. 
2005). To increase the efficiency of gene delivery, physical methods such as 
ultrasound or hydrodynamic injection could be added to these synthetic vectors 
CWo Iff and Rozema, 2008). 
Although promising data have come out of the experiments previously described. 
to date no clinical experiments have been performed to confrrm these data in 
human subjects. If we would plan a clinical trial with the virus produced in this 
thesis, intratumoural or intra-hepatic injection would be envisaged. Possible 
indications would then be for example multiple colonic cancer liver metastases. 
Currently the primary treatment for colorectal cancer and solitary metastases 
remains surgery. Multiple liver metastases pose a more complicated problem. 
Laparoscopic coagulation or laser treatment is available for the metastases that are 
accessible by this technique but metastases deep in the liver or posterior located 
may not be amenable to this technique. Adenoviral injection into the hepatic artery 
would be a good alternative and could be combined with radioiodine therapy. 
Animal studies performed by Faivre et ai. (Faivre et al.. 2004) and the clinical 
study performed by Penuelas et al. (Penuelas et aI., 2005b) have provided evidence 
that this approach is possible. 
Another indication could be in F AP patients. The treatment of desmoids poses a 
challenging dilemma. Surgery increases the risk of the development of desmoid 
tumours but if left untreated they can become so large that surgical intervention 
becomes impossible and death is unavoidable. Injection of oncolytic adenovirus 
could reduce the size of tumours and make a previously unresectable tumour 
amenable to surgery. 
The majority of FAP patients also develop duodenal polyps. If these polyps 
progress and become cancerous, the surgical procedure (Whipple' s procedure or 
pancreaticoduodenectomy) to remove them is associated with a high morbidity and 
mortality rate and could trigger the development of desmoid tumours in these 
patient that have already undergone total colectomy. One could envisage 
intratumoural injection of adenovirus via endoscopy with or without treatment with 
radioiodine. 
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The work presented in this thesis has shown that it would be possible safely to 
inject Wnt-specific adenovirus into cancerous growths. In vitro treatment of 
primary cells has demonstrated that two out of six samples were refractory to 
treatment. Possibly the infectability of cancer cells and the Tcf status should be 
determined before therapy is envisaged. In the future, adenoviruses could be further 
modified as described above to enhance their potency in the treatment of cancer. 
Who would have thought 20 years ago that a surgeon would be sipping coffee in 
front of a computer console while operating a patient in an operating theatre 1000 
miles away? Today this is a reality (www.intuitivesurgical.com). Genetically 
modified adenoviruses with or without therapeutic transgenes may one day become 
a routine therapy for a wide range of cancers. 
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